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There are currently approximately 50 million individuals worldwide with dementia resulting in predicted 
global societal costs of up to US $1 trillion. Approximately 60-70% of these individuals have Alzheimer’s 
disease, which results in a chronic and insidious decline in memory. One of the main proteins that misfolds 
in this disease is Tau protein, which aggregates into toxic oligomers and neurofibrillary tangles. It is these 
aggregates, which cause damage to the brain resulting in dementia. As a result, it is imperative to be able 
to prevent or suppress the pathogenic aggregation of this protein, so the onset of dementia is halted or 
delayed, improving quality of life. Certain amino acid sequences in Tau such as VQIINK and VQIVYK play 
important roles in aggregation. Targeting these sequences can potentially prevent aggregation. This 
project aims to produce effective peptide inhibitors based on the human Tau peptide sequences VQIINK 
and VQIVYK, to specifically target pathogenic Tau aggregation. Using molecular docking softrware ‘ICM-
Pro’ the potential binding locations of a variety of peptide candidates were computationally investigated 
to determine which will be most successful in a laboratory setting. Recombinant TauΔ1-250 was incubated 
in the prescense of heparin and subsequently aggregated to display highly ordered parallel, in-register β-
strand structures; including fibrils and paired helical filaments presenting the characteristic twist under 
transmission electron microscope. This aggregation was achieved using of 20µM Tau at pH 7.4 in the 
presence of 20mM Tris buffer, 1mM DTT, 5µM Heparin, and 15uM ThT and incubated at 37 °C for 48 
hours. The first generation of peptides AG01, AG02, AG02, AG02R4, AG02R5, AGR502, AG02PR5, AG02R6, 
AG02R9, AG02TAT, AG02ΔI, AG02ΔV inhibited approximately 50% of Tau aggregation determined by 
Thioflavin-T (ThT) fluorescence assay. The next generation, AG03 was slightly more effective, however 
when retroinverted (RI-AG03) inhibited over 90% of Tau aggregation, confirmed by Thioflavin-T 
fluorescence assay, transmission electron microscopy, circular dichroism and Congo red birefringence. RI-
II 
 
AG03 was determined to be stable in cells at therapeutic concentrations. After determining stability of RI-
AG03 using SDS-PAGE, thermal circular dichroism and mass spectrometry, it was tested in vivo in rough 
eye Drosophila model. Results suggested that RI-AG03 partially rescued the rough eye phenotype in this 
model. This research demonstrates that retro-inverted peptide RI-AG03 is a potent inhibitor of Tau 
aggregation and can be further developed as a novel therapeutic for Tauopathies like Alzhimer’s Disease. 
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Experiment was run with maximum effort. 
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Potential binding sites for, A:6QJH heparin-induced 2N4R Tau snake filament, 
B:6QJM heparin-induced 2N4R Tau twisterfilament, C:6QJP heparin-induced 2N4R 
Tau jagged filament. Cryo-EM structures from Zhang et al. (2019). 
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Aggregation kinetic model of K18 50µM a) in the presence of different heparin 




ThTmonitered kinetics rate constant plotted against heparin concentration 
(Ramachandran and Udgaonkar,2011). 
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K18 fibril formation in presence of heparin. ThT fluorescence of 50µM K18 with 
37.5µM heparin in 25mM Tris, 50mM NaCl, 1mM DTT, pH7 at 37°C. 
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1hour, 4: 2 hours, 5: 3 hours, 6: 4 hours, 7: 5 hours, 8: over-night. The optimum 
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1. INTRODUCTION TO ALZHEIMER’S DISEASE 
 
1.1 DEMENTIA BACKGROUND 
The syndrome Dementia is an umbrella of brain diseases that originate from different and often multi-
causal pathogenesis resulting in a reduction of cognitive ability. Professor Joshua Thornhill IV (2012), 
defined dementia as a chronic, insidious and acquired decline in memory with impairment of at least one 
other cognitive function: aphasia (communication/language), apraxia (motor execution/visuospatial), 
agnosia (recognition/judgement) and executive function (synthesis). This significantly impairs intellectual 
functioning thus interfering with everyday activities and relationships due to lost problem-solving 
capabilities and emotional control/personality changes. 
Currently there are approximately 50 million individuals with dementia worldwide of which the most 
common variation is Alzheimer’s disease (AD) which accounts for around 60-70% of dementia cases 
(World Health Organisation, 2015). Other causes of dementia include vascular dementia, dementia with 
Lewy bodies, fronto-temporal dementia, Creutzfeldt-Jakob disease, Korsakoff’s syndrome, HIV, and mild 
cognitive impairment (Alzheimer’s Society, 2015). More than one kind of dementia can occur in the same 
patient such as AD and vascular dementia; this is known as mixed dementia.  
1.2 ALZHEIMER’S DISEASE 
AD is a progressive neurodegenerative disease first discovered by Alois Alzheimer (Möller and Graeber, 
1998). Povova et al., (2015) stated that the aetiology of AD is still unknown, however three main risk factor 
groups are identified: vascular, genetic and behavioural. Li et al., (2015), suggested that most AD cases 
have sporadic origins and highlighted distinct established risk factors including old age, female gender, 
vascular disease, cranial trauma or injury, family history of dementia and genetic factors. Distinct 
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controllable risk factors mentioned by Smith et al., (2014) are believed to cause >50% of sporadic or late 
onset AD cases and include: 
• Age 
• Apolipoprotein e4 gene 
• Family history 
• Mild cognitive impairment 
• Cardiovascular disease 
• Obesity 
• Diabetes 
• Sedentary lifestyle 
• Smoking  
• High blood pressure 
• Depression 
• Low levels of education and socioeconomic status 
• Traumatic Brain Injury 
Excluding ~5-10% instances of early onset familial AD due to genetic mutations in Amyloid precursor 
protein, Presenilin-1 and Presenilin-2, it is believed that the disease develops due to multiple factors as 








There is currently no simple clear-cut test to diagnose AD however criteria and guidelines for diagnosing 
the disease were proposed in 2011 by the National Institute on Aging and the Alzheimer’s Association 
(Jack et al., 2011). Typically, a medical screen is initially conducted by obtaining the patients’ medical and 
family history which includes information on any psychiatric and cognitive or behavioural changes. For 
further insight this information could be drawn from people close to the patient. According to Reuben 
(2013), this process usually identifies >90% of individuals with dementia, however, this again is not a 
proper diagnosis. Several hours’ long mental status tests can be performed with a clinician of which, the 
following three are the state of the art: 1) Three item recall test, 2) Mini-cog test (3 item recall plus clock 
drawing), 3) Mini Mental State Examination.  
Unfortunately to date there is no simple, inexpensive and accurate blood test to clinically indicate AD 
however research is currently underway in three main biomarker categories: those for CSF accumulation 
of Amyloid-β (Aβ)/phosphorylated Tau/total Tau and those showing neuron damage/degeneration 
(Dubois et al., 2014; Alzheimer’s Association, 2015).  PET imaging 
In diagnosis it is important to highlight which of the three stages proposed by the 2011 criteria and 
guidelines of AD the patient is at in order to enable the most appropriate course of treatment. The three 
stages of AD include:  
1. Preclinical AD  
i. It is difficult to diagnose these patients as they are pre-symptomatic i.e. show no signs of 
memory loss however insidious changes in brain biochemistry can be detected through 
biomarker testing and brain imaging (Alzheimer’s Association, 2015). This suggests that 
these changes may begin at least 20 years prior to symptomatic development (Villemagne 
et al., 2013).  
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2. Mild cognitive impairment due to AD  
i. Patients have noticeably mild symptoms and however are still able to perform everyday 
tasks. A study by Roberts et al. (2008), indicated that 10-20% of individuals aged >65 have 
mild cognitive impairment and 15% of individuals whom contact their physicians due to 
their symptoms progress to develop dementia each year (Alzheimer’s Association, 2015). 
3. Dementia due to AD 
i. Symptoms of memory loss, thinking and behavioural changes are much more pronounced 
















1.2.2 GLOBAL BURDEN 
Prince et al., (2013) predicted that the world population of individuals suffering from dementia would 
increase to approximately 115 million by 2050 however the World Health Organisation, (2015) report this 
figure to be 135.5 million; suggesting by 2050 there could be potentially ~69-95 million individuals with 
Alzheimer’s (World Health Organisation, 2015; Povova et al., 2015). The number of individuals with 
dementia may double every 20 years (Blennow et al., 2006). This may be linked to the growing incidences 
of diabetes globally (Aggidis et al, 2015). Alzheimer’s Disease International, (2015) released a report 
stating that the global societal cost of dementia has increased by 35% since 2010 and they estimated that 
dementia costs would increase from US $818 billion to US $1 trillion by 2018. This figure approximately 
equates to Apple which is the current largest market valued company in the world at US $1 trillion 
(Shubbar and Smith, 2019). If total costs of global dementia care were likened to a country it would be 
ranked 18 in the largest economies in the world and by 2030 global costs are predicted to reach over $2 
trillion as seen in Figure 1.1 (Alzheimer’s Disease International, 2015). On a smaller scale of appreciation, 
currently the average cost per person in the UK to manage dementia annually is £32,250 (Alzheimer’s 
Society, 2014). This rise in dementia costs can be attributed to more people being diagnosed with 
dementia due to increased life expectancy or enhanced awareness/screening methods. Associated 
demetia costs per person may also be a contributing factor (Wimo et al., 2017). 
Figure 1.1: Predicted global costs of dementia worldwide from 2015-2030 (Alzheimer’s 
disease International, 2015). 
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1.3 AMYLOID BACKGROUND 
The International Society for Amyloidosis, (2018), recognises 36 species of human amyloid (including Tau 
protein) where they define ‘amyloid’ as extracellular proteins that misfold into insoluble non-branching 
fibrils through a series of changes. These fibrils are approximately 10 nm in diameter and subsequently 
deposit within tissues and the extracellular space of organs (Goedert and Spillantini, 2017 and Sipe et al., 
2016). Biopsy amyloid deposits present as amorphous under light microscope however under high 
magnification electron microscopy small non-branching amyloid fibrils can be seen. Congo red dye is the 
current gold standard for detecting amyloid in tissue as it binds to amyloid and displays a characteristic 
apple green birefringence when viewed under polarized lens (International Society for Amyloidosis, 2018). 
Birefringence is discussed further in Section 6.1.1. β‐strands are stretches of polypeptides (~3-10 amino 
acids) which laterally connect to other adjacent β‐strands via backbone hydrogen bond interactions, 
resulting in a β‐sheet. β-Sheets are a common secondary structure motif and are particularly present in 
misfolded insoluble proteins, which are discussed further in Sections 1.3.1 and 1.4.4. From a structural 
perspective, amyloids are defined as fibrils having a backbone consisting of β‐sheets in a cross β‐sheet 
arrangement (where a set of β-sheets are aligned in parallel to the fibril axis and their β-strands are aligned 
perpendicular to the fibril axis giving rise to a pattern of repeating side chains), with meridional and 
equatorial x-ray diffraction reflections of ~4.7 Å parallel to the fibril axis, and 8-12 Å perpendicular to the 







1.3.1 PROTEIN MISFOLDING 
Protein synthesis generates long polypeptide chains without secondary structure. These proteins then, 
via intermediates, follow specific folding pathways following an energy landscape mechanism, resulting 
in stable 3D structures. These specific folds, based on the protein amino acid sequence and the 
surrounding environment, give rise to different individual biological functions. There are however some 
fully functional unordered proteins, such as Tau, which have an increased likelihood of aggregating. These 
folding pathways are said to follow an energy landscape and are depicted as a funnel-like mechanism. 
Unfolded proteins at the top of the funnel systematically adopt random folding conformations to stablise 
their structure via hydrophobic and electrostatic interactions, intramolecular hydrogen bonds and Van 
der Waals forces (Pace et al., 2014). This process continues until the proteins reach their lowest free 
energy, adopting their thermodynamically favourable native fold at the bottom of the funnel. 
Alternatively, proteins may encounter off-pathway kinetic traps within the funnel which result in 
misfolded proteins. These misfolded intermediates may be recovered via Chaperone proteins which can 
reverse the off-pathway fold. Chaperone proteins achieve this by inhibiting intermolecular interactions 
and reducing free energy barriers, enabling the misfolded protein to adopt a different conformation 
(Adamcik and Mezzenga, 2018). Contrary to native proteins where hydrophobic interactions occur within 
the folded protein, misfolded proteins typically display exposed hydrophobic amino acid residues to their 
solvent. If misfolded proteins are too far from their native folding pathway they can interact with other 







1.3.2 AMYLOID & ALZHEIMER’S DISEASE 
AD is a proteopathy manifested through the production Aβ protein and hyperphosphorylated Tau protein 
which misfold (adopting high β-sheet content) and aggregate into their respective fibrils. Aβ is produced 
through the processing of Amyloid precursor protein (APP) which is normally processed by α-secretase 
and γ-secretase. However, in the amyloidogenic pathway, β-secretase and γ-secretase cleave APP, 
resulting in the formation of Aβ (Hardy and Allsop, 1991). Tau protein is found naturally in the brain 
however in AD it becomes hyperphosphorylated and misfolds (discussed further in Section 1.4). 
Aggregation of these proteins causes neurotoxicity and as a result the destruction of basal forebrain 
cholinergic neurones which are necessary for innervating regions such as the hippocampus and the cortex 
(Zheng et al., 2002). Monomeric Aβ and Tau initiate a nucleation process to form semi-soluble oligomers 
and protofibrils with β-sheet structure (Cohen et al., 2013, Hardy and Allsop, 1991, Ballatore et al., 2007). 
They then aggregate to form insoluble Aβ1−40 or Aβ1−42 amyloid fibrils and Tau fibrils which deposit in 
the brain as extracellular amyloid plaques and hyper-phosphorylated intraneuronal neurofibrillary tangles 
(NFTs), respectively, as seen in Figure 1.2 (Kaffy et al., 2016). Interestingly the most neurotoxic form of Aβ 
and Tau is believed to be small aggregates known as oligomers. These oligomers are responsible for 
neurodegeneration, particularly of neuronal synapses, and fibrils have been demonstrated to cause 
damaging redox activity and promote nucleation of oligomers (Mayes et al., 2014). These aggregation and 
deposition processes of Aβ and Tau are known as amyloidopathies and Tauopathies, respectively, and 
sometimes together along with α-synuclein cause AD upon accumulation in the brain (Kumar et al., 2014).  
Soluble α-synuclein is believed to normally play a role in neurotransmitter release through interaction 
with vesicle fusion complexes. In pathogenic conditions α-synuclein is mainly associated with Parkinson’s 
disease and for unknown reasons it misfolds and aggregates to form Lewy Body’s which are insoluble, 
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spherical inclusion bodies. With relation to AD, α-synuclein has shown to be able to bind to microtubules, 
induce aggregation of Tau and potentially be mediated by GSK3β (Twohig and Nielsen, 2019).  
 
Moreira et al., (2007) suggested that these toxic proteins result in massive destruction of neurones and 
synapses, particularly of the hippocampus and cortex. Aβ and Tau are recognised by the Internatinoal 
Society of Amyloidosis as amyloid fibril proteins (Benson et al., 2018). Tau fibrils are classified as amyloid 
proteins and play an intrinsic pathological role in neurodegenerative diseases (Sipe et. al., 2016).  
Amyloid hypothesis was first coined by Hardy and Allsop (1991), who suggested that extracellular Aβ 
deposition was the central event which led to the aetiology of AD; and has been the mainstream concept 
for the last two decades. However, following a vast series of terminated clinical trials, many Aβ targeting 
Figure 1.2: Senile plaques (arrow) and neurofibrillary tangles (arrowhead). Image courtesy 
of Professor D.M.A. Mann from University of Manchester, U.K. (Allsop and Mayes, 2014). 
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drugs have been withdrawn or become inactive (72%), as seen in Appendix A. As a result, researchers 
have begun to investigate other avenues for treatment, such as inflammation and particularly Tau protein. 
There is conflicting research correlating deposition of amyloid with loss of cognition; whereas hyper-
phosphorylated Tau NFT’s and neuronal destruction are more closely linked to memory deficits (Giacobini 
and Gold, 2013). As a result, targeting Tau pathology may be more clinically suitable as opposed to other 
strategies. This is supported by the fact that over 200 candidate treatment compounds have failed in the 
attempt to treat AD; and these have mainly targeted Aβ or the cholinergic system, with very little focus 
applied to targeting Tau (Becker and Greig, 2012). Giacobini and Gold, (2013) discovered that amyloid 
toxicity may be Tau-dependent which would suggest that targeting Tau as a monotherapy could be 
therapeutically effective, regarding Aβ toxicity, but not entirely. This suggests that Aβ is not the only cause 
for cognitive impairment in AD patients and that having more than one target, such as Tau, is more 
effective than anti-Aβ monotherapy (Gong and Iqbal, 2008).  The argument to support Tau as a target is 
backed up by many primary research sources such as those suggesting that NFT load and number of 
neurones, but not amyloid load can independently predict the cognitive status of patients 
(Giannakopoulos et al., 2003; Gold et al., 2001). This is further supported by Pievani et al., (2011) who 
using functional MRI and EEG, discovered that hyper-phosphorylated Tau pathology is linked closely to 
AD related memory deficits, whereas Aβ deposition better correlates with functional network disruption 
rather than cognition (Pievani et al., 2011). Functional connectivity is defined as the co-activation time 
series of different brain regions; therefore, functional network disruptions result in a delay to these time 
series (Giza et al., 2018). This is supported by the study of Desikan et al. (2012), who identified that 
longitudinal clinical decline associated with CSF Aβ in 107 clinically normal older individuals only occurred 
in the presence of increased CSF phosphorylated Tau levels. They suggested that 50% of individuals aged 
over 90 who had high amyloid neuropathology did not have clinical dementia accompanying it. Tansgenic 
mice models are also in agreement with these findings such as Leroy et al. (2012), who using APP/PSEN1 
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mice identified that by eliminating Tau resulted in improvements in memory deficits and synaptic loss. 
Similar results were also seen by Roberson et al. (2007), who stated that all cognitive deficits were 
prevented when they crossed APP transgenic mice with Tau knockout mice. 3xTg-AD mice contain three 
mutations including human APP, PS1 and Tau transgenes. Oddo et al., 2003 demonstrated that 
intraneuronal Aβ preceeded accumulation of somatodendritic Tau. It was then demonstrated via 
immunotherapy that removal of this Aβ later resulted in removal of Tau also, on the condition that the 
Tau was not aggregated (Oddo et al., 2004). Oddo (2008), identified that proteasome function is inhibited 
by Aβ oligomers which may prevent degredation of excess Tau (LaFerla and Green, 2012). This evidence 
clearly shows a close relationship between Aβ and Tau. Jack et al., (2013) used Pittsburgh compound B 
(radioactive analogue of thioflavin-T) positron emission tomography to image Aβ and discovered variation 
in cognitive impairment amongst individuals with high amyloid load. Villemagne et al., (2013) stated that 
Aβ aggregation needs to reach a certain threshold (~19 years) to be possibly detected with current 
technology in AD patients. These suggest that targeting Tau would be a wise decision, and wiser still to 
devise a therapeutic approach which would also combat Aβ aggregation that is known to have an 










1.4 TAU BACKGROUND 
Tau protein is a neuronal microtubule associated protein which is naturally found mainly in neurones of 
the central nervous system. Tau proteins bind to microtubules through the 4 repeat domains (Figure 1.3) 
and supresses microtubule shortening thereby stabilising axon structural integrity. This process lowers 
the critical concentration of tubulin polymerization to promote microtubule assembly and supports 
intracellular transport between the cell body and nerve terminals (Kadavath et al., 2015). Microtubules 
are located throughout the cytoplasm and are formed through the polymerisation of α-tubulin and β-
tubulin dimers. Microtubules are involved in maintaining cell structure, cellular process (e.g. intracellular 
trafficking), cell division and cell morphogenesis. 
Figure 1.3: Illustrates the structure and function of Tau including phosphorylation by the kinase 
catalytic domain of Src protein (Morris et al., 2011). Tau binds to microtubules through its four 
repeat domains. The proline rich region of Tau can bind to the src Homology-3 (SH3) domain of 




Tau exists as six isoforms which derive from alternative splicing of the microtubule-associated protein Tau 
(MAPT) gene consisting of 16 exons. This gene is located at position 17q21 which is over 100kb on the 
long arm of chromosome 17 and transcribes into a Tau primary transcript (Buée, et al., 2000). The Tau 
primary transcript comprises 13 exons as 4A, 6 and 8 are not transcribed in humans. Exons 2, 3 and 10 are 
adult brain specific and alternative splicing of these in the central nervous system results in six mRNAs 
which are translated into the six Tau isoforms as seen in Figure 1.4 with constitutive exons: 1, 4, 5, 7, 9, 
11, 12 and 13 (Buée, et al., 2000).  Exons 9, 10, 11 and 12 are each responsible for encoding a microtubule 
binding motif whereby each of these are imperfect copies of an 18 amino acid repeat which are separated 
by 13-14 amino acid inter-repeat sequences (Lee and Leugers, 2012). The presence or absence of exon 10 
determines whether a Tau isoform has four or three repeats, respectively, as seen highlighted in the panel 
on the right-hand side of Figure 1.4. It is these repeat regions, specifically residues 306-378 which form 









Figure 1.4: Schematic of the six human CNS Tau isoforms and two constructs (adapted from Buée, et al., 
2000 and Johnson and Stoothoff, 2004) – From N terminal (left) to C terminal (right): including ht40, ht39, 
ht34, ht37, ht24 and ht23 R1–4 indicates the four microtubule-binding domains encoded by exons 9–12. 




suggested that there are similar quantities of 3R and 4R Tau expressed in the cerebral cortex of adults. In 
addition to the six isoforms of Tau, there also exists ‘Big Tau’ expressed in the peripheral nervous system, 
which includes an additional exon at the N-terminal (Goedert et al., 1992 and Couchie et al., 1992). 
The two main domains of Tau isoforms are the N terminal projection and the microtubule binding repeat 
domains (R1-R4) as seen in Figure 1.5 which are also both largely hydrophilic making it a highly water-
soluble protein. The second half of the N terminal domain is acidic due to high proportion of Glutamic 
Acid and Aspartic Acid. This is followed by a Proline-rich region (P1 and P2) between residues 150-240 
whereby prolines are mainly preceded by either Serine or Threonine phosphorylation sites. Six PXXP 
motifs exist within P1 and P2 which allow proteins comprising SH3 domains to bind (Mandelkow and 
Mandelkow, 2012). Next comes the repeat domains (R1-R4) which is also forms the basic part of the 
protein and then the C-terminal tail (Kolarova et al., 2012). This suggests that Tau is a dipole protein as 
each domain possesses opposing charges to the other. The N terminal defines the intermolecular spacing 
between plasma membranes and bundled microtubules as well behaving as mediator between their 
interactions (Ganguly et al., 2015). It projects out from the microtubule surface to interact with other 
cytoskeletal elements including the neuronal plasma membrane and mitochondria; whereas the repeat 













Figure 1.5: Schematic of the amino acid sequence for 2N4R Tau: N1 and N2 encoded by exons 2 and 3 represent 
the polypeptide sequences; P1 and P2 represent the proline-rich regions; R1–4 encoded by exons 9-12 represent 
the microtubule-binding domains; 275VQIINK280 (R2) and 306VQIVYK311 (R3) are critical region sequences with β-
structure (Kolarova et al., 2012). 
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1.4.1 TAU PHOSPHORYLATION 
Tau is regulated by several post-translational modifications including oxidation (oxidation of cysteine 
residues results in disulphide cross-bridges), methylation (addition of methyl groups), glycation (addition 
of carbohydrate to lysines), acetylation (addition of acetyl groups to lysines) and phosphorylation 
(addition of phosphate groups). Phosphorylation is the most abundant and involves attaching negatively 
charged phospates to the side chains of serine, threonine and tyrosine, of which are 85 potential sites in 
Tau (Medina et al., 2016; Arendt et al., 2016).  KXGS motifs in Tau (residues 244-370) are key 
phosphorylation sites and are closely involved in both physiological functions and pathological 
dysfunctions of Tau through their participation in microtubule assembly and paired helical filament (PHF) 
aggregation, respectively. Kamat et al. (2016), suggested that Aβ promotes the production of reactive 
oxygen species and oxidative stress mediated hyperphophorylation of Tau, as seen in Figure 1.6. Behl, 
(2012) demonstrated the relationship that oxidative stress levels increased with age. It is also important 
to note that Aβ levels also increase with age.  Reactive oxygen species are chemically reactive molecules 
which cause oxidative stress upon breaching oxidant defences, resulting in damage to cells, including 
Figure 1.6: Synaptic dysfunction because of Aβ causing MAPK and mitochondrial oxidative stress 
mediated Tau hyper-phosphorylation (Kamat et al., 2016). 
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cellular lipids, DNA, RNA and proteins; contributing to ageing (Sayre et al., 2001). The reduction of 
molecular oxygen O2 results in the formation of superoxide (O2 + e− → ·O2−) which is the precursor of most 
reactive oxygen species (Turrens, 2003). Superoxide then reacts to produces hydrogen peroxide (2H+ + 
·O2− + ·O2− → H2O2 + O2). Hydrogen peroxide is then reduced to water (H2O2 + H2O2 → H2O + H2O + O2) or 
partially reduced to hydroxyl radical (H2O2 → HO · + ·OH) (Kissova et al., 2006). In AD the brain is 
excessively phosphorylated to the extent of around 3x that of the normal brain (Funk et al., 2014). 
Phosphorylation of Ser-262 (localised within a KXGS motif of the first repeat domain, as seen in Figure 
1.7) is believed to be the initiator of the phosphorylation cascade resulting in Tau hyper-phosphorylation. 
Mutation of either Ser-262 or Ser-356 into alanine is reported to rescue Tau microtubule assembly 
properties and reduce toxicity in wild type phosphorylated brain extracts (Yu et al., 2012). These motifs 






Figure 1.7: Schematic illustration of the main phosphorylation sites identified in Tau441 PHF from AD brains 




A list of phosphorylation sites identified in 2N4R Tau are summarised by the Hanger group, Muckle group 
and Kuret group in Table 1.1 (Morris et al., 2015 and Funk et al., 2014). Cytosolic Tau is usually maintained 
in an equilibrium through kinases and phosphatases which phosphorylate and dephosphorylate Tau, 
respectively (Kolarova et al., 2012). When protein kinases phosphorylate proteins, the newly covalently 
bound phosphate group changes the proteins structural conformation, resulting in activation, 
deactivation or altered protein function. Hyper-phosphorylation of Tau reduces its binding affinity to 
tubulin resulting in the disassembly of microtubules which interferes with axonal flow and the 








Table 1.1: 2N4R Tau phosphorylation sites from AD and control brains summarised by the Hanger group, Muckle group and Kuret group (Adapted 
from Kings College London, 2019). Residues highlighted in yellow have no currently identified associated kinase. Kinases involved in Tau 
phosphorylation are grouped into 3 classes: proline-directed protein kinases (blue), non-proline-directed kinases (black) and tyrosine kinases (red) 
(Morris et al., 2015; Funk et al., 2014). Abbreviations: 5' adenosine monophosphate-activated protein kinase (AMPK), Brain-specific kinase 1/2 
(BRSK1/2), Calcium-calmodulin kinase II, Cyclin-dependent kinase-5 (cdk5), Casein kinase 1 (CK1), Casein kinase 2 (CK2), Cyclic AMP-dependent protein 
kinase (PKA), Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), Glycogen synthase kinase-3 (GSK-3), Microtubule affinity-
regulating kinase (MARK), Mitogen and stress activated protein kinase-1 (MSK1), p42/p44 mitogen-activated protein kinases (ERKs1/2), p38 mitogen-
activated kinase (p38MAPK),  Protein kinase C (PKC), Protein kinase N (PKN), Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), 







1.4.2 TAU AGGREGATION 
Following hyperphophorylation, specifically T231, S396, S422 and S404 which promote filament formation 
of Tau (Cown and Muder, 2013; Alonso et al., 2004; Gamblin et al., 2003; Jackson et al., 2002). Increased 
concentrations of cytosolic and sequestered Tau begin to misfold, inducing a polymerisation cascade 
which assembles filaments through the repeat binding regions and some sequences in the C-terminus, 
whereas the rest of the N-terminus forms a fuzzy coat around the core amino acids 306-378 (Fitzpatrick 
et al., 2017). This aggregation cascade begins with Tau monomers which aggregate to form soluble dimers 
and larger oligomers. As aggregation increases these oligomers become increasingly insoluble and form 
off pathway oligomers or protofibrils which subsequently form mature fibrils and ultimately aggregate 
into NFTs of PHFs, as seen in Figure 1.8. Tau morphology and secondary structural transition are discussed 
in Sections 1.4.2 and 1.4.3, respectively. Tau aggregation without mutation, is a result of the suppression 
of phosphatases and/or the activation of Tau protein kinases (involving a loss of microtubule binding 
ability) and exposure to poly-anions (e.g. heparan sulphate) which bind Tau and promote the likelihood 
of Tau proteins interacting together and aggregating (Boutajangout et al., 2011). Contrarily, Arendt et al 
(2003), suggested that formation of hyper-phosphorylated Tau is a reversible phenomenon observed 
during hibernation. In addition to phosphorylation; glycation, acetylation and truncation have also been 
observed to promote aggregation of Tau (Funk et al., 2014). Two important nucleating sequences within 
the repeat domain are 275VQIINK280 and 306VQIVYK311; located at the beginning of R2 and R3, respectively 
(Mukrasch et al., 2005). R3 is present in all Tau isoforms, consistent with their shared ability to all form 
PHFs; R2 is only found in ht40, ht34 and ht24. The interaction of VQIINK and VQIVYK is believed to produce 






Figure 1.8: Schematic illustration of the Tau disassembly from microtubules and its aggregation cascade. Phosphorylation causes unordered 
Tau to transition into beta sheet structures and disassemble from microtubules. Monomeric Tau misfolds and forms off-pathway oligomers or 
dimers. Dimers form phosphorylated soluble oligomers and non-phosphorylated insoluble granular Tau oligomers. Oligomers form protofibrils, 
then fibrils and NFTs. 
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1.4.3 TAU MORPHOLOGY 
Tau straight filaments are ~10nm wide and PHFs typically have an average width of 10-20nm, average 
length of 530nm, and a half periodicity of 80nm (Pollanen and Bergeron, 2000, Sadqi et. al., 2002, Xu et. 
al., 2010, Morozova et. al., 2013). PHFs should look appear as two fibrils twisted around each other with 
the cross over repeats around 75-80nm and a varying width between 10-22nm; suggesting a single strand 
has a diameter of 10nm (Crowther and Wischik, 1985). PHFs from brains, recombinant proteins and 
different length Tau have similar dimensions when viewed under electron microscope as seen in Figure 
1.9A+C. This suggests that most of the protein comprising ~70% of residues (1-240 and 379-441) that 
makes up the fuzzy coat, offers little to the morphology due to their natively unordered structure as seen 
in Figure 1.9B (Drechsel et al., 2017 and Barghorn et al., 2004). 
Figure 1.9: Negative stained electron micrographs of PHFs. A: AD brain PFHs with arrowheads pointing 
to crossover repeats of ∼80nm (Mandelkow and Mandelkow., 2012). B: AD brain PHFs immunogold 
labelled using PHF1 (epitope S396/404) to emphasise the fuzzy coating (Rissman et al., 2012). C: 
K18ΔK280 Recombinant Tau PHFs (Madelkow and Mandelkow, 2012).  
A. B. C. 
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As PHFs accumulate, they form NFTs. The separate maturation states of NFTs are 0, 1, 2 and 3 which 
correspond to healthy cells, pretangles, classic NFTs and ghost tangles, respectively (Uematsu et al., 2017). 
These stages can be summarised by Figure 1.10. Ghost tangles are extracellular and are formed from the 






Figure 1.10: Monoclonal antibody DC8E8 immunostaining of A: human preclinical AD, B: clinically 
incipient AD, C: fully developed AD. Hippocampal immunostaining of D: pretangles, E: intracellular 
tangle, F: extracellular tangle. Scale bar: A-C 100 µm; D-F 10 µm (Kontsekova et al., 2014). 
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1.4.4 TAU SECONDARY STRUCTURE 
Native Tau has a very low secondary structure content of α-helix and ß-strands and so has an unordered 
secondary structure as determined by Circular Dichroism (CD). Pathogenic aggregation of Tau is 
manifested as a structural transition from unordered to β-sheet structure around some some hexapeptide 
motifs of the repeat domain which form the core of PHF’s and can be summarised as a nucleation 
elongation reaction. These core β-sheet sequences (residues 306-378) identically stack in register and in 
parallel to one another to form protofilaments, and then mate anti-parallell to one other. (Fitzpatrick et 
al., 2017). as seen in Figure 1.11.  
C. D. 
Figure 1.11: Tau PHF protofilament core comprising two microtubule-binding repeats; R3-R4, 
demonsrating in register and in parallel β-sheet stacking. A: Rendered secondary structure view of the 
protofilament core, B:  Demonstrates backbone atoms similarity between SF (green) and PHF (blue) 
protofilament cores C: Cross-section of the SF cryo-EM structure D: Cross-section of the PHF cryo-EM 





Using X-ray microcrystallography, Sawaya et al., (2007) suggested that the VQIVYK hexapeptide forms a 
Class 1 steric zipper, in which β-strands are stacked into parallel, antifacial β-sheets which stack face to 
face with sheet edges facing up. This can be visualised by Figure 1.12 which also demonstrates the 
symmetry relationship between sheet mates by a 180° rotation about the arrow. This relationship allows 
side chains to interlock between the side chains of their sheet mate and when viewing these 
protofilaments down the fibril axis, the interlocking side chains resemble teeth from a zipper and so are 
dubbed steric zippers (Eisenberg and Sawaya, 2017, Sawaya et al., 2007). The term ‘unordered’ will be 
used instead of ‘random coil’ throughout this thesis as native monomeric Tau does not have a random 
structure and neither is it a coil. It has a structure, but it does not follow a well-defined secondary structure 
motif like α-helix or β-sheet. Turns also have less defined bond angles and so are also unordered.   
 
Figure 1.12: A: Illustrative example of a Class 1 steric zipper amyloid spine. β-strands have an N and C 
terminus, front/back faces and up/down edges. Arrow indicates symmetry axes demonstrating that the 
sheets are related by a 180° rotation.  Adaptaed from (Eisenberg and Sawaya, 2017). B: Example of 




1.4.5 TAU TOXICITY & PROPAGATION 
There is some dispute as to which species of Tau are toxic (Eisenberg and Sawaya, 2017). Bakota and 
Brandt, (2016) stated that it is still currently unclear whether it is Tau oligomers or higher aggregates 
which are most toxic. They also suggested that higher aggregates such as PHFs or NFTs may be a self 
defence mechanism whereby cells store toxic misfolded Tau monomers and oligomers in a more inert 
form. As a result, approaches to disassemble higher aggregates may exacerbate cognitive impairment. It 
is difficult to conceive however that a neuron can function effectively when it contains tangles occupying 
most of the cytoplasm which inevitably result as ghost tangles which demonstrate cell death. It is generally 
appreciated that soluble Tau oligomers are most toxic, however, there is some evidence to suggest that 
not all oligomers are toxic and that it remains unknown which size oligomers are responsible for toxicity 
and what conformation and phosphorylation state are they in (Cowan and Mudher, 2013).  For example, 
there is currently evidence of monomeric Tau and granular Tau oligomers (GTOs) forming PHFs, however 
no evidence suggesting that small soluble oligomers can form GTOs (Maeda et al., 2007). It is not yet 
understood if GTOs are a neuroprotective strategy although Cowan et al. (2015), illustrated in a Drosophila 
model of tauopathy that GTOs are not phosphorylated and are not toxic, suggesting they could be an 
alternative aggregation pathway to PHFs (Cowan et al., 2015). GTOs are not completely understood with 
regards to potential toxicity because although insoluble, they are too small to sediment in current assays 
and do not enter PAGE resolving gels (Maeda et al., 2007). On the other hand, soluble Tau oligomers are 
highly phosphorylated and believed to be toxic (Maeda et al., 2018; Cowen et al., 2015). There is a lot of 
evidence in both Drosophila and mouse models suggesting that neurodegeneration occurs without the 
presence of NFTs (Mudher et al., 2004; Wittman et al., 2001; Andorfer et al., 2005). Using inducible mouse 
models Eckermann et al. (2007) and Spires et al. (2006), expressed full length Tau-ΔK280 or P301L, 
respectively. Expression was switched off after NFTs had formed but cell loss was stabilised despite the 
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presence of NFTs, suggesting aggregates smaller than NFTs cause degeneration but larger insoluble 
aggregates are less toxic, suggesting NFT formation is neuroprotective.  
Tau propagation has been demonstrated to intracellularly spread in a “prion-like” manner. Prion stands 
for “proteinaceous infectious particle” (Prusiner, 1982).  It achieves this by infiltrating healthy neurones 
and promoting pathogenic misfolding of stable Tau and inducing aggregation through templated seeding, 
without being infectious to other humans (Frost et al., 2009; Goedert and Spillantini, 2017, Mudher et al., 
2017). The initial transformation from healthy monomeric Tau into aberrant Tau is still not properly 
characterised (Mudher et al., 2017).  Clavaguera et al. (2009), suggested that oligodendrocytes and nerve 
cell processes are the main areas of filament induction. However, oligomers have also been demonstrated 
to induce NFT pathology in various mouse models (Hu et al., 2016; Wu et al., 2013, Lasagna-Reeves et al., 
2012). Approximately 90% of extracellular Tau is free Tau.  Mechanisms by which Tau has been suggested 
to potentially leave its host cell and infiltrate its recipient cell include exocytosis and heparan sulphate 
proteoglycan (HSPG), Amyloid precursor protein (APP) or non-receptor-mediated 
endocytosis/macropinocytosis, diffusion, in ectosomes or exosomes and through nanotubes (Dujardin et 
al., 2014; Wang et al., 2017; Simon et al., 2012). Exact mechanisms how free Tau enters the synaptic cleft 
remains unknown, but this species is believed to be mainly un-phosphorylated (Mohammed et al., 2017). 
It is believed that Tau transported in vesicles is phosphorylated and so pathogenic, however the 
mechanism how it is chaperoned via vesicles, how it exits its vesicle and then how it enters its recipient 






1.4.6 OTHER TAUOPATHIES 
A list of Tauopathies and their Tau isoforms identified with are summarised by Table 1.2. The most 
prevalent Tauopathies include, progressive supranuclear palsy (PSP), Argyrophilic grain disease (AGD), 
Corticobasal degeneration (CBD), Pick’s disease (PiD), Frontotemporal dementia and parkinsonism linked 
to chromosome 17 (FTDP-17), Post‐encephalitic parkinsonism, Parkinsonism-dementia complex (PDC) 
Guam, Guadeloupean parkinsonism, Dementia pugalistica and Down’s syndrome (Williams, 2006). Other 
diseases with Tau neuropathology not summarised in Table 1.2 include aging-related Tau astrogliopathy, 
Hallevorden–Spatz disease, Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, Lewy 
body disease, Meningioangiomatosis, Post-encephalitic Parkinsonism, Prion protein cerebral amyloid 
angiopathy, Progressive subcortical gliosis, Subacute sclerosing panencephalitis and Tuberous Sclerosis 
(Castellani and Perry, 2019). There are two Tau mutations in FTDP‐17 which increase aggregation 
propensity of Tau; ΔK280 and P301L (Mandelkow et al., 2007). Aside from NFTs, other large non-fibrillar 
Tau aggregates include Pick bodies and Argyrophilic grains. Most Tauopathies are associated with 4R-Tau 
pathology except PiD which predominantly has 3R-Tau and AD which has both 3R and 4R-Tau inclusions 
(Mudher et al., 2017 and Buee and Delacourte, 1999). According to Grinberg et al. (2013), acetylated Tau 
is found in a all Tauopathies except AGD, which is characterised by neuropil grains, NFTs and 
oligodendroglial coiled bodies; suggesting it to be a distinct Tauopathy. Tau filament morphologies vary 
between diseases, despite deriving from the same Tau isoforms (Goedert and Spillantini, 2017). For 
example, PiD straight filaments, PSP twisted filaments and CBD twisted ribbons have diameters of 15-

























Table 1.2: Four classes of Tau isoform aggregation and respective diseases they are found in. Class I is 
characterised by aggregation of all six isoforms. Class II and Class II are characterised by aggregation of Tau 
isoforms containing four and three repeat domains. Class IV is characterised by the aggregation of Tay 
lacking exons 2 and 3 (Adapted from Sergeant et al., 2008). 
Alzheimer's disease
Amyotrophic lateral sclerosis
Cerebral aging (over 75 years)
Chronic traumatic encephalopathy
Dementia pugalistica





Niemann-Pick disease type C












Aggregation of six Tau isoforms
Class III
Aggregation of 3R Tau
Class IV
Aggregation Tau lacking exons 2 and 3
Class II
Aggregation of 4R Tau
Exon 2 Exon 3 Exon 10
Class I 
Aggregation of six Tau isoforms 
Class II 
ggregation of 4R Tau 
Class III 
Aggregation of 3R Tau 
Class IV 
Aggregation of Tau lacking exons 2 and 3 
Alzheimer's disease 
Amyotrophic lateral sclerosis 
Cerebral aging (over 75 years) 
Chronic traumatic encephalopathy 
Dementia pugalistica 
Diffuse neurofilament tangles with calcification 
Down's syndrome 
Familial British dementia 
FTDP-17 
Guadeloupean Parkinsonism 
Niemann-Pick isease type C 
arkinsonism–dementia complex of Guam 
ost-encephalitic parkinsonism 
Primary age-related Tauopathy 
 
Argyrophilic grain disease 
Corticobasal degeneration 
FTDP-17 








1.5 CURRENT THERAPEAUTIC STRATEGIES 
The only approved drugs for the treatment of AD by the FDA modulate neurotransmission and only 
provide symptomatic treatment as opposed to altering the disease course. These include 
acetylcholinesterase inhibitors and an 1.5.2 N-methyl-D-aspartate (NMDA) receptor antagonist. Anand et 
al., (2014) summarised the potential therapeutic strategies for AD in Appendix B. 
1.5.1 ACETYLCHOLINESTERASE INHIBITORS 
Cholinergic hypothesis originated from research which demonstrated that cholinergic neurones located 
through the low to the high areas of the brain involved in memory are selectively lost in early AD; thereby 
effecting short term memory by diminishing nerve cell communication. This theory suggests that levels of 
choline acetyltransferase and pyruvate dehydrogenase complex decrease, and as they are responsible for 
the synthesis of acetylcholine, results in the decrease of cholinergic transmission (Kuca et al., 2016).  
Preganglionic fibers secrete acetylcholine and bind either postganglionic muscarinic or nicotinic receptors 
which innervate skeletal muscle and peripheral tissues, respectively. Upon acetylcholine stimulation, 
muscarinic receptors form G coupled-protein receptor complexes to open ion channels, whereas nicotinic 
receptors use ligand gated ion channels which open directly upon stimulation. Diminished cholinergic 
transmission causes impairment of muscarinic receptor function, especially M1 receptors found 
abundantly in the brain (Pákáski and Kálmán, 2008). On top of this impairment of muscarinic receptors, 
nicotinic receptor numbers are diminished, (especially subtypes α7 and α4β2) due to the high affinity of 
toxic Aβ to these receptors (Okada et al., 2013). This exacerbates the reduction in cholinergic 
transmission. This decrease in cholinergic transmission is associated with a reduction in cognitive function 
and so it can be postulated that amyloid and cholinergic theories may well be intertwined cascades. Figure 
1.13 demonstrates how acetycholine is broken down in the synaptic cleft by acetylcholinesterase. As a 
result, drugs which inhibit the decomposition of acetylcholine or activate central M1 muscarinic and 
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nicotinic receptors have beneficial effects for dementia patients (Kuca et al., 2016). However, there are 
currently no M1 muscarinic receptor agonists for AD on the market, despite keen interest from the 
pharmaceutical industry. This is because although they are effective at improving cognition, however in 
high doses they have negative side effects which halted further clinical trials (Greig et al., 2013). 
Current drugs are mainly acetylcholinesterase inhibitors and include Donepezil (Acricept), Galantamine 
(Reminyl) and Rivastigmine (Exelon). The downside to these drugs is that they are only for symptomatic 
treatment and can only delay cognitive decline for 6-12 months in roughly 50% of patients with AD 
(Blennow et al., 2006). They also have side effects such as nausea, vomiting, loss of appetite and diarrhoea 
being the mains ones and muscle cramps fatigue, dizziness and insomnia being the others. 
Gastrointestinal side effects can be controlled by beginning treatment with low doses and consuming with 




Figure 1.13: Mechanism of the cholinergic system (Scarpini et al., 2003). Choline acetyltransferase 
catalyses Acetyl CoA + Choline to form Acetylcholine which enters the synaptic cleft, binds to 
receptors and is degraded back into Acetate and Choline. 
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1.5.2 NMDA RECEPTOR ANTAGONIST 
Memantine is a non-competitive, voltage dependent NMDA receptor antagonist which effects 
glutamatergic transmission dysfunction, as seen in Figure 1.14. It is currently the only drug used in 
advanced AD, however its effect is modest.  In normal, resting physiological brain conditions NMDA 
receptor channels are blocked by Mg2+ ions which are revealed upon a glutamate synaptic signal. When 
this signal occurs, the post-synaptic membrane depolarises, allowing Ca2+ to enter the post-synaptic 
neurone (Parsons et al., 2013). Glutamate and its interactions with NMDA receptor are involved in 
learning and memory, however in abnormal circumstances such as in AD, excess glutamate reduces NMDA 
receptor function which is fatal to nerve cells. In AD, glutamate and amyloid cause continuous membrane 
depolarisation which removes Mg2+ from NMDA channels and therefore allow Ca2+ to continuously flow 
into the post-synaptic neurone resulting in constant stimulation at rest. This excess stimulation of NMDA 
receptors causes excitotoxicity. NMDA receptor activation along with Aβ toxicity alters the function of the 
synapse which is associated with the inhibition of protein phosphatase and hyper-phosphorylation of Tau. 
Mediation of oxidative stress and production of reactive oxygen species through NMDA receptor 
activation may be one of the main causes for Tau hyper-phosphorylation and synapse dysfunction (Kamat 
et al., 2016). This excess in glutamate also causes impairment of mitochondrial functions by activating the 
permeability transition pores, increases release of cytochrome c (due to reductions in cytochrome c 
oxidase) and reduces ATP levels along with the simultaneous production of reactive oxygen species.  
Memantine prevents synapse dysfunction from excess stimulation of glutamate to NMDA receptors 
through non-competitive binding with a stronger affinity and voltage dependency than Mg2+ ions (Parsons 
et al., 2013). Memantine restores deficits in cognition and also seems to reduce levels of insoluble and 
soluble Aβ in triple-transgenic mice with AD like pathology and protect against associated synaptic 
deterioration (Martinez-Coria et al., 2010). Ultimately the mechanisms by which Memantine links to its 
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clinical efficacy in AD are still not yet fully understood. Li et al., (2004) discovered using a hippocampal 
slice culture model that memantine may also influence PP2A as it reversed Tau hyper-phosphorylation 
induced by okadaic acid. So perhaps Memantine has pleiotropic mechanisms of action against AD. 
 
1.6 TAU RELATED PIPELINE TREATMENTS 
Over 70% of Aβ targeting drugs have been terminated or become inactive, as seen in Appendix A. 
Following these developments and research suggesting that Tau pathology correlates more closely with 
clinical symptoms of AD than Aβ does, Tau targeting drugs has become a new focus. Table 1.3 summarises 
the compounds targeting Tau that have been taken forward into clinical trials. The only current Tau 
aggregation inhibitor in clinical trials is LMTM (TauRx Therapeutics) and the only peptide in clinical trials 
is the NAPVSIPQ (NAP) peptide (Allon Therapeutics Inc. / Paladin Labs Inc.). LMTM and NAP are discussed 
in Sections 1.6.1.2 and 1.6.1.3, respectively. 




Drug Company Mechanism of Action Indication Clinical Phase Clinical Trial Identifier Status 
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AbbVie Passive Immunotherapy Early AD Phase 2 NCT03712787 Active 
12 JNJ-63733657 Janssen Passive Immunotherapy Mild AD Phase 1 NCT03375697 Active 



















Passive Immunotherapy AD Phase 1 NCT03605082 Active 
18 CCT020312 Academic PERK Activator 
Progressive 
Supranuclear Palsy 






c-Abl inhibitor AD + Parkinsons Phase 2 NCT02954978 Active 
20 AZP2006 AlzProtect Autophagy Stimulator AD or Tauopathies Phase 1 N/A Active 
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21 MK-8719 Alectos Therapeutics O-GlcNAcase inhibitor 
Progressive 
Supranuclear Palsy 
Phase 1 N/A Active 













Phase 1 N/A Active 
25 IVIg 
Baxalta now part of 
Shire 





Table 1.3: Current pipeline treatments in clinical development for Tauopathies associated with AD. 19 are active, 2 are 




Immunotherapy is one of the most promising approaches to treat AD and the past 10 years has seen 
a lot of emphasis on preventing the aggregation of Aβ in the brain (Kuca et al., 2016). Active 
immunotherapy involves inducing a humoral immune response whilst passive immunotherapy 
involves administering monoclonal antibodies, as summarised by Figure 1.15. The preferred method 
although expensive is passive immunotherapy as active immunotherapy could potentially induce Tau 
pathology as seen in transgenic mice studies (Clavaguera et al., 2014). Chronic administration however 
may lead to the formation of anti anti-bodies which could neautralise the therapy. Lovestone et al., 
(2015) and Agadjanyan et al., (2015) suggested that immunotherapy aimed at targeting Tau pathology 
will have greater therapeutic impact as Tau neurofibrillary tangles correlate very strongly with 
cognitive deterioration in AD patients. Clearance of Aβ plaques did not appear to stop progression of 
AD and Aβ immunotherapy approaches do not affect tangle pathology (Holmes et al., 2008). Boche et 
al., (2010) and Serrano-Pozo et al., (2010) mentioned that only plaque associated Tau had been 
reduced with application of Aβ immunotherapy. Oddo et al., (2004) used the 3XTg mouse model for 
Aβ targeted immunotherapy and discovered a reduction in early Tau pathology but not in hyper-
phosphorylated or aggregated Tau, suggesting an appropriate focus on oligomeric Tau.  
Figure 1.15: Schematic of active and passive immunotherapy approaches to clearing Aβ (Winblad et al., 
2014). mAb, monoclonal antibody; BBB, blood–brain barrier; CNS, central nervous system. 
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Goyal et al. (2017), summarised the physiochemical influences for BBB permeability to include 
molecular weight, charge, lipid solubility, molecule size and surface activity. Positively charged small 
molecules which are <600 Da and form <8 hydrogen bonds can cross the blood brain barrier (BBB) via 
lipid mediated diffusion; however, these properties are absent in most drugs (Partridge 2012). The 
BBB consists of brain capillary endothelial cells and tight junctions which restrict the transport of 
molecules in order to protect the brain. As a result, the development of therapeutic antibodies for 
neurodegenerative diseases are limited by their poor BBB permeability and in fact, 95% of molecules 
for drug development stumble upon this hurdle (Dong, 2018). Georgieva et al. (2014) summarised 
mechanisms of molecular transport across the BBB in Figure 1.16. Drugs can be enhanced through 
reengineering to utilise endogenous transport systems such as carrier mediated transport and 
receptor mediated transcytosis. (Partridge, 2012). BBB transport mechanisms described for peptides 
include: 1) passive diffusion – mainly associated with lipophilic peptides, 2) carrier-mediated 
transcytosis - associated with transporters at the endothelial surface, 3) receptor mediated 
transcytosis – associated with a specific receptor and 4) adsorptive-mediated transcytosis - associated 
with non-specific positively charged peptides (Dong, 2018).  
Figure 1.16: Schematic of mechanisms by which molecules can cross the BBB include: (a) diffusion, which is 
non-saturable and driven by a concentration gradient often involving hydrophobic molecules (b) paracellular 
transport, involving soluble molecules (c) carrier-mediated transport, e.g. gluocse (d) receptor mediated 
transcytosis, e.g.insulin transporter (e) adsorptive transcytosis, involving non specific positively charged 
amino acids and (f) active efflux, involving proton pump efflux transporters (Georgieva et al., 2014). 
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Current pipeline anti-Tau active immunotherapies include AADVac-1 (Axon Neuroscience SE), ACI-35 
(Janssen/AC Immune) and IVIg (Baxalta now part of Shire). Current pipeline anti-Tau passive 
immunotherapries include BMS-986168 (Biogen/Bristol-Myers Squibb), ABBV-8E12 (AbbVie), 
RO7105705 (AC Immune/Genentech Inc.), UCB0107 (UCB Biopharma S.P.R.L.), NI-105 (Biogen), JNJ-
63733657 (Janssen) and LY3303560 (Eli Lilly). 
AADvac-1 (Axon Neuroscience SE) is an immune-stimulant phospho-tau specific vaccine which is 
liposome based containing synthetic Tau peptides from amino acids 294-305 and coupled to the 
carrier metalloprotein ‘keyhole limpet hemocyanin’ with an aluminium hydroxide adjuvant to 
promote a humoral immune response and stimulate antibody production (Kontsekova et al., 2014). 
This drug has demonstrated safety, immunogenicity and a preference for hyperphosphorylated 
truncated Tau than healthy Tau (Novak et al., 2017; Zilka et al., 2006. This drug is currently in a phase 
II safety and efficacy trial for patients with mild to moderate Alzheimer’s disease.ACI-35 (Janssen/AC 
Immune) is an immune-stimulant phospho-tau specific vaccine which is liposome based containing 16 
copies of synthetic Tau fragments phosphorylated at residues S396 and S404 anchored to the lipid 
bilayer with a monophosphoryl lipid A adjuvant (Bakota and Brandt, 2016 and Hickman et al., 2011). 
As a result, autoimmune B or T cell response to normal Tau is voided. This drug completed a phase Ib 
randomized, double blind, placebo controlled clinical trial to evaluate safety, immunogenicity and 
tolerability for mild to moderate, however results have not yet been published (Medina et al., 2018; 
AC Immune, 2015).  Theunis et al., (2013) reported that this drug is safe and active based on a mouse 
tauopathy model. It is suggested this drug creates an extracellular sink to remove all extracellular Tau 
present in the CSF and tau leaked from neurones. By removing extracellular tau this may inhibit the 
propagation of Tau from one neurone to another (Yanamandra et al., 2013). It is also suggested based 
on brain slices that the monoclonal anti-tau antibodies can be taken up by cells (Gu et al., 2013). 
IVIg (Baxalta now part of Shire) is a polyclonal serum of IgG derived from human plasma and believed 
to contain Tau specific antibodies targeting recombinant Tau residues 155-421 (Krestova et al., 2017). 
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When tested in a phase III, randomised, double blind, placebo controlled clinical trial, it demonstrated 
good tolerability with low doses over 18 months, however failed to demonstrate improvements in 
cognition or function for participants with mild-moderate AD (Relkin et al., 2017). 
ABBV-8E12 (AbbVie) is an IgG4 monoclonal antibody targeting N-terminal Tau amino acid residues 25-
30 with the aim of inhibiting seeding by clearing extracellular Tau (West et al., 2017). Safety and 
tolerablility was demonstrated when administered as 50mg/kg injections. RO7105705 (AC 
Immune/Genentech Inc.) is is an IgG4 monoclonal antibody also targeted at the N-terminus of 
extracellular Tau without discrimination between species of Tau in healthy and disease brains. BMS-
986168 (Biogen/Bristol-Myers Squibb) is an IgG4 monoclonal antibody and again targets the N-
terminus of Tau but with the aim of interacting with N-terminal fragments of Tau to reduce their 
involvement in secondary Aβ pathology (Novak et al., 2018). 
UCB0107 (UCB Biopharma S.P.R.L.) is a monoclonal antibody targeteting N-terminal Tau amino acid 
residues 235-246 in the second proline rich region with the aim of inhibiting seeding by interfering 
with cell to cell propagation of Tau; previously demonstrated in cell and mouse models. Alzforum 
(2019b), stated that according to Courade, other antibodies targeting phosphorylated S202/T205 in 
the Tau N-terminus only partially inhibited seeding due to heterogeneity between seed 
phosphorylation states. This further highlights the importance of not only targeting pathogenic 
phoshorylated Tau, but also different variants of pathogenic Tau which have different phosphorylation 
profiles. UCB0107 however has demonstrated almost 100% inhibition at 300 nM, performing equally 
effectively in Tau isolated from PSP and frontotemporal dementia.  
NI-105 (Biogen) is an IgG1 monoclonal antibody classified as a pan-Tau antibody which can interact 
with monomeric and fibrillar Tau species without discrimination for healthy and disease Tau 
(Czerkovicz et al., 2018). JNJ-63733657 (Janssen) has an undisclosed targeting region however 
presumably the mid region of Tau and aims to eliminate Tau seeds (Novak et al., 2018). LY3303560 
(Eli Lilly) is a monoclonal IgG1 antibody derived from the MC1 antibody which targets amino acid 
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residues 313-322 entailing the VQIVYK sequence and residues 7-9 in the third repeat domain and the 
N-terminus, respectively (Novak et al., 2018; Jicha et al., 1997). According to Riazul et al. (2017) it 
priorises selectivity of aggregated Tau rather than monomeric Tau. 
1.6.2 TAU AGGREGATION INHIBITORS 
TRx0237 (LMTM) - TauRx Therapeautics 
The first generation of Tau aggregation inhibitors taken forward by TauRx Therapeautics was 
Methylene blue (“Rember”) and was claimed to block Tau aggregation based on a phase 2 clinical trial 
which compared oral 30, 60 and 100 mg. Rember was reported to demonstrate benefits in mild-
moderate AD and cognition for the two lower doses. It was claimed that the 100 mg dose did not work 
due to interactions with gelatine in the capsule wall. Rember exists in an equilibrium of reduced and 
oxidised forms. TRx0237 (leucomethylthioninium) is a stabilised and reduced version of Rember 
(methylthioninium) which has improved bio-availability and tolerability. This compound is also 
uncharged colorless, unlike Rember which is a blue dye. Braddeley et al. (2015), demonstrated that 
LMTM had increased uptake into red blood cells in vitro and in vivo. They also demonstrated that food 
interfered with absorption of Rember, but not TRx0237 and that Rember was ionised at intestinal pH, 
but TRx0237 was not. Phase 3 clincal trial NCT00515333 demonstrated that TRx0237 failed to slow 
cognitive decline in mild-moderate AD patients (ClinicalTrials.gov, 2008). A beneit was claimed for a 
small sub-group not on other AD drugs, however controversially the statistical analysis of the research 
was flawed as the sub-group was compared with the placebo group which included individuals on 
other AD drugs (Alzforum 2016; Gauthier et al., 2016). Crowe et al., (2013) reported that in 1996 
methylene blue elicited oxidation when incubated in vitro with Tau which may involve oxidation of 
cysteines to disulphides in the microtubule binding region. When incubated with 4R Tau this oxidation 
inhibited fibrilisation through intramolecular bonding of the two cysteine residues in 4R Tau. However, 
when 3R Tau is oxidised it promoted intermolecular bonding to form dimers capable of fibrilisation as 
3R Tau has only 1 cysteine residue. Zweckstetter, (2013) mentioned that according to his research the 
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metabolites of methylene blue; azure A and azure B, modify cysteine residues to sulphenic, sulphinic 
and sulphonic acids Zweckstetter, (2013) confirming methylene blue induced oxidation of cysteine 
residues. Daebel et al., (2012) used NMR spectroscopy to show that cysteine residues upon oxidation 
cause conformational changes in the Tau second hexapeptide. Methylene blue has pleiotropic 
properties which allows various therapeutic uses such as in non-neurodegenerative disorders such as 
methemoglobinemia where it accelerates enzymatic reduction of methemoglobin. As a result, it 
should not be exclusively considered as a Tau based therapy (Bakota and Brandt, 2016).  
1.6.3 MICROTUBULE PEPTIDE STABILISERS 
NAP (Davunetide) 
This intranasal neuropeptide therapy entails a sequence of eight amino acids (NAPVSIPQ) derived from 
the Activity-dependent neuroprotective protein (ADNP) which is essential for brain formation, 
cognitive function and regulates RNA transcription and splicing (Gozes et al., 2014). Deficiencies in 
ADNP leads to Tauopathies and administration of NAP to AD mice represented an increase in ADNP 
(Fernandez-Montesinos et al., 2010). NAP protects microtubules by enhancing Tau-microtubule 
interaction 20-fold. It achieves this through its ADNP association motif ‘SIP’ that binds to microtubule 
end protein1/3 (EB) which then interacts with microtubule growing ends and Tau (Ivashko-Pachima et 
al., 2017; Sayas et al., 2015; Oz et al., 2014). NAP has also demonstrated to stimulate neurite growth 
and synapse formation (Ivashko-Pachima et al., 2017). Matsuoka et al., (2008) discovered that NAP 
reduces Tau hyper-phosphorylation and stabilises microtubules. It was shown to reduce Tau hyper-
phosphorylation in mice over expressing α-synuclein for a Parkinsons disease model as well as improve 
their behavioural deficits (Magen et al., 2014). There definitely is a link as phase II clinical trials in 
patients with mild cognitive impairment showed improved cognition and the drug also proved to be 
safe and well tolerated (Morimoto et al., 2013). Bakota and Brandt (2016), reported that existing 
evidence for a direct relation between NAP and Tau remains weak and so further research is required. 
They also suggested the drug to have pleiotropic effects as intranasal administration lowered levels of 
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Aβ1-40 and 1-42 and Tau hyperphosphorylation in triple transgenic AD mice (expressing the APPswe, 
TauP301L, and   PS1M146V   transgenes) and protected against oxidative stress and zinc intoxication 
(Matsouka et al., 2007; Gozes et al., 2005; Divinski et al., 2006, respectively). Zinc intoxication results 
in the breakdown of microtubules, however NAP protects microtubules by promoting reorganisation 
(Gozes et al., 2005). Matsouka et al. (2008), explained using a “pure” Tauopathy mouse model that 
mice treated with NAP over 6 months performed better in the Morris water maze. However, NAP 
failed to show efficacy in a clinical trial for progressive supranuclear palsy which is a pure Tauopathy. 
It may be possible that this drug is valid for AD but not all Tauopathies (Giacobini, and Gold, 2013; Oz 


















2. AIMS AND OBJECTIVES 
Aggregation of Tau protein plays important roles in neurodegenerative diseases such as AD. The two 
following sequences are essential for Tau aggregation: 275VQIINK280 and 306VQIVYK311 which are found 
in R3 and R4 Tau isoforms, respectively. This project aims to develop effective peptide-based inhibitors 
against these specifically stated binding sequences to prevent Tau from pathogenically aggregating. 
This project aims to demonstrate this by: 
1) In silico investigations of potential binding sequences and binding locations using two aggregation 
hot spot prediction softwares Aggrescan/Camsol and docking software Molsoft ICM-Pro, respectively. 
2) In vitro investigations of the peptides listed in Table 2.1 in their ability to inhibit Tau aggregation. 
Lead peptide was N-methylated or retro-inverted to improve peptide stability. Peptide N- and C-
termini were acetylated and amidated, respectively, to mimic native protein and improve activity. 
Peptide ID Sequence Purity % 
AG01 Ac - R G V Q I I N K G R - NH2 >90 
AG02 Ac - R G V Q I V Y K G R - NH2 >90 
AG02R4 Ac - R R G V Q I V Y K G R R - NH2 >90 
AG02R5 Ac - R G V Q I V Y K G R R R R - NH2 >90 
AGR502 Ac - R R R R G V Q I V Y K G R -N H2 >90 
AG02PR5 Ac - R G V Q I V Y K P G R R R R - NH2 >90 
AG02R6 Ac - R R R G V Q I V Y K G R R R - NH2 >90 
AG02R9 Ac - R G V Q I V Y K G R R R R R R R R - NH2 >90 
AG02TAT Ac - R G V Q I V Y K G R Y G R K K R R Q R R R - NH2 >90 
AG02∆I Ac - R G V Q K(Ac) V Y K G R - NH2 >90 
AG02∆V Ac - R G V Q I K(Ac) Y K G R - NH2 >90 
AG03 Ac - R G V Q I K(Ac) Y K P G R R R R R R R R - NH2 >95 
AG03-Cys Ac - R G V Q I K(Ac) Y K P G R R R R R R R R C - OH >95 
Scramble AG03 Ac – R G Q P K I K(Ac) Y V G R R R R R R R R - NH2 >95 
AG03M Ac - R G V(m) Q I(m) K(Ac) Y(m) K P(m) G R R R R R R R R - NH2 >95 
RI-AG03 Ac - r r r r r r r r G p k y k(ac) i q v G r - NH2 >95 
FAM-RI-AG03 Ac - k(FAM) r r r r r r r r G p k y k(ac) i q v G r - NH2 >95 
Poly-R R R R R R R R R R - NH2 >95 




Table 2.1 List of peptide inhibitor designs customly synthesised for research in this thesis. 
Underlined sequence corresponds to Tau binding region. Peptide inhibitors were custom made by 
Peptide Synthetics (Fareham, UK) with >90% purity and Severn Biotech (Kidderminster, UK) with 




3) In vitro experiment to investigate effectiveness of the lead peptide when attached to liposomes. 
4) In vitro experiments to investigate peptide stability of the lead peptide for suitability as a drug 
candidate in vivo using N-methylation (AG03M [Ac-RGV(m)QI(m)K(Ac)Y(m)KP(m)GRRRRRRRR-NH2]) 
and retro-inversion and (RI-AG03 [Ac-rrrrrrrrGpkyk(ac)iqvGr-NH2]) to stabilise the peptide. These 
experiments include testing against enzymatic degregation and temperature stability.  
5) In vitro experiments to investigate toxicity and cell penetration of the retro-inverted lead peptide 
candidate (RI-AG03 [Ac-rrrrrrrrGpkyk(ac)iqvGr-NH2]) for suitability as a drug candidate in vivo using 
HEK-293 cell lines. 
6) In vivo experiments to investigate the effects of feeding the lead peptide candidate (RI-AG03 [Ac-
rrrrrrrrGpkyk(ac)iqvGr-NH2]) to a rough-eye Drosophila model of Tauopathy by observing any 
















3. MATERIALS AND METHODS 
3.1 DESIGNING PEPTIDE INHIBITORS 
 
3.1.1 AGGRESCAN AND CAMSOL INTRINSIC 
 
Two web-based softwares were utilised to predict potential aggregation prone sequences of full 
length Tau441: 
1. AGGRESCAN : http://bioinf.uab.es/aggrescan (Conchillo-Solé et al., 2007). 
2. CamSol Intrinsic : http://www-mvsoftware.ch.cam.ac.uk  (Sormanni et al., 2015 and 
Sormanni et al., 2017). 
In FASTA format the full length Tau441 sequence was inputted: 
“MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP 
TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG HVTQARMVSK SKDGTGSDDK 
KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT 
REPKKVAVVR TPPKSPSSAK SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV 
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI THVPGGGNKK IETHKLTFRE 
NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV DSPQLATLAD EVSASLAKQG L” 
AGGRESCAN service was run using Mandrake Linux 9.0 on a Pentium 4 1300 MHz (willamette) with 
1GB RDRAM, using experimental data derived from de Groot et al. (2006), AGGRESCAN calculated the 
aggregation propensity value for each amino acid residue (a3v), highlighted regions above the 
precalculated threshold and the regions predicted to be potential aggregation “hot spots”. NH3+ and 
COO- were added to the N and C terminus of each peptide sequence, respectively, to quantify charge 
effects. The a3v average (a4v) was calculated using sliding windows (5 for < 75 residues, 7 for < 175 
residues, 9 for < 300 residues, and 11 for > 300 residues) and compared with 57 amyloidogenic 
proteins with experimentally known “hot spot” locations. Peptide aggregation profiles were defined 
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as the a4v. The sum of a4v and average of a3v, divided by the sequence (a4vSS and a3vSA, 
respectively) were calculated. “Hot spots” were defined as regions (excluding regions containing 
proline) with ≥ 5 continuous residues with an a4v greater than the “hot spot” threshold. The average 
a4v from each “hot spot” was calculated (a4vAHS). The area of the aggregation profile greater than 
the hot spot threshold (AAT), the total area and the area greater than the hot spot threshold of each 
hot spot, were integrated using the trapezoidal rule. The normalised a4vSS value across up to 100 
residues was finally calculated and is termed the Na4vSS. Results were generated in both tabulated 
and graphical formats for the entire sequence (Conchillo-Solé et al., 2007). 
CamSol calculated and scored the intrinsic solubility profile of Tau and for regions within the amino 
acid sequence whereby scores >1 denoted high solubility and scores <-1 denoted poor solubility 
(Sormanni et al., 2015). High solubility and poor solubility were colour coded blue and red, 
respectively. The CamSol method employs four specific steps: calulating the residue intrinsic solubility 
profile, calculating structural correction, identifying suitable mutation sites, screening possible 
variants for the most soluble version. The equations employed to calculate the intrinsic solubility 
profiles are Equations 1, 2 and 3 (Pavlou and Reichert, 2004; Leader et al., 2008; Goodman, 2013). The 
equations employed to calculate the structurally corrected solubility profiles are Equations 4, 5, 6, 7, 
8 (Carter, 2011; Winter et al., 1994; Sidhu, 2000; Hoogenboom, 2005; Bradbury et al., 2011). The 
equation employed to calculate the solubility score is Equation 9 (Lee et al., 2013). These equations 
are discussed in detail by Sormanni et al. (2015). 
Calculation of the intrinsic solubility profiles:  






In Equation 1, “𝑠𝑖” denotes the solubility score. To calculate the solubility score, each residue (denoted 
as “𝑖”) is assessed for: hydrophobicity (𝑝𝑖
𝐻), charge at neutral pH (𝑝𝑖




) using the linear combination parameters denoted as “𝑎” which are 
documented as 0.598, 0.318, 5.77, and -4.807, respectively (Sormanni et al., 2015).  
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In Equation 2, the solubility score is smoothed over a window of seven residues to compensate for 
the effect of neighbouring residues, corrected to compensate for potential patterns of 
hydrophilic/hydrophobic patterns (𝐼𝑖
𝑝𝑎𝑡
) and acknowledges same sign charge influences (𝐼𝑖
𝑔𝑘
). The 
structurally corrected solubility score is denoted as “𝑆𝑖” (Sormanni et al., 2015).   
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐𝒂:      𝐼𝑖
𝑔𝑘






Equation 2a calculates the 𝐼𝑖
𝑔𝑘
 which takes into consideration the relative distance of charged amino 
acids along the sequence where 𝐶𝑖+𝑗  denotes the charge of amino acid 𝑖 + 𝑗 (Sormanni et al., 2015).  
Calculation of the structurally corrected solubility profiles: 










Equation 3 calculates the structurally corrected solubility propensity score of residue “𝑖” (𝑆𝑖
𝑠𝑢𝑟𝑓
).  This 
value applies the intrinsic solubility profile of residue “𝑖” (?̃?𝑖
𝑖𝑛𝑡) to the protein surface. The ?̃?𝑖
𝑖𝑛𝑡 is 
smoothed over by applying the sum to all amino acids within 8 Å of residue “𝑖” which are not next 
together in the sequence as these amino acids are already considered by the ?̃?𝑖
𝑖𝑛𝑡. This equation also 
takes into consideration the exposure weight (𝑤𝑖
𝐸) denoting the exposure of residue “𝑗” to the solvent 
and the smoothing weight (𝑤𝑗
𝐷) which are defined in Equations 3a and 3b, respectively. ?̃?𝑖
𝑖𝑛𝑡 and ?̃?𝑗
𝑖𝑛𝑡 
are calculated using using Equation 7 and a modified version of this equation, respectively (Sormanni 
et al., 2015). 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑𝐚:      𝑤𝑗




Equation 3a calculates the smoothing weight. 𝑑𝑖𝑗 denotes the distance between residues “𝑖” and “𝑗”, 
suggesting that closer residues have a greater contribution to local surface aggregation propensity 
than distant residues do. The patch radius (𝑟𝐴) is defined as 8 Å, consistent with the smoothing window 
of seven residues used to calculate the intrinsic solubility profile in Equation 2 (Sormanni et al., 2015). 
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𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑𝐛:      𝑤𝑗




Equation 3b calculates the exposure of residue “𝑗” to the solvent. The relative exposure of residue “𝑗” 
is denoted as 𝑥𝑗  which is the solvent accessible surface area of residue “𝑗” divided by the solvent 
accessible surface area of residue “𝑗” in a Gly-Xxx-Gly peptide.  Heaviside step function “ϑ” (positive 
and negative argument values are 1 and 0, respectively) is used as a correction to exclude residues 
with < 5% solvent exposure. "𝑎" and "𝑏" are parameters set at -10 and 0.3, respectively to assign 
residues not exposed to the solvent a value of 0, that they be excluded from subsequent algorithms 
(Sormanni et al., 2015).  













Equation 4 employs a weighted average of the smoothing window of seven residues using the relative 
exposures of residue “𝑗” (?̃?𝑗) linearly rescaled (in the range of [0.25, 1] to prevent division by zero.  
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟒𝐚:      𝐼𝑖
𝑔𝑘






In Equation 4a, 𝐼𝑖
𝑔𝑘
 is similar as in Equation 2a except that the gatekeeping effect of charges from the 
same sign are now calculated three-dimensionally (𝐼𝑖
𝑔𝑘
). 𝑥𝑗
𝐶  denotes the relative exposure of the 
charged atom in residue “𝑗”. 
Calculation of CamSol solubility score: 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟓:      𝑆𝑃 =  
1
𝑁
 ∑  {  0      𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                       




Equation 5 calculates the overall solubility score (𝑆𝑃) from the intrinsic solubility profile and the 
number of amino acids in the protein sequence (𝑁). Scores of ~-1 or less are poorly soluble whereas 
scores of ~1 or greater are considered more soluble. ±0.7 thresholds are used for sensitivity to single 




3.1.2 QUALITATIVE MODEL ENERGY ANALYSIS (QMEAN) 
 
5o3l PHF and 5o3t SF PDB cryo-EM structures depict the cores a paired helical filament and straight 
filament in Alzheimer’s disease, respectively, from Fitzpatrick et al. (2017). These structures were 
acquired using resolution method FSC 0.143 CUT-OFF, reconstruction software Relion, a FEI Titan Krios 
microscope with a Gatan K2 Quamtum (4k x 4k) detector and have a resolution of 3.4 Å (Protein Data 
Bank in Europe, 2017). 6QJH, 6QJM, 6QJP PDB from Zhang et al. (2019) are cryo-EM structures 
depicting different heparin induced 2N4R Tau conformations and are and acquired using resolution 
method FSC 0.143 CUT-OFF, reconstruction software Relion, a FEI Polaria 300 microscope with a FEI 
Falcon III (4k x 4k) detector and have a resolution of 3.3 Å (Protein Data Bank in Europe, 2019). 
PDB structures were loaded onto SWISS-MODEL QMEAN to determine the global and local quality 
estimates of these structures by relating their structural features to similar sized experimental 
stuctures (Benkert et al., 2011). Before docking experiments are conducted it is advised to test the 
quality of the PDB structure in case there are errors such as incomplete data. QMEAN combined 
several statistical potentials and agreement terms in a linear manner (Benkert et al., 2008; Benkert et 
al., 2009). Benkert et al. (2011), described that the QMEAN methodology analyses secondary structure 
dependent long range ineractions, local back-bone geometry, residue burial status and two agreement 
terms for secondary structure and solvent accessibility. Prediction of secondary structure and solvent 
accessibility is achieved by PSIPRED amd ACCpro, respectively; which are calculated by DSSP (Jones, 
1999; Cheng et al., 2005; Kabsch and Sander, 1983). Evaluation of experimental structures are 
determined by the QMEAN4 score; structures scoring less than -4 are deemed low quality and 
structures scoring less than -5 are generally rejected for further computational experimentation. 






3.1.3 BUILDING AND DOCKING INHIBITORS USING (ICM)-PRO 
SOFTWARE 
 
PDB structures were loaded onto Molsoft ICM-Pro (version 3.8-7) graphical user interface (GUI) and 
converted from PDB format into an internal coordinate mechanics (ICM) object (for compatability with 
the ICM-Pro docking software). Water was kept tight and His, Pro, Asn, Gln and Cys side chains were 
optimised (because crystallographers are unable to see the correct orientation) to correct their 
orientation and the H-bond network. Docking probes were prepared on the outer chains and assigned 
to a specific directory.  Standard ICM-dock three-dimensional grid potential maps (potential binding 
site regions) were calculated with 0.5 Å grid spacing (Totrov and Abagyan, 1997; Neves et al., 2012). 
The Merck molecular force field (MMFF94) assigned ligand atom types and charges (Lam et al., 2019; 
Halgren, 1996). 
Peptides were initially contructed as .txt files containing sequence codes e.g: 
#line 1: “ml AG03”  
#line 2: “se 0 ace arg gly val gln ile lys tyr lys pro gly arg arg arg arg arg arg arg arg conh2” 
#line 3: “modres 6/nz NC(=O)C”.  
Line 1 command establishes the name of the peptide sequence “AG03”. Line 2 command writes the 
code for peptide sequence: “Ac-RGVQIKYKPGRRRRRRRR-NH2”. Line 2 command writes the code to 
acetylate lys at position 6 in the sequence. The .txt file was saved as AG03.txt into the same directory 
as the docking probe files. Using Windows command prompt the directory containing all the docking 
files was navigated to using the “cd” command. To virtually generate the peptide sequence for use in 
docking experiments; “AG03.txt” was converted into “AG03.se” using the following command: “copy 
AG03.txt AG03.se”. To run the docking experiment the following command was inserted: "c:\Program 
Files\Molsoft LLC\ICM-Pro\icmconsole64.exe" "c:\Program Files\Molsoft LLC\ICM-Pro_dockScan" 5o3l 
input=AG03.se effort=10. -S confs=5". This command docked the ligand (AG03.se) onto the receptor 
(5o3l PHF) using ‘peptide docking mode’ (forcefield) with maximum sampling effort factor (10) and 
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recorded top 5 poses with highest binding affinity. This docking setup applied flexible ring sampling 
(2) and biased probability Monte Carlo to randomly select independent subspaces according to 
predefined continuous probability distribution. Each random subspace was followed by local 
minimisations in torsion angle space (Abagyan and Totrov, 1994). Once the simulation completed, the 
experiment hit lists were fetched using the Molsoft ICM-Pro GUI. Chemicals were downloaded from 
PubChem and docked onto structure using “small molecule mode” forcefield. ICM scores of -32 are 
considered strong binds depending on the properties of the receptor, such as pocket exposure or 
presence of metal ions may produce scores higher than-32. Lower hydrogen bond and hydrophobic 
scores indicate stronger binding and hydrophobic energy exposing a surface to water, respectively. 
Lower Van der Waals scores also indicate a better binding (Molsoft, 2019). Convergence of simulations 
were monitored closely by running multiple identical simulations and comparing the results. If top 
poses weren’t the same or similar, the results were deemed random.  
3.1.4 OPTIMAL DOCKING AREA (ODA) IN ICM-PRO 
ICM object format 5o3l PHF was loaded onto Molsoft ICM-Pro (version 3.8-7) GUI. ODA was performed 
on chains B and J of with maximum sampling effort factor (10) to analyse surfaces for favourable 
energy change once buried as a protein-protein complex. The lower the ODA value was, the more 
likely the residue is predicted to be involved in protein-protein interactions on protein surfaces (red); 
whereas high values indicated an unlikely propbability (blue). It calculates atomic solvation 
parameters derived from experimental research to generate optimal surface patches which have the 
lowest docking desolvation energy values (Fernandez-Reico et al., 2005).  
3.1.5 ICM POCKET FINDER IN ICM-PRO 
 
This function was utilised to identify binding pockets on Tau; if they matched with the binding 
locations of compounds in the in vitro Tau aggregation mix (consisting of TauΔ1-250, inhibitor, 
heparin, ThT and dithiothreitol) and if there was any competition for these binding pockets. The main 
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objective was to predict that the inhibitor did not directly compete for binding sites on Tau with 
heparin (this prediction was later confirmed in Section 6.2.2). 
ICM object format of structure was loaded onto Molsoft ICM-Pro (version 3.8-7) GUI. ICMPocketFinder 
was performed on the entire protein structure with maximum sampling effort factor (10). Based on 
the protein structure alone, ICMPocketFinder identifies potential ligand binding pockets based on 
physical interaction by predicting the position and size of ligand binding pockets found in the 
structure’s cavities and clefts through a series of calculations. Calculated binding pockets denote 
continuous regions of space where the receptor has significantly favorable van der Waals interaction. 
Factors calculated include the volume of the pocket; area of the pocket; buriedness of the pocket 
signifying how open (>0.5) or closed (1.0) the pocket is; hydrophobicity of the pocket signifying the 
percentage of pocket surfaces which make contact with hydrophobic residues; compactness of the 
pocket and nonsphericity of the pocket signifying pocket sphericity (1.0 is spherical) which is 
calculated using the radius (3/4 Volume / π )1/3. Buriedness is calculated by measuring the pocket 
solvent accessible surface area (PSASA) using a probe radius of 1.4 and then measuring the PSASA 
covered by its shell. The fraction buried is determined as a ratio of the PSASA covered by its shell to 
the PSASA. Drug-Like-Density (DLID) is an additional algorithm employed to calculate the drugability 
of a pocket; values >0.5 are considered druggable (drug-like molecules meaning those with molecular 
weight < 500 with moderate lipophilicity. These predictions are calculated using a transformation of 
the Lennard-Jones potential through convolution with a specific sized Gaussian kernel, a binding 
potential grid map and equipotential surface construction along the maps (Abagyan and Kufareva, 






3.2 RECOMBINANT EXPRESSION 
 
Expression plasmid pRK-172 containing genes for human TauΔ1-250 and ampicillin resistance (kindly 
donated by Professor M. Hasegawa; Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) 
was transformed into E. coli BL21(DE3) chemically competent cells (Agilent Technologies) for 
recombinant expression. Methodology based on Hasegawa and Smith, (1998). Taniguchi-Watanabe 
et al. (2016), constructed the deletion mutant using PCR using 4R1N in pRK172 as a template. They 
cloned TauΔ1-250 cDNA into NdeI and EcoRI restriction sites of bacterial expression vector pRK-172 
and verified construct by DNA sequencing. Taniguchi-Watanabe et al. (2016) received 4R1N in pRK-
172 from Dr. Michel Goedert; University of Cambridge, Cambridge, UK (Goedert and Jakes, 1990).   
 
3.2.1 CONFIRMATION OF CONSTRUCT 
A DNA digest was performed using 2µL of 100ng µL plasmid, 2µL digest buffer 15µL with and without 
0.5µL NdeI and 0.5µL EcoRI (New England Biolabs). An uncut sample without enzymes was also 
prepared using 16µL water. Samples were mixed via gentle agitation, spun for 5 seconds on a desktop 
centrifuge and incubated for 1 hour at 37°C. A 0.4% agarose gel was prepared by dissolving 0.4g 
agarose in 40 mL Tris acetate EDTA (TAE) buffer, heated for 1 minute in a microwave and then added 
3µL SYBR Safe DNA gel stain (Invitrogen, UK).  The 0.4% gel solution was poured into a gel cast, 
ensuring no bubbles were present and left to set over 10 minutes at 4°C. 2.5µL FAST DNA ladder (New 
England Biolabs) was pipetted into the first well. For each sample, 4µL of 6x sample buffer was mixed 
with 20µL sample and 16µL of each sample was loaded into subsequent wells. Agarose electrophoresis 
was run at 75V for 60 minutes and imaged under UV light using the Chemidoc™ XRS+ System and 
Image Lab 4™ software.  A plasmid vector map was prepared using SnapGene® software and the base 
pairs of the Tau plasmid and vector calculated from the plasmid vector map were compared to the 
weight of the bands in the agarose gel.  
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3.2.2 PLASMID CONSTRUCT AGAROSE GEL ELECTROPHORESIS 
Using the genetic sequences of TauΔ1-250 and pRK172 empty vector, a plasmid vector map was 
prepared using SnapGene, as seen in Figure 3.1. To confirm the codons for the TauΔ1-250 sequence 
were correct, they were translated into their amino acids as seen in Figure 3.2 and matched to the 
known Tau amino acid sequence. The TauΔ1-250 insert and empty vector were calculated to be 579bp 
and 2538bp, respectively. Plasmid digest (20 µL mix) was performed using 2 µL 100 ng plasmid, 2 µL 
10x Digest buffer, 0.5 µL NdeI and 0.5 µL EcoRI enzymes at 37°C for 1 hour. A 1.5% agarose gel was 
prepared using SYBR-Safe. To prepare samples; 4uL of 6x sample buffer was added to 20 uL sample. 
2.5 µL FAST DNA ladder (New England Biolabs) was used as a reference. Electrophoresis was 
performed at 76 V for 1 hour.  
Figure 3.1: Plasmid map of pRK172 expression vector containing the of TauΔ1-250 DNA of interest, 







Figure 3.2: DNA and amino acid sequences of the pRK172 expression vector containing the 
TauΔ1-250 DNA of interest (highlighted region). This figure was made to check that the DNA 
sequence associated with the plasmid sent by Tokyo Metropolitan Institute of Medicine 
matched the known amino acid sequence for Tau 251-441. 
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3.2.3 TRANSFORMATION INTO E. COLI 
Transformation entails altering the genome of competent cells through the introduction of an 
exogenous engineered plasmid vector, which usually contains antibiotic resistance genes and genes 
to synthesize proteins of interest. In this research two E. coli cell lines were transformed; XL1Blue and 
BL21 (DE3) for plasmid storage and recombinant expression, respectively. 
3.2.3.1 TRANSFORMATION INTO XL1BLUE CELLS 
50μL of E. coli XL1 Blue cells were thawed on ice before the addition of 1.7μL of β-mercaptoethanol 
(Agilent Technologies, UK) to improve cell wall permeability and then left on ice for 10 minutes 
(Brzobohaty and Kovac, 1986). Under sterile conditions 5μL of plasmid pRK-172 DNA was added and 
gently mixed before leaving on ice for 30 minutes. Cells were then heat shocked at 45°C for 45 seconds 
and returned to ice for 2 minutes to allow E. coli to take up the plasmid. Cells were slowly 
supplemented with 900μL of sterile SOB media and then incubated at 37°C for 1 hour with agitation. 
Using aseptic technique 200μL of culture was distributed over the surface of LB agar plates containing 
0.1% ampicillin and incubated at 37°C overnight. As the plasmid contained ampicillin resistance, any 
growth on the agar plates suggested that it had been successfully taken up by the E. coli. Individual 
colonies were selected and transferred into 30ml sterile LB media containing 0.1% ampicillin and 
incubated at 37°C overnight. From this overnight culture 50% glycerol stocks were produced and 
frozen at -80°C for future use. 
3.2.3.2 TRANSFORMATION INTO E. COLI BL21 (DE3) CELLS 
Following the same transformation methodology (Section 4.1.3.1), plasmid vectors were also 
transformed into E. coli BL21(DE3) expressing cell-line (Agilent Technologies, UK) to enhance protein 
expression. Producing glycerol stocks of this cell-line ensured that overnight cultures could be 
prepared immediately; without having to first isolate the DNA from the XL1 Blue cell-line and 
transforming into BL21 (DE3). 
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3.2.4 PRODUCTION OF TAU 
3.2.4.1 RECOMBINANT PROTEIN EXPRESSION 
Using a pipette tip scratching from the glycerol stocks previously mentioned, overnight cultures of E. 
coli containing the pRK-172 plasmid vector were prepared in 30ml LB media containing 0.1% 
ampicillin. This culture was utilised to inoculate 1L of sterile LB media which was incubated at 37°C 
with agitation until an OD600 of 0.6 was reached. This ensured adequate growth without the formation 
of any toxic species. When OD600 was suitable, 1ml of culture was collected for SDS-PAGE analysis and 
culture was induced with 1mM isopropyl β-D-thiogalactoside (IPTG) which bound to the LacI repressor 
causing a conformational change. This resulted in the liberation of the LacUV5 promoter which is 
otherwise inhibited by the LacI repressor. Consequentially T7 polymerase was able to express which 
subsequently bound to the T7 promoter which drives the expression of the TauΔ1-250 peptide. 
Following guidelines from Hasegawa et al. (1998), protein expression was optimised for induction 
incubation at 37°C for 3 hours and with agitation following experimental inductions at various 
temperatures which were sampled (20µL) on an hourly basis over 5 hours and overnight for SDS-PAGE. 
3.2.4.2 CELL HARVEST AND LYSIS 
To harvest the cells after induction, cells were centrifuged at 5,000 RPM for 15 minutes at 4°C.  Cells 
were re-suspended in lysis buffer (50mM PIPES, 1mM EGTA, 1mM DTT, 0.5mM PMSF, 0.5μg/ml 
leupeptin, pH 6.8) and frozen at -20°C to assist lysis. After thawing, cells were sonicated at 20 microns 
for 6 cycles of 30 seconds with 60 second breaks on ice. Lysed cells were centrifuged at 15,000 rpm 
for 15 minutes at 4°C to remove cell debris. Supernatant was collected and supplemented with 1% β-
mercaptoethanol to prevent disulphide cross bridging and dimer formation which could affect 
subsequent column binding. Tau as an intrinsically disordered protein is heat-stable (Uversky, 2019; 
KrishnaKumar and Gupta, 2017). The crude protein mix was boiled at 100°C for 5 minutes (to degrade 
bacterial cell wall for protein release and to denature contaminating proteins) and then centrifuged 
again at 15,000 rpm for 15 minutes at 4°C before recovering the supernatant. 
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3.2.4.3 IMMOBILISED CATION-EXCHANGE CHROMATOGRAPHY 
The heat-stable supernatant of the E. coli was collected and loaded onto a sulphopropyl (SP) sepharose 
column (bed volume 3ml), pre-equilibrated in purification buffer (50mM PIPES, 1mM EGTA, 1mM DTT, 
pH 6.8). TauΔ1-250 has an isoelectric point (pI) of 9.5. To remove any non-specifically binding proteins 
the column was washed in purification, followed by purification buffer + 0.1M NaCl. Proteins were 
eluted with purification buffer +0.35M NaCl and collected as 1ml fractions. Finally, the column was 
washed with purification buffer +1M NaCl to flush the column out. 1mL elution fractions were 
collected and protein concentrations were analysed using a Nanodrop 2000 (Thermo Scientific, UK). 
Fractions with high protein concentration were pooled for ammonium sulphate precipitation. 20µL of 
the pooled sample was analysed by SDS-PAGE. 
3.2.4.4 AMMONIUM SULPHATE PRECIPITATION 
The pooled elution fractions were brought to 35% ammonium sulphate. This solution was left mixing 
at 4°C for 3 hours to allow precipitation to occur before centrifugation at 21,000 x g using an ‘FA-45-
24-11 rotor’ in an ‘Eppendorf Centrifuge 5424’. The supernatant was removed, and pellet was 
reconstituted in ddH20. Supernatant was then dialysed against Tris buffer (30mM), pH 7.5 overnight 
and subsequently frozen at -20°C (Takahashi et al., 2015). 
3.2.4.5 DIALYSIS AND ULTRACENTRIFUGATION 
A suitable length of 14kDa BioDesignDialysis Tubing™ (Thermofisher Scientific, USA) was washed with 
ddH2O for 10 seconds, three times. The inside of the tubing was filled with ddH2O three times and 
emptied to remove glycerol. A knot was tied at one end of the tubing and capped off before sample 
was loaded. Once sample was loaded a knot was tied in the other end and capped. Sample was 
suspended using a float and was dialysed against 4L of 30mM Tris (30mM), pH 7.5, with three washes: 
2 hours, 2 hours and overnight. Dialysed sample was transferred to a falcon tube and DTT (1mM) was 
added, before boiling sample for 3 minutes. Sample was ultracentrifuged at 113,000x g for 20 minutes 
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at 4°C (using Ti 70.1 rotor and 10.4ml ultra-centrifuge tubes) and supernatant (Tau monomers) was 
collected. 
3.2.4.6 PROTEIN CONCENTRATION QUANTIFICATION 
Protein concentration was determined through ultraviolet absorbance at A280 and corrected using 
Equation 10 which takes into consideration the number of tryptophan, tyrosine and cystine residues: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏𝟎:        ε(280) (M  ͞^(  1)  cm ͞  ¹)  = (#𝑊 𝑥 5500) + (#𝑌 𝑥 1490)  + (#𝐶 𝑥 125) 
The extinction coefficients for 1M solutions of tryptophan, tyrosine and cystine are 5500 M-1 cm-1, 
1490 M-1 cm-1 and 125 M-1 cm-1 respectively. Cystines are dimers of two cysteine molecules joined via 
disulphide bonding. The calculated extinction coefficient was then divided by protein molecular 
weight to give concentration in the absorbance of a 1mg/ml solution of target protein (Gill and von 
Hippel, 1989 and Pace et. al, 1995). 
3.2.4.7 SDS POLY-ACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
To determine the level of expression and purity of the end-product, SDS-PAGE was conducted at 
each stage of the process, using 15% polyacrylamide gels in a Bio-Rad gel electrophoresis system. 
16μL of each sample was mixed with 2 μL of 10x sample buffer (20% v/v 1M Tris, 40% glycerol, 
2% β-mercaptoethanol, 5% v/v 0.5M EDTA, 4% SDS and 29% ddH20). To assist the denaturing 
process samples were heated at 95°C for 5 minutes before being loaded onto 15% polyacrylamide 
stacking gel. 5μL of PageRuler™ Unstained Broad Range Protein Ladder (Thermo Scientific) was 
loaded into the first well to serve as a reference baseline. Gels were run at 200V for approximately 
1 hour which following completion were stained with 10% v/v acetic acid and 6% v/v Coomassie 
blue G-250 overnight with agitation. Gels were then treated with 10% acetic acid de-stain and imaged 
on UV light using the Chemidoc™ XRS+ System and Image Lab 4™ software. 
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3.3 TAUΔ1-250 AGGREGATION 
Each Tau aggregation mix replicate consisted 60μL of monomeric TauΔ1-250 (20µM), ThT (15µM), 
heparin (5μM), dithiothreitol (1mM) and Tris (30mM), pH 7.4. Samples were aggregated at 37˚C with 
10 seconds of shaking every 10 minutes for 24 hours. Heparin concentration was calculated using the 
average of the estimated molecular weight range reported by the manufacturer. General salts and 
chemicals such as were sourced from Fisher Scientific (Newcastle, UK) and Sigma-Aldrich Ltd. 
(Gillingham, UK). Heparin sodium salt was sourced from porcine intestinal mucosa with an average 
MW of 4650 Da and obtained from Iduron (Manchester, UK). 
3.3.1 THIOFLAVIN-T (ThT) FLUORESCENCE 
Each Tau aggregation mix replicate consisted 60μL of monomeric TauΔ1-250 (20µM), ThT (15µM), 
heparin (5μM), dithiothreitol (1mM) and Tris (30mM), pH 7.4 in a black clear flat bottom 384 well 
microplate (Corning®) at 37˚C for 24 hours. When investigating the effect of inhibitors, various 
concentrations were co-incubated. Condition were conducted in at least in triplicate. Plates were 
monitored for fluorescence every 10 minutes following a 10s shake of the plate (λex=442nm, 
λem=483nm) in a FlexStation 3 microplate reader or a BioTek Synergy 2 microplate reader (Wolfe et 
al., 2010).  Fluorescence was taken as an average of each triplicate experiment. Statistical analysis 
data was expessed as mean ± standard error of mean.  ThT was sourced from Sigma-Aldrich Ltd. 
Standard Tau vs Inhibitor experiment concentrations were equimolar to keep experiments even. One 
factor repeated measures ANOVA + Tukey post hoc statistical analysis investigated lead peptides. 
3.3.2 CONGO RED BIREFRINGENCE 
Sixty microlitre mixtures of monomeric Tau (20µM), heparin (5μM) dithiothreitol (1mM) and various 
concentrations of inhibitor were incubated in Tris (30mM), pH 7.5, in a micro Eppendorf tube at 37˚C 
for 24 hours. Each condition was conducted at least in triplicate. After 24 hours, samples were mixed 
with Congo red (90µM) and 10 μL was placed on a microscope slide and left to dry in a dessicator. 
Samples were analysed on a a Zeissp axioscope A1 microscope in transmission mode. An unpolarsised 
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light source was passed through a linear polariser, then through the sample and then projected onto 
a second polariser. Samples were observed at 10x objective lens with 0° polarised lens and 90° 
polarised lenses for uncrossed and crossed measurements, respectively. 
3.3.3 CIRCULAR DICHROISM 
Using the same aggregation conditions as above, TauΔ1-250 was aggregated under the same 
conditions as above and then pipetted into a Quartz cuvette and far-UV CD measurements were 
obtained using a Chirascan plus qCD spectrometer (Applied Photophysics) between 180 and 260nm 
with a bandwidth of 1 nm and a path length of 2mm. CD is further discussed in Section 5.2.3. 
3.3.4 TRANSMISSION ELECTRON MICROSCOPY 
TauΔ1-250 (20μM) was aggregated under the same conditions as above. Samples were loaded onto 
Formvar/Carbon 300 mesh carbon-coated copper grids (Agar Scientific) at a volume of 10μL per grid 
and left for 3 minutes. Excess sample was wicked away before each grid was counter stained with 
10μL of filtered 2% phosphotungstic acid, pH 2. After 2 minutes of staining excess phosphotungstic 
acid was wicked away by allowing the solution to soak into Whatman filter paper. Grid samples were 
loaded onto a Jeol JEM-1010 electron microscope and were visualised and photographed at various 
magnifications under the training and supervision of Dr. Nigel Fullwood at Lancaster University. 
Several random fields were photographed per sample. Fibrils presented as transparent as they are 
less dense than the phosphotungstic acid which presented as black areas. This model of electron 
microscope utilised gelatin and silver bromide film which after exposure to light subsequently required 
processing in a dark room under red light. Wearing protective Marigold gloves, the developer (Ilford 
Phenisol) was mixed with water at a 1:4 ratio at 20°C. Film was agitated in developer for 10 seconds 
per minute for 4 minutes. This reduced the silver bromide which was exposed to electron, into metallic 
silver. Film was gently agitated in water for 1 minute to wash away excess developer and then agitated 
in Fixer for 10 seconds per minute for 4 minutes. This stabilised the film and washed away unreduced 
silver bromide. Film was then left to wash in water for 1 hour to remove anything unbound to the film. 
 65 
 
Detergent was pipetted into the water bath before removing the film to ensure even drying. Film was 
dried overnight before being scanned into digital format. Repeats were performed in triplicate across 
independent experimental repeats. 
3.3.5 PRODUCTION OF RI-AG03 LIPOSOMES  
Liposomes were prepared using sphingomyelin, cholesterol and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-MAL) in a molar ratio of 
47.5:47.5:5. Lipids were resuspended in chloroform/methanol at 2:1 and then dried under nitrogen 
gas stream. Complete evaporation was ensured by one hour under vacuum. The dried lipid film was 
resuspended in PBS with vortexing and sonication for ~5-15 minutes. They were then frozen in liquid 
nitrogen and defrosted at 45°C several times to disrupt multimellar liposomes. Using a Mini-Extruder 
with two Hamilton 1000l syringes at each end, the liposomes were extruded 11 times through a 100 
nm pore polycarbonate filter under 20 bar nitrogen pressure at room temperature to produce ~130 
nm liposomes. To covalently link peptide inhibitors, these liposomes were incubated with solid RI-
AG03-Cys at 1.2 x 2.5% total lipid concentration for 2 hours at 37°C and incubated overnight at 4°C. 
Peptides reacted with the lipids via click chemistry. CysOH denotes cysteine capped with OH to the C-
terminal to prevent further elongation. Maleimide is a sulfhydryl-reactive chemical group and at pH 
6.5-7.5, it selectively crosslinks with the free/reduced sulfhydryl group on the side-chain of cysteine 
to form a stable and non reversible covalent thioether linkage, as seen in Figure 3.3. To remove 
unbound peptides, the sample was centrifuged at 171,000g for 1 hour and then resuspended in PBS. 
Amount of RI-AG03 in the liposome fraction was quantified using BSA assay and the amount of 
phosopholipid was quantified using the Phospholipid C test from Fujifilm WAKO diagnostics USA 
(Gregori et al., 2017).  




3.4 RI-AG03 TOXICITY IN HEK-293 CELLS  
Tau is largely found intracellularly so it is important for RI-AG03 to be able to act within cells. An 
enzyme stability assay was conducted to determine if RI-AG03 was resistant to enzymatic degredation. 
Following this a lactose dehydrogenase (LDH) cytotoxicity assay was conducted to investigate 
potential toxicity of RI-AG03 in SH-5Y5 cells. Due to availability, a cell uptake assay was conducted in 
HEK-293 cells to confirm proof of principle that RI-AG03 could penetrate cells, before conducting 
experiments in Drosophila.  
3.4.1 CULTURING PROTOCOL 
The hood and equipment were cleaned with ethanol prior to use. Equipment (not including fluids) 
were placed inside the hood and steralised with UV for at least 20 minutes. Growth medium used in 
cell culture was Dulbecco's Modified Eagle Medium/Ham’s F12 (DMEM/F12) in a 1:1 ratio, 
supplemented wih 10% FBS and 1% antibiotics (Streptomycin and Penicillin 1:1 ratio) to prevent 
contamination. Cells were incubated at 37C and 5% CO2. Growth medium was replaced every 3-7 
days with pre-warmed growth medium and cells were split once they reached 80% confluency. To split 
cells in T-75 flasks; old medium was aspirated, and cells were washed with 5 mL 1x PBS to wash away 
any excess old medium. This was important as medium inhibits trypsin which is used to detatch cells 
from the flask. PBS was removed and 5 mL 1x trypsin was added to the cells which were subsequently 
incubated for 5-10 minutes at 37C, 5% CO2. The flask was gently agitated, and cells were examined 
under a microscope to ensure they had detached. 5 mL pre-warmed growth medium was added to 
neutralise the trypsin. Cells suspended in growth medium were transferred to a sterile Falcon tube 
and spun at 1,000 RPM for 5-10 minutes at 20C. Supernatant was decantered into the waste and the 
pellet was resuspended in 1 mL growth medium and transferred into a fresh T-75 flask which was 





3.4.2 ENZYME STABILITY 
RI-AG03 amino acid sequence was processed using ExPASy peptide cutter tool (Gasteiger et al., 2005). 
RI-AG03 (20µM) was incubated at 37 °C for 24 hours with and without an equimolar concentration of 
Trypsin. To determine stability, samples and controls were run on SDS-PAGE gels, following 
methodology previously described. 
3.4.3 CELLULAR UPTAKE 
VWR pcs Cover Glass 13 mm were sterilised in 100% ethanol and placed flat into wells of a 12 well 
plate. HEK-293 (human embryonic kidney) cells were seeded into individual wells at 20,000 cells and 
supplemented with  5(6)-carboxyfluorescein (absorption maximum at 494 nm and emission maximum 
of 512 nm) tagged RI-AG03 (15μM) and DMEM/10% FBS pre-warmed to 37°C. Cells were incubated at 
37˚C and 5% CO2 for 24 hours before being fixed using 4% formaldehyde and washed with TBS. 
Samples were mounted to microscope slides using ProLong™ Gold Antifade Mountant and visualised 
on a Nikon Eclipse Ti fluorescent microscope using the FITC filter. 
 
3.4.4 CELL TOXICITY 
HEK-293 cells were incubated in DMEM/10% FBS at 37˚C and 5% CO2 and transferred during the 
exponential growth phase to a 96 well plate at 10,000 cells/100 μl per well. RI-AG03 was dissolved in 
30mM Tris (pH 7.5) and was supplemented at 0, 2, 4, 10, 15, 20, 30, 40 and 100 μM to the growth 
medium in triplicate and incubated as previously over 24 hours. Potential peptide toxicity towards the 






3.5 TESTING RI-AG03 IN A ROUGH-EYE DROSOPHILA MODEL. 
2N4R wild type human Tau fly line 51361 was sourced from the ‘Bloomington Drosophila Stock Centre’. 
These flies were homozygous stable Tau flies recombined to GMR stable lines. Control flies had the 
driver by itself (GMR-GAL4). No crosses were conducted. Preliminary experiments were conducted 
before in vivo testing. Drosophila media preparation involves high temperatures and RI-AG03 was 
added to the fly food. Thermal stability CD was conducted to ensure temperature did not change RI-
AG03 secondary structure e.g. adopting β-sheet structure. Fly media was changed every week, so RI-
AG03 had to be stable for this period and was confirmed using reversed phase ultra high-performance 
liquid chromatography mass spectrometry (RP-UHPLC). 
3.5.1 THERMAL STABILITY 
Using the same aggregation conditions in Section 3.3, TauΔ1-250 was incubated in a Quartz cuvette 
with the temperature steadily increasing from 20-90˚C over 5 hours. Far-UV CD measurements were 
obtained every two minutes using a Chirascan plus qCD spectrometer (Applied Photophysics) between 
180 and 260nm with a bandwidth of 1 nm and a path length of 2mm.  
3.5.2 MASS SPECTROMETRY 
RP-UHPLC positive ion electrospray ionisation mass spectrometry of RI-AG03 was conducted using a 
maXis (Bruker Daltonics, Bremen, Germany) time of flight (TOF) mass spectrometer, with the 
assistance of Dr. Julie Herniman at the Department of Chemistry at Southampton University.  Samples 
(50μM) were dilued 50:50 in water. Injection sample volumes of 2 μL were introduced to the mass 
spectrometer via a Dionex Ultimate 3000 autosampler and UHPLC pump at a flow rate of 600 μL/min. 
UHPLC was performed using a Restek Force C18 (50 mm x 2.1 mm 1.7µm) column and a column 
temperature of 40˚C. Solvent used were: A (water + 0.2% formic acid) and solvent B (acetonitrile + 
0.2% formic acid, with a gradient of 0% A for 2 minutes, 100% B until 7.8 minutes, held at 100% B for 
2.2 minutes. UHPLC, instrument control and processing softwares used were Chromeleon Xpress, 
Bruker otofControl V 3.2 (Build 41) and Bruker DataAnalysis V 4.0, respectively. 
 69 
 
3.5.3 ROUGH-EYE MODEL 
Human Tau441 and Drosophila Tau370 amino acid sequences were compared to ensure that Drosophila 
Tau370 did not contain VQIINK or VQIVYK sequences which would interact with the binding sequence 
of RI-AG03. In FASTA format the following sequences for human Tau441 and Drosophila Tau370 were 
inputted into BLAST blastp suite to determine similarities in amino acid alignment. Appendix C 
confirmed that Drosophila Tau370 does not contain VQIINK or VQIVYK sequences. 
Human Tau441 sequence: 1 MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG 
SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG HVTQARMVSK SKDGTGSDDK 
KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT 
REPKKVAVVR TPPKSPSSAK SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV 
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI THVPGGGNKK IETHKLTFRE 
NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV DSPQLATLAD EVSASLAKQG L 441 
Drosopihila Tau370 sequence: 1 MADVLEKSSL LDAVPPLGDP HPPLPHQQLQ QEAAAAAAAN AAPPAPPQQQ 
QPPPHQLQQQ QPQQQQLQQK PANARANQDQ KEGDNDSGVD ESTQEKDRNG PNSPSSPVKT PTSTSSKPDK SGTSRPPSAT 
PSNKSAPKSR SASKNRLLLK TPEPEPVKKV PMNKVQVGHA PSPNLKAVRS KIGSLDNATY KPGGGHVKIE SKKIDIKAAP 
RIEAKNDKYM PKGGEKKIVT TKLQWNAKSK IGSLENAAHK PGGGDKKIET LKMDFKDKAK PKVGSTANVK HQPGGGDIKI 
QTQKLEIKAQ SKVGSLDNVK HKPGGGEKKI FDDKDYLKNV EHSVALTTPP TQFALQGRLI ATIHLEFGLC NSDCVCNNIF ESLFK 370 
Training in the fly lab was provided and experiments were supervised by Dr. Shreyasi Chatterjee. An 
appropriate volume of fly food was prepared based on the standard Bloomington fly media recipe as 
seen in Table 3.2, following standard methodology (Bloomington Drosophila Stock Centre, 2019). 
Based on experimental data at Southampton University, an approximate concentration of Tau found 
in the heads of mutant Drosophila was calculated. RI-AG03 was mixed into the fly food at different 
concentrations; 0.08μM, 0.8μM, 20μM and 40μM. Homozygous stable Tau flies recombined to GMR 
stable lines (GMR-hTau) were used in this research. The ‘healthy’ control was the driver by itself (GMR-
GAL4). Four fresh homozygous males and four homozygous flies’ females were incubated per vial 
containing 10 mL fly food supplemented with RI-AG03 at 25°C. An equal number of healthy flies were 
also introduced to drug food in another separate vial. Parents were discarded after hatching larvae in 
the drug food. Once the larvae had matured to adult flies, they were transferred to fresh vials weekly 
and incubated at 25°C. Flies were monitored daily using a Nikon microscope and 1-day old live flies 
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were imaged (n=5/condition) and processed on ImageJ. One factor repeated measures ANOVA was 
conducted with Tukey post hoc testing using IBM SPSS Statistics 23. 
Ingredients Amount required 
Distilled water (L) 1 
Malt extract (g) 46.2 
Sugar (g) 48 
Agar (g) 6 
Soya flour (g) 10 
Yeast (g) 17.5 
Yellow Maize Meal (g) 73.1 
Extra water (ml) 80 
Propionic acid (ml) 5 
 
 
3.5.4 SCANNING ELECTRON MICROSCOPY 
Flies were euthanised and fixed in 2.5% glutaraldehyde in PBS at Southampton University in 
collaboration with Dr. Shreyasi Chatterjee. Samples were prepped for SEM and analysed in 
collaboration with Dr. Nigel Fullwood. Three 5-minute washes in PBS were performed, before 
dehydrating the sample for 30 minutes at each ethanol concentration of 50%, 70%, 80%, 90%, 100%. 
hexamethyldisilazane (Sigma Aldrich, UK) has reduced surface tension and was used to dry SEM 
samples and reduce sample fracturing by providing strength through cross-linking proteins. Two one-
hour changes of hexamethyldisilazane was conducted and then left in hexamethyldilizane overnight 
with the top off vial under a fume hood; allowing hexamethyldisilizane to sublimate off. Samples were 
sputter coated with gold for 4 minutes on an Edwards 150A sputter coater. They were then mounted 
on JEOL SEM stubs under a stereo microscope and examined using a JEOL 5600 scanning electron 
microscope. 
 
Table 3.2: Bloomington fly media recipe per litre (Bloomington Drosophila Stock Centre, 2019) 
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4. DESIGNING PEPTIDIC TAU 
AGGREGATION PEPTIDE INHIBITORS 
4.1 INTRODUCTION 
The purpose of this in silico chapter provides informed guidance on where to begin when designing 
peptide-based aggregation inhibitors for Tau. The information provided includes the predicted binding 
potential for peptides towards their target and if the peptides interact with themselves. If the peptides 
have high interaction together, they could potentially seed aggregation which is undesirable. 
Predictions based on the results in this chapter provided indications for which amino acid sequence 
to target in Tau and which peptide inhibitor amino acid sequences may bind and inhibit aggregation. 
This approach provided some evidence-based direction on which peptides may work. This process 
saved money in the wet lab by filtering out peptides that were predicted to be unsuitable aggregation 
inhibitors. Evidence of potentially successful inhibitors were taken forward into the following chapter 
to be tested in the wet lab. 
4.1.2 PROTEIN THERAPEUTICS 
Protein drugs are becoming increasingly prevalent due to their functional versatility, specificity and 
low on-target toxicity as potential diagnostic and therapeutic molecules (Carter, 2011).  More 
specificity they are less likely to interact with other things but can still be toxic. With small molecules 
the unwanted effects are off-target, however with anti-bodies they can be too specific and in worst 
cases this can be fatal. Protein drugs can be utilised for a broad array of diseases such as administering 
endogenous insulin, interleukin or growth hormone supplements for diabetes, cancer, and auto-
immune diseases, respectively (Elvin et al., 2013; Sormanni et al., 2015). Of the 239 US Food and Drug 
Administration approved peptide and protein therapeutics and their 380 drug variants, only 7 are used 
in neurological disorders, whereas there are 89, 80, 74 and 61 drug varients for metabolic disorders, 
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immunological diseases, haematological diseases and cancer therapy, respectively (Usmani et al., 
2017).  Protein drugs are generally delivered subcutaneously as the preferential route of delivery as 
they are not normally orally active, however they can also be administered intra-nasally which is more 
suitable for neurologically acting drugs. Therapeutic doses are often found as concentrated 
formulations of ≥50 mg/ml which could possibly aggregate. This poses a potential issue especially with 
regards to developing a peptide aggregation inhibitor that specifically targets pathogenically 
aggregating proteins such as Tau. Therefore, it is important when desgning a peptide aggregation 
inhibitor that they are sufficiently polar and hydrophilic to avoid self-association which may result in 
loss of activity, toxicity and seeding Tau aggregation. However, If the peptide is too polar and 
hydrophilic, it may lose binding affinity and specificity to its molecular target, and so a fine balance 
must be made to ensure solubility whilst retaining some aggregation-prone sequences on their surface 
(Sormanni et al., 2015). 
4.1.3 TARGET SEQUENCE 
Tau aggregation is largely facilitated by two hexapeptide motifs at the beginning of the second and 
third repeat domains of Tau which adopt β-sheet structure, namely 275VQIINK280 and 306VQIVYK311, 
respectively (Ganguly et al., 2015). Substituting either of these sequences renders Tau unable to 
assemble (Von Bergen et al., 2001). As these two sequences play a formidable role in Tau aggregation, 
they make excellent therapeutic targets to disrupt pathogenic activity. The importance of these 
hexapeptides originate from their capacity to conformationally change from unordered to β-sheet 
structure (Von Bergen et al., 2005; Murkrasch et al., 2005). Perez et al, (2007) demonstrated that 
deletion of 306VQIVYK311 in Tau prevents heparin induced aggregation and that incubating Tau with 
VQIVYK hexapeptide stimulates aggregation. The interaction of 306VQIVYK311 with 275VQIINK280 is 
believed to produce twisted PHF-like filaments (Von Bergen et al., 2000). 4R Tau includes both 
306VQIVYK311 and 275VQIINK280 sequences, whereas 3R Tau only includes the 306VQIVYK311 sequence, 
therefore the latter may be a more suitable primary target. 306VQIVYK311 is situated on the carboxyl-
terminal half of Tau and is mainly responsible for microtubule binding and pathological aggregation, 
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forming the core of PHF’s (Jeganathan et al., 2008; Von Bergen et al.,2006; Lee et al., 1989). Meng et 
al., (2012) mentioned that recombinant 4R Tau fragment (specifically Tau244–372) was unable to form 
fibrils when 306VQIVYK311 and 275VQIINK280 (included in 3R Tau) were deleted, suggesting their essential 
role in aggregation. This is supported by Ganguly et al., (2015) who concluded that 306VQIVYK311 has a 
greater propsensity of aggregation than 275VQIINK280 or mutant 275VQIINK280ΔK280 and that 
heterodimers of 306VQIVYK311 and 275VQIINK280 were more stable than homodimers of 275VQIINK280. 
This suggests the interaction between these two hexapeptides are important in Tau441 aggregation. 
They also concluded that mutant 275VQIINK280ΔK280 bound more strongly to 306VQIVYK311 than 
275VQIINK280 and so suggested this as a possible mechanism for the pathological loss of normal Tau 
function.  Mizushima et al., (2007), reported that the R3 peptide demonstrated the highest self-
association ability whereas R2 peptide featured long lag times of 6 hours.  Sawaya et al., (2007) 
conducted crystallographic studies of 306VQIVYK311 hexapeptides and concluded that they stack in 
parallel β-sheets whereby two mating sheets form a steric zipper by coming together with their 
hydrophobic side chains orientating inwards. Solid-state NMR and electron paramagnetic resonance 
studies also support this finding as well as that 275VQIINK280 can occupy parallel β-sheet or disordered 
arrangements (Daebel et al., 2012; Margittai and Langen, 2004). Zheng et al., (2011) used x-ray 
crystallography on the VQIVYK peptide (Figure 4.1) and identified that this peptide formed anti-
parallel-layered parallel β-sheet structures. This structure interacted with other VQIVYK parallel β-
Figure 4.1: X-ray crystallographic structure of Tau derived VQIVYK peptide forming antiparallel-layered 
parallel β-sheets (Zheng et al., 2011).  
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sheets via edge-to-edge hydrogen bonding, face-to-face β-sheet layer interactions and in-register 
orientation and packing of side chains, particularly isoleucine and valine which form a hydrophobic 
core (Zheng et al., 2011).  As Tau binds to microtubules via the four repeat domains it is important 
that the inhibitors do not interfere with the normal functioning of microtubules. It is suggested that 
taxol may outcompete Tau for binding sites on β-tubulin. Kar et al. (2003), nanogold labled a 4R-Tau 
repeat motif and observed that Tau bound on the inner surface of β-tubulin close to the taxol binding 
site, as seen in Figure 4.2. 
 
The binding energy within the repeats when bound to microtubules is delocalised through a series of 
weak interactions (affinity ~10-7M) by three or four 18 amino acids, separated by 13-14 linker 
sequences which do not bind. This suggests that Tau exists flexibly on microtubules with the potential 
to migrate along the surface, however this flexible nature could suggest that Tau may be easily 
displaced (Butner and Kirschner, 1991). The low binding affinity of Tau to microtubules is also 
mentioned by Kar et al., (2003) who proposed that loops within the repeat motifs of bound Tau 
Figure 4.2: Tau binding to the inside of microtubules. A: EM image of a frozen hydrated microtubule with 
bound nanogold labelled 4R-Tau (indicated with arrows) B: Reconstructed end-on view of microtubule 
where tubulin is co-assembled with nanogold lebelled Tau (yellow). Notice that Tau is bound on the inside 
of the microtubule (Kar et al., 2003).  
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stabilise microtubules with a low affinity so that assembly is reversible. These loops have the PGGG 
sequence similarity to the α-tubulin extended loop and binds to the same region inside microtubules 
where taxol (a known microtubule stabiliser) does on β-tubulin. Research done by Tsvetkov et al., 
(2012) agrees that there is a low affinity binding site for Tau to tubulin with a Tau:tubulin stoichiometry 
of 0.8, however, that there is also another binding site of high affinity with a Tau:tubulin stoichiometry 
of 0.2. It was suggested by Jho et al., (2010) that Tau repeat domains bind to microtubules via their 
net positive charge interacting with the negatively charged residues in tubulin monomers. As Kar et 
al., (2003) suggested that repeat motifs bind to the insides of microtubules and the N terminal 
projection runs along a protofilament on the outside of microtubules. This could suggest that peptide 
inhibitors specific to Tau repeat domain motifs may be less likely to interact with normal Tau within 
microtubules. Hyperphosphorylated Tau recruits Tau and aggregates, however normal Tau does not 
behave like this. Since Tau requires an inducer of some kind to initiate aggregation, normal Tau should 
not recruit and bind peptide inhibitors. 
Kadavath et al., (2015) reported that the binding residues responsible for binding Tau to microtubules 
are also responsible for pathogenic aggregation of Tau; suggesting that physiological interaction 
competes with pathogenic misfolding. As a result, it is imperative that healthy functioning of Tau on 
microtubules is not hindered.  As all repeats are reported to bind to microtubules this means that 3R 
and 4R Tau both bind to microtubules which indicates that the second repeat absent in 3R is not 
entirely necessary for this binding. This is supported by Kadavath et al., (2015) who suggested that 3R 
and 4R isoforms use similar mechanisms to bind to microtubules based on similar signal broadening 
profiles. Although, R4 Tau is reported to bind much more strongly to microtubules, with great 
importance at the lysine residue in VQIINK which is suggested to be one three most critical lysine 
residues responsible for interactions with microtubules. Acetylation at this position impaired 
microtubule interaction and increased cytosolic Tau (Mietelska-Porowska et al., 2014). Deletion of this 
residue causes Tau to aggregate, even without the presence of a polyanionic inducer. Developing a 
peptide inhibitor which interferes with lysine280 may be detrimental. Mietelska-Porowska et al., (2014) 
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and Mukrasch et al. (2007), stated that the important Tau residues for microtubule interaction include 
240KSRLQTAPV248, 275VQINKKLDLS285, 297IKHV300, 225KVAVVRT231 and 370KIETHK375. Kadavath et al., (2015) 
stated that protofilaments are stabilised by Tau binding to hydrophobic pockets between α-β-tubulin 
heterodimers potentially due to an allosteric mechanism. Flexible regions in between the repeat 
domains of Tau may suggest a dynamic mode of binding to the same α-tubulin molecule and that 
VQIINK may be responsible for this. As a result, VQIVYK which is present in all Tau isoforms may be a 
more suitable target. Using multiscale molecular dynamics simulations, Xu et al., (2016) noted that in 
a phosphorylated environment the domain movements in the filament core become more exposed to 
the solvent environment, especially the third and second repeats, as seen in Figure 4.3.  VQIVYK and 
VQIINK are found in these repeat domains, respectively. This means that in an AD brain which is largely 
phosphorylated, these sequences would be suitable therapeutic targets. Figure 4.3 demonstrates 
these regions in un-phosphorylated Tau are not exposed to the solvent environment which may lead 
to the possibility of un-phosphorylated Tau being unaffected by the peptide inhibitors. This research 









Figure 4.3: Represents conformations for different normal (a) and hyper-phosphorylated (b) Tau filaments. Tau filament N-terminus, repeat domain, and C-




Tau will generally interact with itself at 306VQIVYK311 and 275VQIINK280 as discussed in Section 4.1.3. 
These targets are useful to manipulate self-association propensity. By generating a clone clone of 
these sequences, they can potentially cap this self-association by preventing Tau from binding on top 
or by altering the aggregation pathway in an off-pathway manner. As the peptide inhibitor binding 
sequence represents an internal portion of the Tau amino acid sequence it is important to acetylate 
and amidate the inhibitors N and C-terminus, respectively. This removes the positive charge on the N-
terminal and neutralises the C-terminal. This blocks both ends of the inhibitor, preventing potential 
unnatural introduction of charged groups which do not exist in the native complementary sequence, 
thereby increasing the likelihood of the inhibitor being recognised by its complementary sequence. 
Capping the N and C-terminus also provides the inhibitor with additional resistances to exopeptidases 
which is important for a potential therapeutic (Kim and Seong, 2001). Acetylation and amidation of 
the N and C-terminal reduces the peptide solubility, therefore additional measures must be employed 
to ensure solubility remains viable. C-terminal amidation is also reported by Matharu et al. (2010), to 
increase the activity in preventing oligomer formation.  Flanking the peptide binding sequence with 
spacers such as glycine may improve the peptide binding ability by distancing other potentially 
interfering amino acids, such as cell penetrating sequences, which are necessary as Tau aggregates 
form intracellularly. Other important amino acids include proline which are natural β-sheet breakers 
and provides rigidity to the structure. Eisenberg and Sawaya (2017), highlighted that amyloid steric 
zippers (previously discussed in Section1.4.4) share common features (Figure 4.4) including 1) 
hydrogen bonding of  dipolar amide N-H and C=O groups which stack β-strands together with 4.8 A˚ 
spacing, 2) hydrogen bond ladders can be formed between layers of the β-strands via amides located 
in glutamine and asparginine side chains, 3) tyrosine, serine and threnonine can also form hydrogen 
bond ladders, 4) paired sheets are almost completely devoid of water, save for a few hydrogen bonds 
between them. This kind of information can be utilised to develop a peptide inhibitor which can 
interfere in these important processes in order to prevent aggregation. This research will investigate 
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altering the properties of the inhibitor through addition of hydrophilic and polar molecules, 
acetylation and using glycine spacers, to make sure the inhibitor does not self aggregate and to 
improve its inhibitory properties. 
Figure 4.4: Represents a selection of published amyloid steric zipper crystal structures both parallel 
and perpendicular to their fibril axes. The face and back of each strand are coloured blue and gold, 
respectively. Also demonstrates the organisation of steric zippers into separate symetry classes 
depending on orientation the two sheets of each zipper. Asparagine and tyrosine hydrogen bond 
ladders from GNNQQNY with 4.8 A˚ spacing are visualised in the top right illustration (Eisenberg 
and Sawaya, 2017). 
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4.1.5 ICM-PRO DOCKING 
 
Molecular docking is a powerful tool for structure-based drug design and accurately predicting 
potential interactions between novel ligands (either small molecules or peptides) and receptors 
(Neves et al., 2019). The third part of this chapter aimed at using ICM-Pro to assist in designing peptide 
aggregation inhibitors by assessing their binding behaviour to their target protein.  
ICM-Pro uses five interaction potentials to represent a receptor pocket, including van der Waals 
potential for heavy atom probe (generic carbon of 1.7 Å radius), wan der Waals potential for hydrogen 
atom probe, optimised electrostatic term, hydrophobic term and loan pair based potential reflecting 
hydrogen bonding directional preferences. The energy terms calculated are based on the all-atom 
vaccum force field ECEPP/3 which is specific for peptides and proteins and conducts energy 
minimisations including hydrogen bond potentials, torsion potentials additional terms to quantify 
solvation free energy and entropic contributions (Molsoft, 2019; Shaumann et al., 1990). These force 
fields are parameters utilised to calculate the potential energy of atoms in molecular dynamics 
simulations and are derived from experimental data. “All-atom” refers to the provision of parameters 
for all types of atoms within a system. The biased probability Monte Carlo procedure randomly and 
continuously sample different binding comformations and globally optimises ligand coordinates 
within the grid potential maps space (Abagyan and Totrov, 1994).  
First random moves are introduced to one of the ligands rotational, translational or conformational 
variables, then energy function terms are minimised and desolvation energy is calculated (Neves et 
al., 2012). These random moves to the ligand are regulated by the Metropolis selection criterion 
algorithm which determines if final minimised conformations are accepted or rejected based on if they 
meet favourable energy conditions (Metropolis et al., 1953). These processes are repeated until the 
maximum number of conformations are sampled. Conformations are ranked based on their ICM-score 
which is calculated and weighted according to the ligands internal force-field energy, ligand loss of 
entropy between bound/unbound states, hydrogen bond interactions between the ligand and 
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receptor, polarity solvation energy differences between bound/unbound states, electrostatic energy, 
hydrophobic energy and hydrogen bond desolvation (Arthur et al., 2019). This is discussed in further 
detail by Neves et al. (2012). 
Molecular docking simulations will provide informed guidance on where to begin when designing 
peptide-based aggregation inhibitors for Tau. The information provided includes the predicted binding 
potential for peptides towards their target and if the peptides interact with themselves. If the peptides 
have high interaction together, they could potentially seed aggregation which is undesirable. 
Predictions based on the results in this chapter provided indications for which amino acid sequence 
to target in Tau and which peptide inhibitor amino sequences may bind and inhibit aggregation. This 
approach provided some evidence-based direction on which peptides may work. This process saved 
money in the wet lab by filtering out peptides that were predicted to be unsuitable aggregation 
inhibitors. Evidence of potentially successful inhibitors were taken forward into the following chapter 
to be tested in the wet lab. ICM-Pro does not use confidence scores, the peptides are ranked by their 












4.2.1 IDENTIFYING “HOT SPOT” SEQUENCE IN TAU 
 
When developing peptide-based therapeutics against pathogenic proteins such as Tau for AD, it is 
important to identify sequences which contribute to pathogenic behaviour. Once these are known 
they can then be targeted in order to inhibit pathogenic behaviour. Figures 4.5 and 4.6 aimed to 
identify chief motifs responsible for Tau aggregation. 
In simple words the Camsol algorithm investigates the instrinsic solubility of peptides by assessing 
hydrophobicity, charge at neutral pH, α-helic propensity and β-strand propensity over a window of 
seven amino acids. The Aggrescan algorithm however, investigates the aggregation propensity of 
peptides based on previous experimental data, over several windows (5 for < 75 residues, 7 for < 175 
residues, 9 for < 300 residues, and 11 for > 300 residues). By adapting these algorithms they can be 
used to predict a peptides behaviour with regards to target binding and aggregation. Hydrophobic 
interactions play a key role in aggregation. Camsol was used to investigate potential hydrophobic 
targets in Tau441. VQIVYK was the only hexapeptide highlighted as exceptionally hydrophobic, as seen 
in Figure 4.5. Aggrescan was used to investigate potential aggregation hot spot targets in Tau441 and 
highlighted VQIVYK as the only hexapeptide above the aggregation hot spot threshold as seen in 
Figure 4.6. VQIINK and VQIVYK were chosen as suitable targets to take forward as potential targets. 
Although VQIINK did not come up as particularly hydrophobic in Figure 4.5, it did slightly peak over 
the aggregation hot spot threshold in Figure 4.6. In addition, the hexapeptide itself is touted in 
literature to have crucial involvement in Tau aggregation, therefore it was deemed a worthy target to 






Figure 4.5: Intrinsic residue solubility values for Tau441 residues using CamSol. Note that VQIVYK contains hydrophobic residues (V and I) and the 
hexapeptide flags as an aggregation hot spot. Repeats 1-4 are highlighted in purple, blue, yellow and green, respectively. Repeats 1-4 are highlighted in 



























Figure 4.6: Average aggregation propensity values for Tau441 residues using AGGRESCAN. Note that the hexapeptide VQIVYK massively surpasses the hot 
spot threshold. Repeats 1-4 are highlighted in purple, blue, yellow and green, respectively. Hexapeptides above the blue hot spot threshold are considered 
aggregation hot spot sequences (high propensity to aggregate). 
 
306VQIVYK311 




a3v Sequence Average Hot Spot Threshold 
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4.2.2 DESIGNING PEPTIDE INHIBITORS  
 
Using the chosen targets from Section 4.2.1, the second part of this results chapter aimed to design 
and evolve a suitable peptide which can successfully bind to its target (which in humans is intracellular) 
and in addition to also inhibit Tau aggregation. 
As hexapeptides VQIINK and VQIVYK both form fibrils it was important to make changes to their 
sequence to prevent them from being able to seed aggregation. Tables 4.1 and 4.2 demonstrate the 
exhaustive mutagenesis of the second isoleucine in VQIINK and the second valine in VQIVYK and 
predicts their aggregation propensity using Aggrescan. The native hexapeptide sequences are used as 
reference points and are located on the far-right hand column.  
The rationale behind choosing these sites are thus: The intention was to reduce the aggregation 
propensity of the peptide inhibitor so to avoid potential self-association whilst also maintaining target 
specificity. Since VQIINK and VQIVYK both have VQIxxK motifs, these were left unchanged as they are 
useful reference sequences for the inhibitor to bind to Tau with. For VQIVYK the tyrosine residue was 
not chosen for mutagenesis because as an aromatic amino acid it is a useful as an anchoring residue 
through aromatic stacking interactions. For these reasons the original hexapeptide could not be 
altered too much to avoid risking loss of target specificity. As hydrophobic amino acids have great 
influence in increasing aggregation propensity, the hydrophobic amino acids in the centre of each 
hexapeptide were investigated.  
The optimal amino acid replacement for the second isoleucine in VQIINK (Table 4.1) and the second 
valine in VQIVYK (Table 4.2) was lysine, in both instances. This hydrophilic amino acid lowered the 
average aggregation propensity. Not too little that the average aggregation propensity was still too 
high, nor not so much that the peptide would lose affinity to its target site in Tau. It lowered it to just 
below the hot spot threshold. Histidine was rejected as a replacement for valine as its hydrophobicity 






Residue substitution A C G V L M F S T W Y   VQIVYK 
a3v Sequence Average (a3vSA): 0.358 0.465 0.275 0.630 0.594 0.516 0.656 0.315 0.338 0.537 0.557   0.668 
Number of Hot Spots (#HS): 1 1 0 1 1 1 1 1 1 1 1   1 
Normalized #HS for 100 residues: 16.667 16.667 0.000 16.667 16.667 16.667 16.667 16.667 16.667 16.667 16.667   16.667 
Area of the profile Above Threshold 
(AAT): 
1.286 2.118 0.688 3.405 3.127 2.516 3.613 0.951 1.126 2.681 2.839 
  3.701 
Total Hot Spot Area: 1.286 2.118 0 3.405 3.127 2.516 3.613 0.951 1.126 2.681 2.839   3.701 
Total Area: 1.126 1.766 0.627 2.756 2.542 2.072 2.916 0.868 1.003 2.199 2.321   2.984 
AAT per residue: 0.214 0.353 0.115 0.568 0.521 0.419 0.602 0.159 0.188 0.447 0.473   0.617 
THSA per residue: 0.214 0.353 0 0.568 0.521 0.419 0.602 0.159 0.188 0.447 0.473   0.617 
Normalized a4v Sequence Sum for 100 
residues (Na4vSS): 
18.8 31.6 8.8 51.4 47.1 37.7 54.6 13.6 16.3 40.2 42.7 
  55.9 
Residue substitution R N D Q E H K P   VQIVYK 
a3v Sequence Average (a3vSA): 0.158 0.147 0.058 0.159 0.129 0.192 0.209 0.309   0.668 
Number of Hot Spots (#HS): 0 0 0 0 0 0 0 0   1 
Normalized #HS for 100 residues: 0 0 0 0 0 0 0 0   16.667 
Area of the profile Above Threshold 
(AAT): 
0.395 0.383 0.276 0.397 0.361 0.437 0.457 0.322 
  3.701 
Total Hot Spot Area: 0 0 0 0 0 0 0 0   3.701 
Total Area: -0.078 -0.140 -0.674 -0.069 -0.250 0.129 0.231 0.828   2.984 
AAT per residue: 0.066 0.064 0.046 0.066 0.060 0.073 0.076 0.054   0.617 
THSA per residue: 0 0 0 0 0 0 0 0   0.617 
Normalized a4v Sequence Sum for 100 
residues (Na4vSS): 
-5.3 -6.5 -17.2 -5.1 -8.7 -1.2 0.9 12.8 
  55.9 
Table 4.1: Average aggregation propensity value VQxVYK where x is consecutively replaced with every amino acid. A: aggregatory residues, B: non-
aggregatory residue Note the replacement of isoleucine massively reduces the aggregation propensity. Residues coloured red, blue and black are 





Residue substitution A C G I L M F S T W Y   VQIVYK 
a3v Sequence Average (a3vSA): 0.396 0.503 0.313 0.706 0.632 0.554 0.694 0.353 0.376 0.575 0.595   0.668 
Number of Hot Spots (#HS): 1 1 1 1 1 1 1 1 1 1 1   1 
Normalized #HS for 100 residues: 16.667 16.667 16.667 16.667 16.667 16.667 16.667 16.667 16.667 16.667 16.667   16.667 
Area of the profile Above Threshold 
(AAT): 
1.582 2.414 0.934 3.998 3.423 2.812 3.909 1.247 1.422 2.977 3.136 
  3.701 
Total Hot Spot Area: 1.582 2.414 0.934 3.998 3.423 2.812 3.909 1.247 1.422 2.977 3.136   3.701 
Total Area: 1.354 1.994 0.855 3.212 2.770 2.300 3.144 1.096 1.231 2.427 2.549   2.984 
AAT per residue: 0.264 0.402 0.156 0.666 0.571 0.469 0.651 0.208 0.237 0.496 0.523   0.617 
THSA per residue: 0.264 0.402 0.156 0.666 0.571 0.469 0.651 0.208 0.237 0.496 0.523   0.617 
Normalized a4v Sequence Sum for 100 
residues (Na4vSS): 
23.3 36.1 13.4 60.5 51.7 42.3 59.1 18.2 20.9 44.8 47.2 
  55.9 
Residue substitution R N D Q E G H K P   VQIVYK 
a3v Sequence Average (a3vSA): 0.196 0.185 0.096 0.197 0.167 0.313 0.230 0.247 0.347   0.668 
Number #HS: 0 0 0 0 0 1 0 0 0   1 
Normalized #HS for 100 residues: 0 0 0 0 0 16.667 0 0 0   16.667 
Area of the profile Above Threshold 
(AAT): 
0.441 0.428 0.322 0.443 0.406 0.934 0.495 0.556 1.078 
  3.701 
Total Hot Spot Area: 0 0 0 0 0 0.934 0 0 0   3.701 
Total Area: 0.150 0.088 -0.446 0.159 -0.022 0.855 0.357 0.459 1.056   2.984 
AAT per residue: 0.073 0.071 0.054 0.074 0.068 0.156 0.083 0.093 0.180   0.617 
THSA per residue: 0 0 0 0 0 0.156 0 0 0   0.617 
Normalized a4v Sequence Sum for 100 
residues (Na4vSS): 
-0.7 -2.0 -12.7 -0.6 -4.2 13.4 3.4 5.4 17.4 
  55.9 
Table 4.2: Average aggregation propensity value VQIxYK where x is consecutively replaced with every amino acid. A: aggregatory residues, B: non-
aggregatory residues. Note the replacement of valine massively reduces the aggregation propensity. Residues coloured red, blue and black are 




Figures 4.7 and 4.8 represent the aggregation propensity and intrinsic residue solubility, respectively, 
for each of the following peptides: VQIVYK, VQIHYK, VQIKYK and VQKVYK. In Figure 4.7 VQIHYK, 
VQIKYK and VQKVYK were well under the hot spot threshold which VQIVYK exceeded. Although in 
Table 4.2 histidine generated a similar aggregation propensity value to lysine; VQIHYK was rejected 
for further investigation based on Figure 4.8 as it had the same intrinsic solubility score as native 










































Figure 4.7: Aggrescan calculations for the average aggregation propensity value for Tau residues 301-315. Residues highlighted in orange are mutated; 
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Figure 4.8: CamSol calculations of the Intrinsic residue solubility for Tau residues 301-315. Residues highlighted in orange are mutated. A: 
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Figure 4.9. demonstrated that the circled regions indicating the 306VQIVYK311 sequence are rich in 
hydrogen bond acceptors. By acetylating the substituted lysine in the peptide inhibitor [Ac-VQIKYK-NH2], 
this lysine residue becomes a hydrogen bond donor and it may promote interaction with 306VQIVYK311 
(circled), which has many hydrogen bond acceptors. Heparin predominantly has hydrogen acceptor sites, 
and it was also predicted that heparin would likely bind to the hydrogen bond donor sites in the centre 




Paired Helical Filament Straight Filament 
Figure 4.9: Binding properties of PDB 5o3l PHF and PDB 5o3t SF, including hydrophobic areas (green), 
hydrogen bond acceptor potential (red) and hydrogen bond donor potential (blue). VQIVYK sequences 
are circled in black. This figure demonstrates that the outside of Tau consists mainly of hydrogen 




4.2.4 OPTIMAL DOCKING AREA (ODA) FOR INHIBITORS 
 
Peptide inhibitors were named to help quickly identify their features in the lab. The following three 
nomenclature refer to their peptide binding residues: AG02 corresponds with [RG-VQIVYK-GR], AG02ΔI 
corresponds with [RG-VQK(Ac)VYK-GR] and AG02ΔV corresponds with [RG-VQIK(Ac)YK-GR]. 
Figure 4.10 was used to predict sites on the following peptides which were likely for protein-protein 
interactions. This was useful to identify important recognition and binding residues for the peptide 
inhibitors AG02 [RG-VQIVYK-GR], AG02ΔI [RG-VQK(Ac)VYK-GR] and AG02ΔV [RG-VQIK(Ac)YK-GR]. 
Position 5 and 7 (from left to right) on these sequences play an important role in binding. In the native 
peptide, position 5 and 7 entails isoleucine and tyrosine, respectively. This confirmed the choice of 
keeping isoleucine which is important in native binding and to keep tyrosine which can act as an anchoring 
molecule via aromatic stacking. The preferred mutation around these bases of interactions to modulate 


































Figure 4.10: Optimal docking areas for 1) AG02 [RG-VQIVYK-GR] which includes I6 and Y8, 2) AG02∆I 
[RG-VQK(Ac)VYK-GR] which includes X6 and Y8 (X6 denotes acetyllysine), 3) AG02∆V [RG-VQIK(Ac)YK-
GR] which includes Q7, I6 and Y8. Notice I6 and Y8 are important binding molecules for these peptides. 
X6 denotes acetyllysine. 
 94 
 
AG02ΔI [RG-VQK(Ac)VYK-GR] and AG02ΔV [RG-VQIK(Ac)YK-GR] were docked onto copies of themselves 
to see how strongly they interact with themselves. Table 4.3 demonstrated that AG02ΔI associated with 
itself much more strongly than AG02ΔV did. From this it was predicted that AG02ΔV would be a more 

















 Self Association of peptides 
Ligand ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv 
AG02ΔI -34.24 -8.26 -7.02 -48.46 20.76 4.01 
AG02ΔV -24.07 -7.62 -5.96 -47.87 25.36 4.78 
Table 4.3: Triplicate average of computationally calculated values describing self-association properties of AG02ΔI 
and AG02ΔV. ICM score of < -32 suggests a strong bind; Natom denotes the number of atoms in the docked ligand; 
Nflex denotes the number of rotatable torsions; Hbond denotes hydrogen bond energy; Hphob denotes 
hydrophobic energy to expose a surface to water; VwInt denotes strong van der Waals interaction energy (< 0); 
Eintl denotes strong ligand internal conformation energy (< 0); Dsolv denotes desolvation of exposed hydrogen 
bond donors and acceptors; SolEl denotes solvation electrostatics energy change upon binding; mfScore denotes 
potential of average force score; dTSc denotes loss of entropy via rotatable side-chains.  
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4.2.5 ASSESSING PDB STRUCTURE QUALITY 
 
Before docking simulations were conducted it was advised to test the quality of the PDB structure in case 
there are errors e.g. incomplete data. This supported an informed decision approach when subsequently 
conducting docking experiments by providing evidence based confidence into the decisions being made. 
The QMEAN of  PDB structures were scored to describe the local geometry over 3 consecutive amino 
acids, long range residues interactions, residues burial status, solvent accessibility and 
predicted/calculated secondary structure. These scorings are then compared to an ensemble of alter-
native models in order to select the best model (Benkert et al., 2008). Figure 4.11 did not pass the 











Figure 4.11: Predicted structure quality of PDB 5o3t SF. A: QMEAN4 score was less than -5 (-5.12) and 
deemed unsuitable for further computational analysis. B-C: Predicted local similarity to target was 












Figure 4.12: Predicted structure quality of PDB 5o3l PHF. A: QMEAN4 score was greater than -
5 (-4.43) and deemed suitable for further computational analysis. Scores less than -0.4 suggest 
global models of low quality. B-C: Predicted local similarity to target was above 0.6 suggesting 































Figure 4.13: QMEAN4 values. A: 6QJH.pdb heparin-induced 2N4R Tau snake filament = -2.30, 
B: 6QJM.pdb heparin-induced 2N4R Tau twisted filament = -1.14, C: 6QJP.pdb heparin-
induced 2N4R Tau jagged filament = -1.67. All structures scored satisfactory global quality. 






4.2.6 TAU SMALL MOLECULE BINDING POCKETS AND BINDING PARTNERS 
 
Figure 4.14 illustrates the main binding pockets on Tau306-378 and describes the raw data used to calculate 
the pockets. This was investigated to predict where other important binding locations may be in relation 













Pocket Volume (Å) Area (Å) Hydrophobicity Buriedness DLID Nonsphericity 
Blue 385.87 348.64 65% 0.88 0.63 1.36 
Red 246.90 277.80 60% 0.67 -0.65 1.46 
Cyan 243.74 266.78 68% 0.77 -0.06 1.41 
Green 124.59 185.91 40% 0.53 -2.15 1.54 
Orange 118.43 180.00 66% 0.80 -0.53 1.54 
Purple 104.99 173.52 47% 0.58 -1.93 1.61 
Figure 4.14: ICM-Pro display of PDB 5o3l using the icmPocketFinder function,  A: Six binding 
pockets were predicted and displayed in blue, red, cyan, green, orange and purple, B: Raw data 
describing the compactness of the binding pockets which are calculated based on the 
Volume of the pocket; Area of the pocket; Hyrdophobicity signifying pocket surfaces in 
contact with hydrophobic protein residues; Buriedness suggesting how open (> 0.5) or closed 
(1.0) pockets were; DLID is the druggability of the pocket (> 0.5); Nonsphericity representing 

























Compound PubChem ID ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl mfScore 
Sodium Heparin 22833565 -34.73 -10.77 -4.11 -32.35 1.24 23.24 -8.43 -86.57 
Thioflavin-T 16953 -28.45 0.00 -5.17 -25.99 1.74 -4.50 5.06 7.60 
Dithiothreitol 446094 -12.86 -2.82 -2.10 -12.11 1.31 2.81 1.04 -6.47 
Figure 4.15: ICM-Pro display of PDB 5o3l with computationally 
docked compounds at their highest energy binding sites 
Tau306-378; A: Sodium Heparin; B: ThT; C: DTT; D: Raw data 
describing the docked compounds. ICM score of < -32 
suggests a strong bind; H bond Score denotes hydrogen bond 
energy; Hydrophobicity denotes hydrophobic energy to 
expose a surface to water; Van der Waals denotes strong van 
der Waals interaction energy (< 0); Eintl denotes strong ligand 
internal conformation energy (< 0); Dsolv denotes desolvation 
of exposed hydrogen bond donors and acceptors; 
SolEl denotes solvation electrostatics energy change upon 
binding; mfScore denotes potential of average force score.      
E: Superimposed image of A-C with highlighted binding 
pockets. Compounds in the Tau aggregation mix maximally 
bind to different binding pockets in PDB 5o3l. DTT binds to the 
green pocket, ThT binds to the red pocket and Heparin binds 
to the blue pocket. Circled in black is the theoretical binding 
















As peviously mentioned in Section 3.3.1, The Tau aggregation mix included sodium heparin (to induce 
aggregation of Tau), ThT (reporter dye) and DTT (to prevent disulphide cross-bridging). Figure 4.15 
illustrates the predicted binding locations for sodium heparin, ThT and DTT on Tau306-378 and describes the 
raw data used to calculate the binding sites. This provided some indication of where these molecules 
predicted binding sites were in relation to each other. This was an important prediction so that there was 
a degree of confidence that these molecules may not competitively bind with one another or with the 























4.2.7 PEPTIDE INHIBITOR DOCKING AREAS ON TAU 
 
avgeODA 
Residue  A B       
V306 -12.08 -20.13 L325 -1.72 -6.10 L344 -2.68 -2.45 V363 -7.94 -9.07 
Q307 -6.56 -16.66 G326 -1.55 -8.99 D345 5.87 -0.71 P364 -2.39 -7.45 
I308 -11 -17.86 N327 0.55 -2.44 F346 -4.29 -2.18 G365 0 -5.41 
V309 -7.36 -12.48 I328 -4.33 -9.02 K347 6.49 3.67 G366 0 -4.38 
Y310 -6.15 -9.01 H329 -0.9 -5.60 D348 1.85 0.65 G367 -0.52 -6.91 
K311 -4.34 -8.92 H330 -1.88 -8.60 R349 1.87 1.12 N368 1.2 -5.43 
P312 -4.4 -6.29 K331 -1.53 -2.13 V350 -1.69 -2.55 K369 1.39 -3.23 
V313 -6.74 -8.20 P332 -1.16 -1.07 Q351 1.12 -0.14 K370 -2.15 -2.68 
D314 -6.21 -6.59 G333 -0.48 -1.02 S352 -1.83 -0.84 I371 -0.52 -1.27 
L315 -4.87 -4.96 G334 0.21 0.67 K353 1.7 1.38 E372 0.18 -2.32 
S316 -1.61 -0.90 G335 0.18 0.40 I354 -4.21 -0.89 T373 0.61 0.12 
K317 1.82 2.15 Q336 0.84 1.59 G355 0 0.10 H374 -4.16 -1.75 
V318 0.61 0.42 V337 -0.47 -0.01 S356 0.87 0.27 K375 3.91 2.68 
T319 -0.81 3.11 E338 1.73 1.96 L357 0 -0.34 L376 -6.1 -10.95 
S320 -0.93 2.74 V339 -0.74 0.54 D358 6.19 -0.49 T377 -4.87 -7.07 
K321 0.32 4.70 K340 2.25 3.14 N359 0.7 -0.73 F378 -20.58 -18.50 
C322 -2.02 3.90 S341 -1.02 -0.27 I360 -2.55 -2.31 
G323 -1.07 -0.37 E342 2.02 1.32 T361 -7.94 -8.63 







Figure 4.16: Optimal docking areas for PDB 5o3l PHF on A: top of PHF, including V306, Q307, I308, 
V309 and F378; B: bottom of PHF including V306, I308 and F378. C: Average optimal docking area 




Figure 4.16 demonstrates that residues V306, Q307, I308, V309 and F378 for the PHF structure PDB 5o3I are the 
optimal docking areas for peptides. Interestingly VQIV residues are target residues for the peptide 
inhibitor. Note that Isoleucine is highlighted as an important docking area for Tau as well as for the 
inhibitor in Figure 4.10. This is probably due to the highly hydrophobic nature of isoleucine which 





























Peptide binding sequences were docked onto Tau to predict which residues they would interact with. 
Figure 4.17 illustrates that the predicted binding site for VQIVYK peptide to its complementary 
306VQIVYK311 sequence in Tau306-378 is variable as the peptide is bound in parallel to the top of the 
protofilament but is bound in anti-parallel to the bottom of the protofilament. This docking experiment 























Figure 4.17: VQIVYK bound to complementary 306VQIVYK311 sequence (cyan) on the PDB 5o3l PFF 
structure. A: bound in parallel and shifted to the top of the protofilament, B: bound in anti-parallel 


















Figure 4.18 illustrates the predicted binding sites for VQIK(Ac)YK to its complementary 306VQIVYK311 
sequence in Tau306-378. VQIK(Ac)YK bound in parallel in both instances however also interacted with amino 
acids in the parallel β-sheet. Increasing the length of the peptide (to include cell penetrating peptide) 
would not be possible to dock accurately. This docking experiment served as an indication if the inhibitor 
binding sequence bound close to its complementary 306VQIVYK311 sequence in Tau. 
A. 
B. 
Figure 4.19: VQIK(Ac)YKP bound close to the 306VQIVYK311 sequence (cyan) in PDB 5o3l PFF structure. A: bound in 
parallel to the top of the protofilament, B: bound in anti-parallel to the bottom of the protofilament. Notice it the 


















Figure 4.19 illustrates the predicted binding sites for VQIK(Ac)YKP to its complementary 306VQIVYK311 
sequence in Tau306-378. Addition of proline appeared to bind in a distinctly different manner compared to 
the native VQIVYK peptide and the modified sequence without proline. Increasing the length of the 
peptide (to include cell penetrating peptide) would not be possible to dock accurately. This docking 
experiment served as an indication to see how the bind would change with an additional proline.  
A. 
B. 
Figure 4.18: VQIK(Ac)YK bound to 306VQIVYK311 sequence (cyan) in PDB 5o3l PFF structure. A: bound in 
parallel to the top of the protofilament, B: bound in parallel to the bottom of the protofilament and 














Table 4.4 Summarises the raw data for the average (n=3) of peptides docking to Tau306-378. Based on the ICM score, the control peptide VQIVYK 
bound more strongly to the top of the protofilament than modified VQIK(Ac)YK did, however with the additional proline, VQIK(Ac)YKP bound the 


















 Bound to top of PHF 
Ligand ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl mfScore 
VQIVYK -15.49 -8.28 -5.68 -40.66 19.83 13.61 17.60 -61.58 
VQIK(Ac)YK -11.40 -4.41 -6.02 -31.54 6.09 9.46 9.07 -41.93 
VQIK(Ac)YKP -18.90 -10.88 -7.28 -39.04 17.44 19.29 11.86 -105.84 
 Bound to bottom of PHF 
Ligand ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl mfScore 
VQIVYK -21.15 -7.59 -6.24 -34.26 13.88 14.15 2.05 -62.82 
VQIK(Ac)YK -25.51 -7.80 -5.77 -40.01 17.89 11.96 -0.28 -85.69 
VQIK(Ac)YKP -19.67 -10.91 -6.80 -40.02 13.77 18.58 15.91 -67.79 
Table 4.4: Summary table of the average computationally calculated values describing the docked compounds to Tau306-378, as seen in Figure 
4.17-4.19. A: peptides bound to the top of the PHF, B: peptides bound to the bottom of the PHF. ICM score of < -32 suggests a strong bind; H 
bond Score denotes hydrogen bond energy; Hydrophobicity denotes hydrophobic energy to expose a surface to water; Van der Waals denotes 
strong van der Waals interaction energy (< 0); Eintl denotes strong ligand internal conformation energy (< 0); Dsolv denotes desolvation of 
exposed hydrogen bond donors and acceptors; SolEl denotes solvation electrostatics energy change upon binding; mfScore denotes potential 





Table 4.5 Summarises the raw data for the highest energy bindings of peptides docking to Tau306-378. Based on the ICM score, the control peptide 
VQIVYK bound more strongly to the top of the protofilament than modified VQIK(Ac)YK did, however with the additional proline, VQIK(Ac)YKP 
bound the most strongly. When binding to the bottom of the protofilament VQIVYK and VQIK(Ac)YKP bound with similar energy, however 













 Highest Energy Bindings to Top of PHF 
Ligand ICM Score No. H Bonds H Bonds 
VQIVYK -16.36 4 V1-I308; V4-Y310; V6-P312; Y5-K6 
VQIK(Ac)YK -13.45 6 Q2-I308; I3-I308; K(Ac)4-I308; Y5-Y310; K(Ac)4-K6; Y5-K6 
VQIK(Ac)YKP -28.23 7 Q2-I308; Q2-Y310; K(Ac)4-Y310; Y5-H374; K6-P312; P7-H374, K(Ac)4-K6 
 Highest Energy Bindings to Bottom of PHF 
Ligand ICM Score No. H Bonds H Bonds 
VQIVYK -24.22 7 V1-K311; Q2-K311; Q2-K311; V4-V309; V4-V309; K6-Q307; K6-Q307 
VQIK(Ac)YK -26.20 6 V1-Q307; V1-V309; Q2-K311; I3-V309; K4(Ac)-K6; K6-K6 
VQIK(Ac)YKP -22.50 8 V1-K317; Q2- S316; I3-L315; I3-L315; I3-V313; Y5-V313; P7-K311; K(Ac)4-K6 
A. 
B. 
Table 4.5: ICM scores, number of hydrogen bonds and hydrogen bond partners for A: highest energy bindings to the top of the PHF, B: highest 
energy bindings to the bottom of the PHF Potential. 
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Figure 4.20 illustrates the potential binding sites for the predicted lead sequence Ac-VQIK(Ac)YKP-NH2 on 
to three differently folded heparin-induced 2N4R Tau filaments: A: 6QJH snake filament, B: 6QJM twister 
filament, C: 6QJP jagged filament. The potential binding locations include the target VQIVYK (red), VQIINK 
(black) and DLLSNV (blue). It was previously mentioned in Section 4.1.3, that during Tau aggregation, 
VQIVYK and VQIINK interact. Since the peptide inhibitor is designed to bind to 306VQIVYK311, it was 
hypothesised that it may also bind with 275VQIINK280 based on this logic. 282LDLSNV287 packs directly 



















































Figure 4.20: Potential binding sites for, A: 6QJH heparin-induced 2N4R Tau snake filament, B: 6QJM 
heparin-induced 2N4R Tau twister filament, C: 6QJP heparin-induced 2N4R Tau jagged filament. 






Figure 4.21 illustrates the predicted peptide binding sites on the heparin-induced 2N4R Tau snake 
filament: A: VQIVYK (control peptide) binds in parallel to both 306VQIVYK311 and 275VQIINK280 sequences, B: 
VQIK(Ac)YKP binds in anti-parallel to 306VQIVYK311 and in parallel to 275VQIINK280.
Figure 4.21: Docked peptides to PDB 6QJH heparin-induced 2N4R Tau snake filament; each 
binding to the 306VQIVYK311 and 275VQIINK280 sequences. A: Ac-VQIVYK-NH2 binding in parallel 
to the filament, B: Ac-VQIK(Ac)YKP-NH2 binding in anti-paralell to the filament at 306VQIVYK311 






Table 4.6 summarises raw data for the predicted peptide binding sites of Ac-VQIVYK-NH2 and Ac-VQIK(Ac)YKP-NH2 on the heparin-induced 2N4R 
Tau snake filament. Based on the ICM-score, VQIVYK bound with higher energy to 275VQIINK280 than it did with its complementary 306VQIVYK311 
sequence, whereas VQIK(Ac)YKP bound with higher energy to its complementary sequence 306VQIVYK311 than it did with 275VQIINK280. These 




 Binding Positions 
Ligand Receptor ICM Score No. H Bonds H Bonds 
VQIVYK 
VQIVYK -17.55 7 Ace-V306; Q2-V306; Q2-Q307; Q2-I308; V4-I308; V4-Y310; K6-V313 
VQIINK -22.11 8 V1-V275; Q2-C322; -I3-V275; I3-I277; Y5-I277; Y5-N279; K6-N279; Y5-K6 
VQIK(Ac)YKP 
VQIVYK -20.19 11 
Q2-Y310; Q2-Y310; K(Ac)4-Y310; K(Ac)4-Y310; Y5-N286; Y5-S285; K6-V306; K6-V306; 
K6-G302; Q2-K4, K6-P7 
VQIINK -17.45 10 
Ace-Y310; Q2-V275; Q2-V276; Q2-I277; K(Ac)4-I277; K(Ac)4-N297; Y5-S316; P7-L282; 
K4-P7; K6-P7 
Ligand Receptor ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl 
VQIVYK VQIINK -22.11 -9.19 -6.37 -31.07 11.37 21.41 -2.13 
VQIVYK VQIINK -20.58 -9.81 -6.21 -31.40 9.63 26.02 -0.76 
VQIVYK VQIVYK -17.55 -9.59 -5.42 -34.72 16.92 22.61 4.47 
VQIK(Ac)YKP VQIVYK -20.19 -11.19 -6.13 -37.51 10.69 28.59 5.88 
VQIK(Ac)YKP VQIINK -17.45 -12.86 -6.72 -38.09 11.99 33.37 11.28 
VQIK(Ac)YKP VQIVYK -16.16 -9.25 -5.75 -36.30 7.72 24.60 9.55 
Table 4.6: Summarises the raw data for the highest energy bindings and hydrogen bond data of peptides (VQIVYK and 
VQIK(Ac)YKP) dockedto the snake filament, A: peptides binding to the 306VQIVYK311 and 275VQIINK280 sequences, B: Summarise 





Figure 4.22 illustrates the predicted peptide binding sites on the heparin-induced 2N4R Tau snake 
filament: A: VQIVYK (control peptide) binds in parallel to its complementary 306VQIVYK311 sequence, B-C: 
VQIK(Ac)YKP binds in parallel and in anti-parallel to 306VQIVYK311, respectively. 
Figure 4.22: Docked peptides to PDB 6QJM heparin-induced 2N4R Tau twister filament; each binding to the 
306VQIVYK311 sequence. A: VQIVYK binding in parallel to fibril, B: VQIK(Ac)YKP binding in paralell to the fibril 






Table 4.7 summarises raw data for the predicted peptide binding sites of VQIVYK and VQIK(Ac)YKP on the heparin-induced 2N4R Tau twister 






 Binding Positions 
Ligand Receptor ICM Score No. H Bonds H Bonds 
VQIVYK VQIVYK -32.14 8 
Ace-Q307; Q2-Q307; I3-Q307; I3-V309; Y5-V309; Y5-K311; Ace-Q2; Ace-Q2; K6-
CONH2 
VQIK(Ac)YKP VQIVYK -22.95 9 V1-S305; V1-Q307; Q2-Q288; I3-Q307; I3-N286; Y5-S285; CONH2-D283; Q2-K4; K6-P7 
Ligand Receptor ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl 
VQIVYK VQIVYK -32.14 -11.08 -5.24 -41.46 13.69 21.67 2.11 
VQIK(Ac)YKP VQIVYK -22.95 -8.00 -6.79 -38.94 3.04 29.24 -1.48 
VQIK(Ac)YKP VQIVYK -20.64 -10.47 -6.83 -38.40 4.22 36.12 1.85 
VQIK(Ac)YKP VQIVYK -19.97 -8.99 -6.48 -39.18 2.01 34.61 1.71 
Table 4.7: Summarises the raw data for the highest energy bindings and hydrogen bond data of peptides (VQIVYK and VQIK(Ac)YKP) docked to 
the twister filament; A: peptides binding to the 306VQIVYK311 sequences; B: Summarise the top 3 applicable bindings poses and locations of 






Figure 4.23 illustrates the predicted peptide binding sites on the heparin-induced 2N4R Tau jagged 
filament. VQIVYK (control peptide) bound in parallel to both 306VQIVYK311 and 275VQIINK280 sequences, 
whereas VQIK(Ac)YKP bound in parallel only to 306VQIVYK311. 
 
Figure 4.23: Docked peptides to PDB 6QJP heparin-induced 2N4R Tau jagged filament. A: VQIVYK 
binding in parallel to fibril at the 306VQIVYK311 and 275VQIINK280 positions, B: VQIK(Ac)YKP binding in 





Table 4.8 summarises raw data for the predicted peptide binding sites of VQIVYK and VQIK(Ac)YKP on the heparin-induced 2N4R Tau snake 
filament. Based on the ICM-score, VQIVYK bound with higher energy to 306VQIVYK311 sequence than it did with 275VQIINK280, whereas VQIK(Ac)YKP 







 Binding Positions 
Ligand Receptor ICM Score No. H Bonds H Bonds 
VQIVYK 
VQIVYK -21.87 7 V1-S305; V1-Q307; I3-Q307; I3-V309; Y5-V309; Y5-K311; CONH2-P312 
VQIINK -17.29 7 V1-V275; V1-I277; I3-I277; I3-N279; Y5-N279; Y5-K281; CONH2-K281 
VQIK(Ac)YKP VQIVYK -25.48 10 
V1-S305; Q2-S305; Q2-P307; K(Ac)4-Q307; K(Ac)4-V309; K6-V309; P7-K311; V1-Q2; 
Q2-K(Ac)4; K6-P7 
Ligand Receptor ICM Score H Bond Score Hydrophobicity Van der Waals Eintl Dsolv SolEl 
VQIVYK VQIVYK -21.87 -11.17 -6.25 -36.93 14.67 25.35 7.09 
VQIVYK VQIINK -17.29 -9.71 -6.53 -28.72 14.27 20.31 2.39 
VQIVYK VQIVYK -14.29 -8.73 -6.19 -32.52 15.91 20.55 6.82 
VQIK(Ac)YKP VQIVYK -25.48 -8.03 -5.64 -35.80 1.59 20.06 0.64 
Table 4.8: Summarises the raw data for the highest energy bindings and hydrogen bond data of peptides (VQIVYK and VQIK(Ac)YKP) docked to 
the jagged filament; A: peptides binding to the 306VQIVYK311 and 275VQIINK280 sequences as applicable; B: Summarises the top 3 bindings poses 








Figures 4.5 and 4.6 illustrated the intrinsic residue solubility profile and the A4V for Tau441, respectively. 
In both figures, VQIVYK is highlighted as the sequence with the lowest intrinsic solubility profile and the 
highest aggregation propensity. Based on this it was determined that the most suitable sequence to target 
using a peptide aggregation inhibitor was the 306VQIVYK311 sequence. This coincides with the literature 
which highlights the importance of 306VQIVYK311 for the aggregation of Tau. Perez et al, (2007) 
demonstrated that deletion of 306VQIVYK311 in Tau prevents heparin induced aggregation and that 
incubating Tau with VQIVYK hexapeptide stimulates aggregation. This data is also supported by the fact 
that when the Aβ sequence is run through these algorithms, they highlight the 16KLVFF20 sequence as the 
aggregatory seqeunce. 
When developing peptide aggregation inhibitors with high selectivity for their pathogenic target 
sequence(s), it is important that the inhibitor itself does not have propensity to self-associate; thus, self-
defeating the original purpose of an aggregation inhibitor. Based on the findings in Figures 4.5 and 4.6, a 
peptide inhibitor to target 306VQIVYK311 must share some similarities to bind to its complementary 
sequence. Professor David Allsop’s research group developed a successful Aβ aggregation inhibitor 
utilising the 16KLVFF20 binding sequence; widely appreciated as the aggregation hot-spot for Aβ (Taylor et 
al., 2010). Following similar logic whilst at the same time safeguarding the possibility of peptide self-
association, potential modifications to 306VQIVYK311 were investigated. Tables 4.1 and 4.2 demonstrates 
aggregation propensity for VQxVYK and VQIxYK, respectively. ‘x’ denotes amino acid substitutions of the 
native Tau 306VQIVYK311 sequence with alternative amino acids. All conformations of VQxKYK and VQIxYK 
which contained hydrophobic residues except proline were identified as aggregation hot-spots. This is 
likely because proline is widely acknowleged as a β-sheet breaker due to the bulkiness of its pyrrolidine 
ring placing steric comformational constraints on its preceding residue and that its dihedral angle fixed at 
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-65˚ is incompatible with β-sheets (Zhang et al., 2019; Li et al., 1996). As a result of these constraints, 
proline interferes with hydrogen bonding between Tau molecules and generates disordered structures. 
This is supported by mutations P301L and P301S in Tau which accelerates aggregation (Barghorn et al., 
2000). Conformations containing hydrophilic residues cysteine, serine, threonine and tyrosine also 
identified as aggregation hot spots. This suggests that substituting the native hydrophobic amino acids 
with any hydrophilic residue does not necessarily lower the hexapeptide aggregation propensity below 
the aggregation threshold. Na4vSS values are the final calculated aggregation propensity values. For both 
VQxKYK and VQIxYK, lysine was chosen as the optimum replacement as VQKVYK and VQIKYK had higher 
Na4vSS values than the other conformations, except proline. A high Na4vSS value but below the 
aggregation threshold was desired as it is a logical assumption that there is a fine line between pathogenic 
aggregation and functionality of proteins. If the Na4vSS value was too low, then it may result in a weak 
interaction with its target sequence 306VQIVYK311. Proline was not deemed suitable to be included in the 
centre of a binding sequence due to its rigidity placing steric conformational constraints within the peptide 
binding sequence.  
Aggregation hot spots are defined as regions (excluding regions containing proline) with ≥ 5 continuous 
residues with an aggregation propensity greater than the “hot spot” threshold. Sequences which exceed 
the hot-spot threshold are predicted to be aggregation prone. Camsol calculates the intrinsic solubility 
profile of 7 amino acid sequence windows and illustrates hydrophilic and hydrophobic regions with blue 
and red, respectively (Sormani et al., 2015). CamSol calculates the intrinsic solubility profile by evaluating 
as intrinsic factors the amino acid residue aggregation propensity, hydrophobicity, charge and secondary 
structure propensity (Arslan et al., 2019). Figures 4.7 and 4.8 suggests the aggregation propensity and 
intrinsic residue solubility, respectively, for each of the following peptides: VQIVYK, VQKVYK and VQIKYK. 
The entire control VQIVYK sequence was well above the hot-spot threshold and was highlighted as a highly 
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insoluble sequence. VQKVYK was globally under the hot-spot threshold, with lysine (position 3) locally 
exceeding the threshold and according to CamSol was not particularly hydrophobic.  
VQIKYK was also globally under the hot-spot threshold, with isoleucine (position 3) locally exceeding the 
threshold and according to CamSol isoleucine (position 3) was considered particularly hydrophobic. Based 
on these data, isoleucine appears to be highly important for hydrophobic binding interactions in VQIVYK. 
This is supported by the C-beta carbon in isoleucine having two non-hydrogen substituents attached to it, 
resulting in restricted conformations and being involved in binding/substrate recognition (Betts and 
Russel, 2003). Peptide solubility is important; however, they also need to be able to bind to their molecular 
targets which requires aggregation-prone sequences of amino acids e.g. VQI (Sormanni et al., 2015). As 
306VQIVYK311 sequences interact with one another perpendicularly to the fibril axis (as seen below in Figure 
4.24) through hydrophobic interaction, VQIKYK was favoured to be the more suitable binding sequence.  
Figure 4.24: Atomic resolution structure of Tau 306VQIVYK311 peptide determined by MicroED, 
demonstrating perpendicular stacking to the fibril axis (de la Cruz et al., 2017). 
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Using ICM-Pro, PDB 5o3l PHF and PDB 5o3t SF were analysed using the binding properties mesh as seen 
in Figure 4.9. This mesh scans all residues for their ability to form hydrogenbonds and identifies, hydrogen 
bond donors, hydrogen bond acceptors and hydrophobic areas. Hydrogen bond donation is an 
electrostatic interaction. Hydrogen bonding occurs when the partial positive charge from a hydrogen 
atom bound to an electronegative atom, usually Nitrogen, Oxygen and Fluorine (hydrogen bond donor) 
attracts a lone pair of electrons attached to another electronegative atom (hydrogen bond acceptor). 
These non-covalent bond interactions are important for binding. Electron donors are reducing agents 
which donate electrons to another compound. When aggregating Tau, the presence of polyanions such 
as heparin are necessary to initiate nucleation. In Tau-heparin interactions, hydrogen bond donor sites on 
Tau will donate their positively charged hydrogens to hydrogen bond acceptor sites on heparin, which is 
negatively charged. The area for this interaction to occur is predicted to be within the horse-shoe shape 
of Tau as seen in Figure 4.9. Here heparin can act as a scaffold via its sulfate groups and interact with 
oligomers through electrostatic interactions. Lysine acetylation is a common modification and by 
acetylating lysine it loses its ability to accept hydrogen bonds and is rendered solely a Brønsted acid where 
it can only donate hydrogen bonds to Brønsted bases, which are hydrogen bond acceptors (European 
Bioinformatics Institute, 2019). The outer regions perpendicular to the fibril axis are largely positively 
charged, whereas the inner regions following the fibril axis are largely negatively charged. As a result, by 
acetylating the substituted lysine at position 4 in the VQIKYK sequence it may promote binding to or near 
its complementary sequence within the negatively charged region, perpendicular to the fibril axis. It also 
removes the charge on lysine which could interfere with binding as positive charges must be neutralised 
for Tau to bind stably (Guo et al., 2017). As acetyllysine is polar and valine is non-polar, introduction of 
VQIK(Ac)YK may decrease the hydrophobicity of the hot-spot sequence in native Tau. Zhang et al. (2019), 
stated that lysine positive charges must be neutralised for Tau to form stable filaments; therefore, this 
modification may allow the inhibitor to bind with more stability.  
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ODA (optimal docking area) analyses surfaces for favourable energy change once buried as a protein-
protein complex to identify. The ODA was calculated for AG02, AG02∆I and AG02∆V in Figure 4.10 which 
revealed that positions 5 (isoleucine) and 7 (tyrosine) are important for docking, even when isoleucine 
was replaced with acetyllyisine in AG02∆I. This agrees with the Aggrescan and CamSol data which formed 
the initial basis of the prediction that VQIKYK would bind better than VQKVYK. Berhanu and Masunov, 
(2012), stated that 306VQIVYK311 forms an apolar dry interface via the side chains of V1 and I3 with tyrosine 
which further highlights the importance of isoleucine and tyrosine in the VQIVYK peptide. Both isoleucine 
and tyrosine are also on the side which packs tightly with the 4th repeat in the hydrophobic PHF core 
(Fitzpatrick et al., 2017). Naruto et al. (2010), reported that CH/π interactions between isoleucine and 
tyrosine in VQIVYK is essential for dry interface formation of steric zippers. This interaction can be seen in 
Table 4.9 when tyrosine from VQIVYK is CH/π hydrogen bonding with isoleucine in 275VQIINK280. These 
interactions occur between soft acids and bases, in polar or non polar environments and are weaker than 
classical hydrogen bonds, however have proven to be very important interactions regarding molecular 
recognition, assembly and behaviour. However, the strength of CH/π bonds involving acetylenic groups 
are more similar to classical hydrogen bonds (Nishio, 2011). The acetyllysine in VQIK(Ac)YKP demonstrated 
to interact with the VQIVYK tyrosine in the PHF (Table 4.8) and the snake filament (Table 4.9). Retaining 
isoleucine and tyrosine in the binding sequene of the peptide inhibitor are clearly important binding 
molecules for VQIVYK interactions. The introduction of acetyllysine also seems to play a role in enhancing 
interactions. AG02∆V [RG- VQIK(Ac)YK-GR] contains the acetyllysine on position 6 (valine) which packs 
tightly with the 2nd repeat (Zhang et al., 2019). 275VQIINK280 is in the 2nd repeat and is touted as the other 
highly aggregatory hexapeptide in Tau. Interfering with residues in the 2nd repeat was deemed favourable 
as this could potentially disturb the usual pathogenic folding of 275VQIINK280 as well as 306VQIVYK311, which 
are both neccessary hexapeptides for Tau aggregation. Having the acetyllysine at position 6 (valine) 
instead of position 5 (isoleucine) retained the docking propensity for glutamine at position 4, which is also 
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seen with AG02 [RG-VQIVYK-GR]. This similarity to the native sequence suggests AG02∆V [RG-VQIK(Ac)YK-
GR] to be a more favourable binding protein than AG02∆I [RG-VQK(Ac)VYK-GR]. To investigate potential 
self-association of AG02∆I [RG-VQK(Ac)VYK-GR] and AG02∆V [RG-VQIK(Ac)YK-GR] they were docked onto 
themselves in ICM-Pro. Table 4.3 demonstrated that AG02∆I binding sequence [VQK(Ac)VYK] interacted 
with itself more strongly than the binding sequence of AG02∆V [VQK(Ac)VYK] by having lower ICM, 
hydrogen bond, hydrophobicity, van der Waals and solvation electrostatics energy change scores. This 
confirmed the choice for ceasing progression of AG02∆I [RG-VQK(Ac)VYK-GR] (which was the weaker 
optimal docking protein and was predicted to self associate) and progressing with the development of 
AG02∆V [RG-VQIK(Ac)YK-GR]. This binding sequence was then modified to include proline [RG-
VQIK(Ac)YKP-GR] which as previously described has useful β-sheet breaker properties. Von Bergen et al 
(2000), demonstrated that mutation of any resiude from VQIVYK into proline results in severe inhibition 
of Tau aggregation due to interrupting necessary chain conformations. Since Tau aggregation largely 
occurs intracellularly, the inhibitor was modified to include octa-arginine for use as a cell penetrating 
peptide (CPP) motif. From this AG03 [RG-VQIK(Ac)YKP-GRRRRRRRR] was proposed and the core binding 
sequence retained similar ODA values as AG02∆V [RG-VQIK(Ac)YK-GR], as seen in Figure 4.10. PDB 5o3l 
PHF and PDB 5o3t SF were the only viable Tau structures available at the time for the docking simulations 
required for this thesis. Before working with these structures, they were first assessed for their structure 
quality with SWISS-MODEL by relating their structural features to similar sized experimental stuctures 
(Benkert et al., 2011). This supported an informed decision approach when subsequently conducting 
docking experiments by providing evidence based confidence into the decisions being made. PDB 5o3t SF 
failed to provide a satisfactory QMEAN4 threshold value and was rejected for further use (Figure 4.11). 
When assessing PDB 5o3I PHF with SWISS-MODEL a low global quality QMEAN4 value was generated 
(Figure 4.12); however, still deemed acceptable. QMEAN mainly uses statistical potentials of mean force 
that compare interactions observed in the model such as pairwise interactions, dihedral angles etc. and 
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with what would be expected from high resolution X-ray structures in a probabilistic manner.  As seen in 
Figure 4.25, PDB 5o3I PHF is a structure from aggregated Tau and does not follow the dogma of a nicely 
packed globular protein, and as a result it may be why the generated global quality score was poor. These 
structures have been ground breaking and perhaps due to their unique structure not previously seen in 
the PDB is why global quality score was poor.  
QMEANDisCo is agnostic of actual physical interactions and assesses the consistency of interatomic 
distances with ensembles of constraints extracted from homologous structures in the PDB. Since the 
actual structure 5ol3 PHF is in the PDB, QMEANDisCo generates good quality local residue scores, with 
average QMEANDisCo scores for chains B and J as 0.78 (out of 1). Based on this the structure passed the 
criteria for the set methodology of pre-requisite docking experiments. QMEAN values for 6QJH.pdb snake 
filament, 6QJM.pdb twisted filament and the 6QJP.pdb jagged filament were scored with good quality, as 
seen in Figure 4.13, and so were also subsequenty used for docking experiments. To verify that the 
peptide inhibitor would not interfere with other compounds in the aggregation mix (Thioflavin-T, Sodium 
heparin and DTT) used to aggregate Tau in vitro, small molecule binding pockets were investigated using 
Figure 4.25: PDB 5o3I cryo-EM structure of PHF in AD brain (Fitzpatrick et al., 2017). 
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ICMPocketFinder on ICM-Pro. This was an important prediction before testing the inhibitors in vitro, 
otherwise fluorescence reports would not be truly measuring the effect of the inhibitors on Tau 
aggregation. They would instead be measuring how the inhibitors prevent heparin and ThT from 
interacting with Tau to generate fluorescence signal. Figure 4.14 highlights six potential pockets where 
small molecules can bind to the PHF core and provides information on each pocket.  Only one pocket 
located between residues 362HVPGGNK369 scored high enough to be considered druggable according to its 
DLID score, which are measurements of the likelihood a pocket will bind a drug-like molecule (Sheridan 
et al., 2010). Once pockets were identified, compounds from the Tau aggregation mix (Heparin, ThT and 
DTT) were docked onto the 5o3l PHF structure. Heparin, ThT and DTT all appeared to dock at their highest 
energy to the blue, red and green pockets, respectively, as seen in Figure 4.15. This demonstrated that 
these compounds did not compete with one another for binding sites on Tau, which meant that heparin 
is freely able to interact with Tau to promote fibrilisation and that ThT is able to freely interact with Tau. 
Both heparin and ThT bind to Tau very strongly with ICM-scores of -34.73 and -28.45. It is important these 
strongly binding compounds have differet binding areas to one another and that of the 306VQIVYK311 
sequence, otherwise the peptide inhibitor would be in competition to the binding sites and produce false 
results. ODA was also performed on the sequence to determine the optimum docking areas for peptides. 
Figure 4.16 highlighted residues V306, Q307, I308, V309 and F378 which is perfect as the peptide inhibitor is 
designed to target the 306VQIVYK311 sequence. By summarising the aggregation mix predicted binding sites 
and the predicted peptide binding site, there was now confidence that these molecules would be less 
likely to interfere with one another. From this it was predicted that any phenomena seen in vitro regarding 
inhibition of Tau aggregation would be because of the inhibitor binding to Tau. 
LEADS-PEP is a benchmark data set consisting of 53 protein-peptide complexes which serves for 
evaluation of docking softwares in terms of their efficiency assessment of docking and scoring 
performance (Hauser and Windshügel, 2016). Hauser and Windshügel (2016), demonstrated that very few 
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complexes were docked reproducibly using peptide lengths over 8 residues, and none of 12 residue 
peptides were re-docked correctly by any of the methods tested as computational difficulty of docking 
grows exponentially with length. In 2018 MolSoft ICM-Pro ranked first place by outperforming other 
methods for docking pose and affinity prediction accuracy for all targets in the Drug Design Data Resource 
(D3R) Grand Challenge 3 (Lam et al., 2019). The D3R Grand Challenge 3 is a blind community-wide test 
enabling developers to validate their methods and compare them to others. AG03 is 18 residues long 
which is outside of the general applicability domain of flexible ligand docking protocols (Hauser and 
Windshügel, 2016). It was feasible instead to use VQIVYK sequence (as the native control) and two 
versions of the inhibitor binding sequence, VQIK(Ac)YK and VQIK(Ac)YKP in docking simulations onto the 
top and bottom of PDB 5o3l PFH fibril axis. Both VQIVYK and VQIK(Ac)YKP docked in parallel to their 
complementary 306VQIVYK311 sequence in the native protein, both at the top and bottom of the fibril axis, 
as seen in Figure 4.17 and 4.19. VQIK(Ac)YKP docked in an anti-parallel manner next to the 306VQIVYK311 
complementary sequence. Within the context of a Tau fibril, 306VQIVYK311 organises into parallel face-to-
face β-strands within the same β-sheet layer and protofilaments are formed by mating identical β-sheet 
layers in an anti-parallel fashion, as seen above in Figure 4.25 (Eisenberg et al., 2017; Ganguly et al., 2015; 
Berhanu and Masunov, 2012). Cheon et al. (2012), observed that free VQIVYK peptides formed β-sheets 
consisting of both parallel and anti-parallel strands which stacked to then form disordered or irregular 
protofilaments. This may suggest why VQIK(Ac)YKP docked in an anti-parallel manner. Ganguly et al. 
(2015), stated that peptides which promote anti-parallel alignments usually have slower aggregation 
kinetics than parallel alignments due to increased difficulty mating β-sheets together. This finding agrees 
with x-ray structures solved by Sawaya et al., (2007).  
According to Table 4.4, VQIK(Ac)YKP docked most strongly to the top of the fibril axis, however bound 
with similar energy to the bottom of the fibril axis when compared with the control VQIVYK. peptide This 
is made apparent when observing the number of hydrogen bonds formed in Table 4.5; the control made 
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7 hydrogen bonds whereas VQIK(Ac)YKP made 8. VQIK(Ac)YKP demonstrated its ability to not only bind 
the native residues of 306VQIVYK311, but also with amino acids in the R4 opposing chain, perhaps due to 
the added rigidity of proline affecting the fold of VQIK(Ac)YKP. 
Structure quality was assessed for 2019 structures: PDB 6QJH Q6JM and 6QJP which are heparin-induced 
induced 2N4R Tau snake, twisted and jagged filaments, respectively (Figure 4.13). All three structures 
scored good global quality scores of -2.30, -1.14 and -1.67, respectively. The interaction of 306VQIVYK311 
with 275VQIINK280 is believed to produce twisted PHF-like filaments, therefore if VQIK(Ac)YKP can bind to 
06VQIVYK311 perhaps it can also bind to 275VQIINK280 due all three sharing the same VQIxxK sequence (Von 
Bergen et al., 2001). Figure 4.20 highlights potential additional inhibitor binding sites, including the 
275VQIINK280 sequence and the 282LDLSNV287 sequence (which in the snake, twister and jagged PDB filament 
structures) packs directly opposite the 306VQIVYK311 sequence and resembles an amphiphilic 
amyloidogenic motif (Seidler et al., 2018). The VQIVYK control peptide docked in parallel to its 
complementary VQIVYK sequence on the snake filament, however VQIK(Ac)YKP docked in an anti-parallel 
comformation, as seen in Figure 4.21. Both control peptide and VQIK(Ac)YKP also docked in parallel to the 
VQIINK sequence, suggesting that the inhibitor can target the two main aggregation sequences in Tau. 
Table 4.6 demonstrated that VQIK(Ac)YKP in-silico docks with more affinity to the 306VQIVYK311 sequence 
than the control peptide does, whereas the control peptide had a stronger affinity to bind to 275VQIINK280. 
The observation of VQIVYK binding strongly to 275VQIINK280 is supported by Ganguly et al., (2015) who 
demonstrated that 306VQIVYK311 forms stable heterodimers with 275VQIINK280 and that homodimers of 
306VQIVYK311 and heterodimers of 306VQIVYK311 and 275VQIINK280 have stronger interactions than 
homodimers of 275VQIINK280. When docking to the twister filament both control peptide and VQIK(Ac)YKP 
docked in parallel to the native 306VQIVYK311 sequence as seen in Figure 4.22. Both docks were strong, 
however the control peptide had an exceptionally higher binding score as seen in Table 4.7. In this 
structure neither peptide bound to the 306VQIVYK311 sequence, however VQIK(Ac)YKP, in addition to 
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binding to its target sequence, also simultaneously bound to S305, Q288, N286 and S285 in the parallel 
R2 region which packs next to 306VQIVYK311. Interestingly with the jagged filament structure, the control 
peptide docked in parallel to both its complementary sequence and the 275VQIINK280 sequence, however 
VQIK(Ac)YKP only docked in parallel to the 306VQIVYK311 sequence but with greater binding energy than 
the control peptide (Figure 4.23 and Table 4.8).  Both 275VQIINK280 and 306VQIVYK311 sequences contain a 
VQIxxK recognition motif which was favourable to maintain in the inhibitor. The fifth amino acid (from left 
to right) in 275VQIINK280 and 306VQIVYK311 are amino acids asparagine and tyrosine, respectively. Asparagine 
can accept two hydrogen bonds and donate two hydrogen bonds, whereas tyrosine can get involved in 
aromatic stacking interactions. These two amino acids play important roles in binding and may interact 
via polar-π interactions involving a polar molecule (asparagine) interacting with a quadrupole moment 
(benzene ring in tyrosine). Quadruple moments in molecules arise from the uneven distribution of charge 
(Chakravarty et al, 2018). In addition to this, the data suggests that both VQIVYK and VQIK(Ac)YKP may be 
able to bind the 306VQIVYK311 and the 275VQIINK280 sequence, perhaps making it a VQIxxK specific peptide, 
as well as the ability to additionaly bind neighbouring residues, which may inhibit aggregation. The 
summary on the next page in Table 4.9 demonstrated that VQIK(Ac)YKP binds with similar intensity to its 
target when compared with the native control. Both peptides were also predicted to interact with 
275VQIINK280. VQIK(Ac)YKP binds to the general region of 305SVQIVYKP312 which includes hydrogen bonding 
to residues G302, H374, N286, S285, Q288. It also binds to the general region of 274HVQIINKK281 which 
includes hydrogen bonding to residues L282, N297, Y310, S316. Notice that H374 (from HVQIINKK 
sequence) is involved in the 306VQIVYK311 bind and that Y310 (from the SVQIVYKP sequence) is involved in 
the 75VQIINK280 bind, suggesting that the inhibitor may be able to interact with the 306VQIVYK311 and 
275VQIINK280 residues simultaneously. As the peptide inhibitor was observed to bind to its target sequence 
306VQIVYK311 in an anti-parallel manner, it may also alter the aggregation pathway. According to Feinstein 
et al. (2016), anti-parallel Tau dimers mediated via two N-terminal tails forming an electrostatic zipper, 
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promote microtubule bundling which may provide an additional benefit to this peptide inhibitor as a 
microtubule stabiliser (Rosenberg et al., 2008). In summary the best inhibitor binding region chosen to 
take forward was VQIK(Ac)YKP because it contains the advantageous deletion of valine, the replacement 
with acetyllysine and the addition of beta sheet breaker proline on the N terminus. This peptide 
demonstrated a lower predicted tendancy to self associate (perhaps due to the replacement of valine and 
the addition of proline) but bound to Tau with similar intensity as the native control (perhaps due to the 
acetyllysine promoting hydrogen bond interactions with the 306VQIVYK311 target) and with a greater 
number of hydrogen bonds, as seen in Table 4.9.  
 











VQIVYK (top) Parallel -16.36 4 Parallel -28.23 7 
VQIVYK (bottom) Anti-parallel -24.22 7 Anti-parallel -22.50 8 
Snake 
VQIVYK Parallel -17.55 7 Anti-parallel -20.19 11 
VQIINK Parallel -22.11 8 Parallel -17.45 10 
Twister VQIVYK Parallel -32.14 8 Parallel -22.95 9 
Jagged 
VQIVYK Parallel -21.87 7 Parallel -25.48 10 





Table 4.9: Summary of the strongest energy bindings, orientations and number of hydrogen bonds for 
VQIVYK and VQIK(Ac)YKP docked onto PDB: 5o3l PHF, 6QJH snake filament, 6QJM twister filament and 
6QJP jagged filament. Significantly stronger energy bindings are highlighted in grey. 
 
VQIVYk and hydrogen bond data of peptides (Ac-VQIVYK-NH2 and Ac-VQIK(Ac)YKP-NH2) docked to the 
jagged filament; A: peptides binding to the VQIVYK and VQIINK sequences as applicable; B: Summarises 





5. DEVELOPMENT OF TAU AGGREGATION 
INHIBITORS 
This chapter explores the recombinant expression and purification of Tau251-441 (Tau∆1-250) and testing 
the peptide inhibitors against Tau∆1-250 aggregation using ThT fluorescence assays, CD, Congo red 
birefringence and TEM. The lead peptide inhibitor is adapted to include retroinversion of its sequence – 
meaning the sequence uses D-amino acids instead of L-amino acids and the sequence is reversed. This 
adapted lead peptide is also investigated for its effectiveness when attached to a liposome. 
5.1 EXPRESSION OF RECOMBINANT TAU∆1-250 
 
5.1.1 PROTEIN EXPRESSION 
 
~50mg of Tau protein was required for this research to test and develop successful peptide aggregation 
inhibitor candidates. It was unfeasible to purchase Tau protein (Sigma Aldrich) at the required quantities 
due to cost, therefore in-house production was necessary. In this research TauΔ1-250 fragment was used 
instead of full-length Tau as the plasmid was already in the lab and this protein fragment aggregates in ~8 
hours whereas full length Tau aggregation can take up to ~72hours (Crespo et al., 2018; Taniguchi et al., 
2005). This slow aggregation of full-length Tau may be due to its high proportion of polar and hydrophilic 
molecules. Recombinant expression of TauΔ1-250 in Escherichia coli (E.coli) was conducted in order to 
facilitate the aim of this research. E. coli expression systems can produce high yields of protein in a short 
amount of time for a low cost.  Disadvantages include no eukaryotic post-translational modifications and 




5.1.2 CATION EXCHANGE COLUMN CHROMATOGRAPHY 
 
Cation exchange chromatography is the separation of negatively charged or polar molecules. There are 
two phases; the stationary phase, where positively charged proteins bind to the negatively charged 
column, and the mobile phase which is the elution of the column. Elution of proteins can be achieved by 
changing the pH or ionic strength of the mobile phase, resulting in ion exchange on the column. In this 
research the stationary phase column consistsed of negatively charged SP-sepharose polymers which 
retained cations. At a protein isoelectric pH, the net charge is neutral, however if the pH is shifted above 
or below the protein isoelectric point the net charge becomes negative or positive, respectively. TauΔ1-
250 (pI 9.5) was positively charged because it was reconstituted in purification buffer (pH 6.8), therefore 
Tau was attracted to the negative beads of the cation exchange column. To secure the protein of interest 
the column was eluted using NaCl. Na+ ions compete with positively charged proteins bound to the 
negatively charged column, causing those proteins to elute. Neutral and negative ions such as Cl - do not 
bind to the column and pass through the mobile phase. Differently charged molecules elute at different 
concentrations of NaCl.  
5.1.3 AMMONIUM SULPHATE PRECIPITATION 
 
Ammonium sulphate precipitation is a technique used to precipitate proteins out from a solution.  This is 
achieved through the manipulation of three main interactions between proteins and water: 1) hydrogen 
bonding between water and polar groups such as Serine, Threonine and Tyrosine, 2) ion hydration 
between charged side chains such as Arginine, Glutamic acid and Lysine and 3) hydrophobic hydration 
between Valine, Isoleucine, Leucine and Phenylalanine (Wingfield, 2001). When low levels of salts are 
introduced to a solution (“salting-in”), they help to stabilise proteins due to their charge, the same way 
magnesium stabilises the backbone of DNA. Native globular proteins maintain their solubility at ~0.3-0.4g 
water per gram protein. At high salt concentrations (“salting-out”), the salt has a higher affinity to interact 
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with water, resulting in fewer protein-water interactions at the hydration layer due to increased solvent 
surface tension.  (Bhattacharyya et al., 1988, Rupley et al., 1983 and Green and Hughes, 1955). This results 
in increased hydrophobic interactions between protein and water; causing proteins to decrease their 
surface area to minimise contact with the salts by self associating and subsequently precipitating out of 




5.2 TAU AGGREGATION EXPERIMENTS 
 
In this research, TauΔ1-250 was used instead of full-length Tau for aggregation experiments as it 
aggregates faster and more readily (Kumar et al, 2014). Tau is difficult to aggregate in vitro without an 
inducer due to its hydrophilic nature, as demonstrated by having ~38% hydrophilic amino acids. 
Hydrophobic conditions are required to bring the Tau molecules together, so they can begin the 
aggregation process. Induced aggregation kinetics for Tau fibril formation is characterised by a lag phase, 
followed with a period of exponential growth and reaching a plateau at equilibrium (Chirita et al., 2005). 
The most studied aggregation assays use either polyanions or fatty acids in oxidative or reductive 
conditions, respectively (Ward et al., 2013; Barghorn and Mandelkow, 2002). The two common anionic 
surfactants are heparin and arachidonic acid which both induce the formation of PHFs in 3R isoform Tau 
(contains three microtubule-binding repeat domains) whereas fibrils are less twisted when aggregating 
4R isoform Tau (contains four microtubule-binding repeat domains) and are straighter (Barghorn and 
Medelkow, 2002). Heparan sulfate is a glycosaminoglycan with a structure very similar to heparin and co-
exists with Tau in the nerve cells of AD patients (Uversky and Lyubchenko, 2013). Calamai et al., (2006) 
stated that removing the sulphate groups from heparin or adding magnesium or calcium ions suppresses 
aggregation. This suggests that Tau aggregation is rather influenced by electrostatics instead of the nature 
of negatively charged polymers (Sibille et al., 2006). According to literature heparin appears to be the 
most widely used polyanion aggregation inducer as it is much cheaper than other inducers such as 
Arachadonic acid (Pickhardt et al., 2007; Li et al., 2009; Hattori et al., 2008; Yao et al., 2003). Depending 
on the isoform, Tau generally has a pI of 8.3-10.0, so is positively charged at neutral pH (Von Bergen et 
al., 2005). K18 is a recombinant construct of Tau that only comprises the 4R repeat domains and has a pI 
of 10.39 and a net charge of +9 at neutral pH (Jeganathan et al., 2008). Tau repeat domains are positively 
charged and are attracted to negatively charged microtubules, however lose their positive charge upon 
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phosphorylation (Gong and Iqbal, 2008).  Since TauΔ1-250 (entails the 4R domain plus the N terminus) 
has a pI of 9.3, it will also have a high net positive charge at neutral pH. Amongst all known biological 
molecules, heparin has the highest negative charge density allowing it to overcome positive charges in 
Tau (Cox and Nelson, 2004). This reduces the activation energy required for aggregation; thereby 
accelerating fibril growth (Zhu et al., 2010). Figure 5.1 demonstrates the kinetic role of heparin allowing 
one heparin molecule to attract two Tau monomers and undergo conformational changes to form an 
aggregation nuclei dimer.  
 
Figure 5.2 illustrates an inverted-U curve where the rate of fibril formation is observed for dependence 
on the concentration of heparin. (Ramachandran and Udgaonkar, 2011). Insufficient heparin results in a 
reduced rate of aggregation, ~1:2 Tau:heparin yields the fastest rate of aggregation, however exceeding 
this ratio causes unbound heparin to increase ionic strength which inhibits aggregation and increasing lag 
Figure 5.2: Aggregation kinetic model of  K18 50µM a) in the presence of different heparin 
concentrations at pH 7:  8.3µM (○), 16.6µM (∆), and 56.2µM (◊) b) Apparent ThT monitered kinetics rate 
constant plotted against heparin concentration (Ramachandran and Udgaonkar, 2011). 
Figure 5.1: Illustrative model demonstrating a single heparin molecule binding two Tau monomers to form 
an aggregation competant dimer (Ramachandran and Udgaonkar, 2011). 
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times (Ramachandran and Udgaonkar, 2011; Zhu et al., 2010; Jeganathan et al., 2008). Similar patterns 
for rate of fibril formation is also dependent upon concentration of protein present. To compare 
exponential growth phases more clearly a conservative molar ratio of Tau:heparin commonly used is 4:1. 
Other potential inducers of aggregation include: poly-glutamate, RNA, alkyl sulphate detergents, 
docosahexaenoic acid, quinones, taurine and hexafluoro-2-propanol (Kampers et al., 1996; Lim et al., 
2014; Barghorn and Mandelkow, 2002; Elbaum-Garfinkle et al., 2010; Santa-Maria et al., 2004; Santa-
Maria et al., 2007; Konno et al., 2004). Fatty acids and detergents behave in a different manner in 
comparison to negatively charged polymers such as heparin and RNA which freely bind with Tau and act 
as scaffolds. Instead, fatty acids and detergents form negatively charged micelles by sequestering their 
hydrophobic tails inwards and displaying their hydrophilic heads outwards. Once they exceed the critical 
micellar concentration they then behave as inducers of aggregation through their negatively charged 
outer surface (Ramachandran and Udgaonkar, 2011; Barghorn and Mandelkow, 2002). This negative 
charge attracts Tau proteins causing increases in concentration which enables the Tau to aggregate by 
overcoming the required energy barrier (Chirita and Congdon, 2005). As Tau forms hydrophobic 
interactions, it reduces its interactions with water promoting fibrilisation. This hypothesis correlates to in 
vivo observations whereby PHFs are often bound to organelle membranes, suggesting that perhaps 
disturbances in lipid metabolism may affect their byproducts or membranes in general and thus induce 
the aggregation cascade of Tau (Kuret et al., 2005). 
Proteins usually either have a net positive or negative charge depending on the pH of the solution they 
are in as this alters the electrostatic properties of the protein surface. Typically, at low pH they have a net 
positive charge whereas at high pH they have a net negative charge. At a pH that equals a specific protein 
isoelectric point the net charge becomes neutral and the protein becomes more insoluble as there is less 
repulsion between molecules resulting in an increase in hydrophobicity and aggregation. According to 
Ruffin et al. (2014), hippocampal neurons in in CO2/HCO3− containing media have a pH of ~7.03–7.46 and 
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extracellular pH of ~7.35 (Raley-Susman et al., 1991; Schwiening and Boron, 1994; Bevensee et al., 1996; 
Church et al., 1998; Vincent et al., 1999). Physiological pH (7.4) was used for the research in this thesis as 
it is similar to the human brain and because within the pH ranges of ~5-10 heparin is efficient in various 
buffers. Outside of these pH values would cause the reaction to break down due to the disappearance in 
the pattern of charged interactions (Jeganathan et al., 2008). Addition of an appropriate buffer to the 
aggregation mix is necessary to resist changes in pH. Sigmoidal ThT growth curves representing amyloid 
aggregation are characteristcally divided into three main phases: 1. lag (represents thermodynamically 
unfavourable nucelus formation), 2. Growth (thermodynamically favourable growth) and 3. Plateau (when 
the concentration of monomers has reached equilibrium). Barghorn and Mandelkow (2002) observed 
sigmoidal ThT curves when aggregating Tau in phosphate buffered saline (PBS). However, Ramachandran 
and Udgaonkar (2011), confirmed PBS follows sigmoidal kinetics but was not very reproducible; whereas 
Tris buffer was more reproducible but appearedd to follow single-exponential kinetics without any lag 
phase at pH 7.5, in both the absence and presence of NaCl (Figure 5.3). 
Many aggregation protocols use 37°C corresponding to physiological temperature (Yao et al., 2003, 
Pickhardt et al., 2005, Hattori et al., 2008 and Li et al., 2009). This coincides with Uversky et al., (2001) 
who suggested that elevating temperatures promoted partial folding through a hydrophobicity-driven 
collapse. Aggregation is a result of electrostatics and should be conducted at 37°C and at a pH which also 
Figure 5.3: K18 fibril formation in presence of heparin. ThT fluorescence of 50µM K18 with 37.5µM 




mimics in vivo conditions.All Tau isoforms comprising the four microtubule-binding repeat domains 
contain two cysteine residues at C291 and C322 which can form intermolecular and intramolecular 
disulphide bonds upon oxidation to produce covalent dimers or compact monomers, respectively (Walker 
et al, 2012). Aggregation studies using mutant Tau containing only one cysteine residue lead to the 
conclusion that these intermolecular disulphide bonds facilitate PHF assembly in 3R Tau (Meraz- Ríos et 
al., 2010; Sugino et al., 2009; Kuret et al., 2005; von Bergen, 2000; Barghorn and Mandelkow, 2002; Di 
Noto et al., 1999). This is supported by in vitro studies which suggested that intramolecular disulphide 
bonds between the two cysteines retard Tau aggregation as they prevent intermolecular disulphide 
bonding (Walker et al., 2012). Figure 5.4 demonstrates that aggregating K19 (3 repeat domains of Tau 
without the second repeat) in reducing conditions reduced rate and extent of aggregation whereas the 
opposite was found for K18 (4 repeat domains of Tau).   
Figure 5.4: Aggregation kinetics. A: K19 in oxidising conditions, B: K18 in oxidising conditions. PHFs in A) 
reducing and oxidative conditions using ThS fluorescence (Barghorn et al., 2005). Thioflavin-S (ThS) is an 
alternative dye to ThT to monitor fibril formation, however reports higher background signal.   
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Sahara et al., (2007) stated that Tau mutants without any cysteine residues still aggregated to form fibrils 
over a 24-hour period; suggesting a more complicated role for intramolecular disulphide bonds. It is 
important to note that the pathological AD brain includes both 3R and 4RTau which undergoes oxidative 
rather than reducing conditions to encourage aggregation (Zhu et al., 2010). Ibáñez-Salazar et al. (2017), 
demonstrated that by inducing oxidative stress in human fibroblast primary cultures transfected with Tau-
gene or untransfected, resulted in higher immunopositivity to phospho-Tau within cell nuclei in both 
models. Fatty acid oxidatation was postulated by Gamblin et al. (2000), to stimulate Tau aggregation in 
vitro, rather than cysteine dependent oxidation of Tau. In short, 4R Tau readily forms fibrils in a reduced 
environment but fibril formation is impaired with oxidation, whereas 3R Tau fibril formation is impaired 
in a reduced environment but readily forms fibrils with oxidation. For the purpose of the in vitro 
experiments in this thesis, DTT was used in the 4R Tau aggregation mix as a reducing agent. This prevented 
Tau from locking itself into compact monomers through cysteine disulphide cross bridging and provided 
necessary charge compensation to enhance the rate and extent of aggregation. 
Aggregating conditions (incubation times and temperatures, voltage, ionic concentration, the buffer pH 
and the length of Tau used) are important to take into consideration such as (Jeganathan et al., 2008). 
The main driving forces for Tau repeat domain filament formation involves intermolecular disulphide bond 
production, electrostatic interactions, hydrophobic interactions and non-covalent interactions like 
hydrogen bonding (Zhu et al., 2010). Peptide inhibtiors can be made proteolytically stable through N-
methylation or retroinversion which alters the structural configuration of peptide backbones; rendering 
them inaccessible to proteolytic enzymes (Cody et al., 1997). These modofications will be explored for the 





5.2.1 THIOFLAVIN-T FLUORESCENCE 
 
Although ThT fluorescence does not quantitatively measure fibrilisation it was used in this research to 
indicate the presence of amyloid. Thioflavin-T (ThT) and Thioflavin-S (ThS) are thiazine salt dyes which 
have positive and negative charges, respectively, as ThS is a sulfonated derivative of ThT. They are 
commonly used to detect real time amyloid assembly by selectively binding (between pH 5-9) in parallel 
to the long axis of β-sheets along surface side-chain grooves and have also been proposed to bind to 
cavities as either planar monomers or dimers, respectively (Wu et al., 2008, Krebs et al., 2005, Stsiapura 
et al., 2007, Voropai et al., 2003, Stsiapura et al., 2008, Friedhoff et al. 1998, Groenning et al., 2007). 
Cavities with an 8–9 Å diameter may be present in the centre or between protofilaments during 
association into protofibrils/fibrils (Blake and Serpell, 1996, Serpell and Smith, 2000, Jiménez et al., 1999, 
Malinchik et al., 1998, Elam et al., 2003). ThT has a central C-C bond as seen in Figure 5.5 flanked by freely 
Figure 5.5: Schematic of the chemical structure of Thioflavin-T ordered in parallel with its long axis to the long 
axis of the Tau VQIVYK fibril (The Protein Data Bank De la Cruz, et al., 2017). In an extended conformation ThT 
requires ~3-4 continuous β-strands in a β-sheet. Note Thioflavin-T C-C bond which rotates upon binding to β-
sheet (red) resulting in the compounds fluorescent properties to red shift with enhanced emission maxima 
at 482 nm when excited at 450 nm (adapted from Groenning, 2010).  
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oscillating benzothiazole and aminobenzoyl rings. Upon binding to consecutive β-sheet strands this 
oscillation becomes restricted by rotating the C-C bond and locking it into a stabilised high energy state 
ThT-amyloid complex (Girych et al., 2014; Chan et al., 2015). This prevents movement of electrons; 
keeping ThT in its locally excited state which causes a red shift in its fluorescent properties resulting in 
fluorescence at emission maxima 482 nm when excited at 450 nm in the presence of amyloid (Wolfe et 
al., 2010; LeVine, 1999; Girych et al., 2014, Amdursky et al. 2012).  ThT does not modulate fibrilisation of 
Tau due to its positive charge and small supramolecular structure (Kuret et al., 2005).  
According to LeVine (1997), ThS is less suitable than ThT for kinetic analysis as ThS fluorescence may 
interfere with the determination of fibril bound species. LeVine (1999), described that in solution ThS 
generates high background fluorescence (~x10) rendering it unsuitable for quantitative analysis 
(Wegmann et al., 2018). This is supported by Kuret et al. (2005), who suggested that ThS is a semi-
quantitative method for estimating aggregation of Tau. In summary kinetic based experiments in this 
thesis will be conducted using ThT at excitation and emission maxima of 450 and 482 nm, respectively.  
Xue et al. (2017), concluded that ThT has very little effect at influencing aggregation kinetics at 
concentrations of 20µM and below and that 50µM or more may influence the aggregation curve. 
5.2.2 CONGO RED BIREFRINGENCE 
 
This technique was used to investigate if the inhibitors could prevent Tau from forming β-sheet secondary 
structures. Birefringence denotes the different refractive indices observed by horizontal and vertically 
polarised light. Congo red dye is the current gold standard for detecting amyloid in tissue as it binds to 
amyloid and displays a characteristic apple green birefringence when viewed under polarized light. 
Amyloid is significantly different in its secondary structural compositions in comparison to other insoluble 
proteins, in that its core has an exceptionally high β-sheet content, whereby hydrogen bonds run in 
parallel to the fibre axis and β-strands are perpendicular; having a distance of ~4.7Å between each β-
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strand, according to X-ray diffraction (Rambran and Serpell, 2008). The exact mechanism as to how Congo 
red binds to amyloid is unknown, however it is reported that Congo red binds with high affinity to β-
sheets, in a similar fashion as ThS does, which is also sulfonated (LeVine, 1993).  
5.2.3 CIRCULAR DICHROISM 
 
This technique was also used in conjunction with congo red birefringence to investigate if the inhibitors 
could prevent Tau from forming β-sheet secondary structures. CD is a spectroscopic technique which 
determines the secondary structure and folding properties of proteins and conformations of other 
macromolecules by analysing samples over a range of wevelengths. Regarding proteins, CD can also 
be used to investigate pH, heat or solvent induced changes and protein un/folding. CD measures 
molecules with chiral centres, whose spectral measreuments can be either positive or negative as a 
result of greater absorption of either left handed or right handed circularly polarised light, 
respectively (Li et al, 2009). These positive and negative measurements are manifested as peaks and 
troughs, respectively, when viewing a CD spectrum. Left and right handed circularly polarised light 
can be summarised through Figure 5.6.  
A. B. 
D. C. 
Figure 5.6: Demosntrates (along z-axis) A: vertically polarised light, B: horizontally polarised light, C: 
left circularly polarised light, D: right circularly polarised light. 
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In CD monochromatic light passes through a polariser which polarises the light and then into a 
photoelastic modulator (modulates polarisation of light sources) to form left and right handed circularly 
polarised light. Left handed circularly polarised light ossilates about the propagation direction in a 
clockwise fashion, whereas right handed circularly polarised light ossilates in an anti-clockwise fashion.  
As circularly polarised light reaches an optically active sample e.g. a protein; some light will be 
differentially absorbed. The electronic structure of the protein results in characteristic bands in respective 
regions of the CD spectrum. Secondary structures such as α-helices, β-sheets, β-turns and unordered can 





Figure 5.7: Examples of far-UV CD spectra for α-helices, β-sheets and unordered (adapted from Wei 




5.2.4 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
 
As ThT could potentially bind to both fibrillar and non-fibrillar β-sheets and emit fluorescence, TEM was 
employed in this research to validate the ThT results. In existing literature, TEM has been utilised 
extensively to monitor formation of oligomers and amyloid fibrils in vitro and to qualitatively identify 
specific characteristics such as fibril length, width curvature, smoothness (for example Tau441 fibrils 
displaying a fuzzy coat due to the N terminus of Tau441), bends and twists (Goldsbury et al., 2000 and Thorn 
et al., 2008). TEM is a microscopy technique which uses the same basic principles as simple optical 
microscopy, however instead of using light, it uses electons; which results in much more powerful 
resolution. An electron gun fires a beam of electrons produced by thermic emission of a super-heated 
tungsten wire. This beam of electrons is focused by condenser lenses in a vacuumed space before reaching 
the specimen suspended grid. As the beam passes through the specimen, certain parts are transmitted 
which are focused by the objective lens. This produces an enlarged visible image on a fluorescent screen 
of the specimen. This process can be summarised by Figure 5.8. 
Figure 5.8: Comparison of the layout and the light/electron beam path of an optical microscope and 





In addition to the peptides discussed in Section 4, a variety of other peptides were also drafted for analysis 
in the wet lab. Tau aggregation is largely facilitated by charge interactions. These peptides utilised arginine 
residues to investigate the effects of their global charge and local charge (depending on the terminus 
arginine residues were added to) on Tau aggregation. Peptide inhibtiors used a nomenclature to make it 
easier to identify their properties when working in the lab. AG01 refers to the core binding sequence 
VQIINK, whereas AG02 refers (to VQIVYK), AG02ΔI (refers to VQKVYK with original replacement of 
isoleucine with lysine), AG02ΔV (refers to VQIKYK with the original replacement of the second valine with 
lysine) and AG03 (which refers to VQIK(Ac)YKP). Peptide inhibitors were flanked with at least 1 glycine 
followed by 1 arginine. The number of arginines were counted for each peptide inhibitor, therefore, 














Peptide ID Sequence Purity % 
AG01 Ac - R G V Q I I N K G R - NH2 >90 
AG02 Ac - R G V Q I V Y K G R - NH2 >90 
AG02R4 Ac - R R G V Q I V Y K G R R - NH2 >90 
AG02R5 Ac - R G V Q I V Y K G R R R R - NH2 >90 
AGR502 Ac - R R R R G V Q I V Y K G R -N H2 >90 
AG02PR5 Ac - R G V Q I V Y K P G R R R R - NH2 >90 
AG02R6 Ac - R R R G V Q I V Y K G R R R - NH2 >90 
AG02R9 Ac - R G V Q I V Y K G R R R R R R R R - NH2 >90 
AG02TAT Ac - R G V Q I V Y K G R Y G R K K R R Q R R R - NH2 >90 
AG02∆I Ac - R G V Q K(Ac) V Y K G R - NH2 >90 
AG02∆V Ac - R G V Q I K(Ac) Y K G R - NH2 >90 
AG03 Ac - R G V Q I K(Ac) Y K P G R R R R R R R R - NH2 >95 
AG03-Cys Ac - R G V Q I K(Ac) Y K P G R R R R R R R R C - OH >95 
Scramble AG03 Ac – R G Q P K I K(Ac) Y V G R R R R R R R R - NH2 >95 
AG03M Ac - R G V(m) Q I(m) K(Ac) Y(m) K P(m) G R R R R R R R R - NH2 >95 
RI-AG03 Ac - r r r r r r r r G p k y k(ac) i q v G r - NH2 >95 
FAM-RI-AG03 Ac - k(FAM) r r r r r r r r G p k y k(ac) i q v G r - NH2 >95 
Poly-R R R R R R R R R R - NH2 >95 
TAT Ac - Y G R K K R R Q R R R - NH2 >95 
Table 5.1 List of peptide inhibitor designs customly synthesised for research in this thesis. Underlined 
sequence corresponds to Tau binding region. Peptide inhibitors were custom made by Peptide 
Synthetics (Fareham, UK) with >90% purity and Severn Biotech (Kidderminster, UK) with >95% purity; 




5.3.1 PLASMID ANALYSIS 
 
 
Figure 5.9 confirmed the successful DNA digest and the size of the sequences for the TauΔ1-250 insert 
and the pRK172 empty vector, as compared to the DNA sequence.  
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Figure 5.9: Agarose gel of the uncut circular plasmid of the pRK172 expression vector containing 
the of TauΔ1-250 DNA of interest and a cut version using NdeI and EcoRI enzymes. 1: Fast DNA 
Ladder, 2: Uncut circular plasmid, 3: Cut plasmid + NdeI + EcoRI. 
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5.3.2 TAU EXPRESSION AND PURIFICATION 
 
5.3.2.1 EXPRESSION OF TAU 
 
Following successful transformation of TauΔ1-250 pRK172 expression plasmid into E.coli BL21 (DE3) 
expressing cell line, an expression protocol was devised and optimised to express large quantities of Tau 
in LB media and ampicillin (0.1%). Protein expression was optimised for induction incubation at 37°C for 
3 hours and with agitation following experimental inductions (at 26°, 37° and 42° for over 1-24 hours), 
which the cell culture samples were sampled (18µL) on an hourly basis over 5 hours and overnight for 
SDS-PAGE, as seen in Figure 5.10. Successful expression of Tau is indicated by the band at 20 kDa which is 
absent prior to induction with IPTG (1mM). Optimum temperature and duration of induction with IPTG 
was determined to be 3 hours at 37°C due to the thicker bands in comparison to the 26°C and 42°C 
controls. After overnight incubations, Tau expression appeared to be lost due to the culture becoming 
saturated causing basal leakage of the expression system resulting in plasmid instability from leaky T7 







Figure 5.10: Coomassie staining of 15% SDS PAGE gels of 
E.coli BL21 (DE3) pre and post induction with IPTG (1mM) 
for 1, 2, 3, 4, 5 hours and overnight (A-C). Samples were 
incubated at various temperatures to determine the 
optimum. A: incubated at 26°C. B: incubated at 37°C. C: 
incubated at 42°C. Lanes 1: PageRuler Unstained Broad 
Range Protein Ladder (Thermo Scientific), 2: Before 
induction with IPTG, 3: 1hour, 4: 2 hours, 5: 3 hours, 6: 4 
hours, 7: 5 hours, 8: over-night. The optimum temperature 
and time was 37˚C for 3 hours. 
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5.3.2.2 PURIFICATION OF TAU 
 
After successfully expressing Tau, purification was necessary which was achieved via cell harvesting, lysis 
and cell debris removal. Figure 5.11 demonstrates that most impurities are removed after boiling and 
ultra-centrifuging the cell lysate, however a significant amount of Tau (or other proteins of similar 
molecular weight) appears to be lost in the latter stage. When conducting cation exchange 
chromatography, a significant amount of Tau is again lost. After washing the column with a series of NaCl 
concentrations, very few impurities remain. The 1M NaCl wash suggests that all the Tau had been 
removed from the column. After ammonium sulphate precipitation and dialysis, most of the impurities 
had been removed leaving behind an average >90% pure stock of Tau, as determined by Figure 5.13. 
Native Tau is a highly hydrophilic and intrinsically disordered protein which has a lack of a defined 
secondary structure, therefore the conformational properties of Tau in this state demonstrate a lower 
dependence on temperature. Tau is therefore heatstable and refolds correctly after heat treatment. Mild 
heat treatment of neuronal cells demonstrated Tau to bind DNA and enhance DNA repair (Sultan et al., 
2011). 
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Figure 5.11: 15% SDS PAGE gel of samples from each stage of the Tau purification process; cell lysate, post 
centrifugation, post boiling, flow through, 0.1M NaCl wash, 0.35M NaCl wash, 1M NaCl wash, (NH4)2SO4 precipitation 
and dialysis. Lanes 1: Ladder, 2: Cell lysate, 3: Post centrifugation, 4: Post boiling + centrifugation, 5: Flow through, 





 The final concentration of Tau was determined using a Nanodrop 2000 (Thermo Scientific) and corrected 
using the equation in Section 3.2.4.5. Accuracy of protein concentration was confirmed using the Pierce™ 





Figure 5.13 demonstrates densitometric analysis of the purified Tau samples. This type of analysis 
determines the densities of any present bands which are directly proportional to the concentration of 
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Figure 5.13: Densitometric analysis of Tau samples. E: 15% SDS PAGE gel of purified 
Tau samples from separate expression batches. A-D: detected band purity from 
lanes 2-5, respectively. Average purity of each Tau band was >90%. 
TauΔ1-250 
20,205.92 Da 











End-point aggregation data (after 24 hours) i.e. final fluorescence data points for Tau aggregated with 
increasing concentrations of heparin can be seen in Figure 5.14. End point data was plotted to observe 
the relationship between heparin concentration and fluorescence signal. This demonstrated that heparin 
is necessary for the aggregation of Tau, and that the ratio of heparin to Tau plays an important role as 
well. The optimal ratio of Tau to heparin on this Figure is 4:1. At higher heparin to Tau concentrations, 
aggregation of Tau becomes increasingly retarded due to unbound free heparin increasing the ionic 
strength of the medium (Zhu et al., 2010). The bi-phasic hill equation reflects the binding of heparin to 
Tau as a function of heparin concentration. 
Figure 5.14: Thioflavin data using FlexStation 3. End-point aggregation of TauΔ1-
250 (20 μM) with increasing concentrations of heparin; 0μM, 1.25μM, 2.5μM, 
5μM, 10μM, 20μM, 100μM. Fitted with the ‘Biphasic Hill equation’ on OriginPro. 
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It was a concern that the positively charged arginine residues would sequester heparin and prevent 
heparin from interacting with Tau. AG02R5 was used in Figure 5.15 as it was the lead peptide tested at 
the time. This figure demonstrated that AG02R5 can inhibit Tau aggregation in the presence of not only 
heparin, but also Tau seeds and Aβ seeds.  This demonstrated that the inhibitor does not simply interfere 
with heparin binding to Tau through charge interactions to reduce fluorescence signal.  
 
 
Figure 5.15: Thioflavin data using FlexStation 3. Average end-point aggregation of TauΔ1-250 (20 μM) with 
either heparin, Tau seed or Aβ seed to induce aggregation, with and without AG02R5 (20 μM). Experiments 
were conducted in triplicate and error bars are reported as standard deviation of the mean. 
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The binding sequence for each inhibitor was based on the VQIVYK sequence of Tau which on its own can 
self assemble and aggregate to form fibrils. For this reason, it was important to test that the inhibitors 
would not seed themselves to form fibrils. Figure 5.16 demonstrated that AG01 [RG-VQIINK-GR] appeared 
to self associate considerably more than AG02 [RG-VQIVYK-GR], therefore additional experiments were 
conducted using AG02. AG02R4 [RRG-VQIVYKG-RR], AG02R5 [RG-VQIVYK-GRRRR], AGR502 [RRRRG-
VQIVYK-GR], AG02PR5 [RG-VQIVYKP-GRRRR], AG02R9 [RG-VQIVYK-GRRRRRRRR] and AG02TAT [RG-
VQIVYK-GRYGRKKRRQRRR] did not appear to self associate based on the fluorescence signal. AG02R5 and 
AGR502 investigated if the position of polyarginine had any significant effect on inhibition of Tau 
aggregation, however none was observed. Increasing the number of arginines past 5 did not seen to show 
any added inhibitory effects against Tau aggregation. AG02R9 and AG02TAT were designed for cell 
penetration and were compared to see any difference for inhibition of Tau aggregation. No differences 
were seen, however AG02R9 seemed to self-associate less than AG02TAT. AG02ΔI [RG-VQK(Ac)VYK-GR] 
self associated the most, whereas AG02ΔV [RG-VQIK(Ac)YK-GR] aggregated much less, despite having one 
difference in amino acid replacement compared to the native sequence. Although not much difference 
was seen for AG02PR5 when comparing it with AG02R5, the additional proline was still taken forward as 
this is also its natural position in native Tau. The angle change was hypothesised to be more effective 
when used in conjunction with a longer polyarginine chain to provide more binding interference. After 
combining several elements from these previous inhibitors, AG03 [RG-VQIK(Ac)YKP-GRRRRRRRR] was 
tested. It did not self associate and reduced Tau aggregation the most based on the fluorescence signal.  
AG03 was chosen as the lead peptide candidate for further development to make it proteolytically stable 
via N-methylation or retroinversion.
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Figure 5.16: Thioflavin data using a Synergy2 
plate reader. A: End-point (24 hr) aggregation of 
TauΔ1-250 (20 μM) with different peptide 
inhibitors (white) and attempted self assembly 
of inhibitors without presence of Tau (black). B: 
Aggregation kinetics of TauΔ1-250 (20 μM) 
incubated with different peptide inhibitors and 
labeled in descending order of fluorescence 
intensity. Experiments were conducted in 
triplicate and error bars are reported as standard 






5.3.6 EFFECT OF RETRO-INVERSO AG03 ON TAU AGGREGATION 
 
Figure 5.17 demonstrated that after 24 hours of incubation at 37˚C, AG03 [RG-VQIK(Ac)YKP-GRRRRRRRR] 
inhibited aggregation of Tau by ~30% and that a core binding sequence scrambled version of itself [RG-
QPKIK(Ac)YV-GRRRRRRRR] and the octa-arginine chain on its own [RRRRRRRR] were unable to inhibit 
aggregation. This showed that it was not just the combination of amino acids causing inhibition i.e. 
through charge effects, but that the location of the amino acids was important. To make AG03 
proteolytically stable it was N-methylated to form AG03M [RG-V(m)QI(m)K(Ac)Y(m)KP(m)-GRRRRRRRR] 
or retroinverted to form RI-AG03 [RG-QPKIK(Ac)YV-GRRRRRRRR]. When testing these theoretical 
proteolytically stable peptides, AG03M reduced inhibition fluorescence slightly when compared to AG03, 
however RI-AG03 reduced fluorescence by >90%. 
Figure 5.17: Thioflavin data using a Synergy 2 plate reader. End-point (24 hr) aggregation of TauΔ1-250 (20 μM) 
with equimolar concentrations of either octa-arginine, scrambled AG03 peptide, AG03, N-methylated AG03 and 
retro-inverso AG03. Experiments were conducted in triplicate and error bars reported as standard deviation. 











Figure 5.18 demonstrated that there is a negative correlation between inhibitor concentration and TauΔ1-
250 aggregation. The more inhibitor present, the greater the inhibition of Tau aggregation. Both the Tau 
stock solution and inhibitors were solubilised in 30 mM Tris solution. Looking at the data it is unlikely that 
inhibition was caused by the Tris because the Tau control also contained 30 mM Tris. 
A. 
B. 
Figure 5.18: Thioflavin data using a FlexStation 3 plate reader, A: End-point (24hr) aggregation of 
TauΔ1-250 (20 μM) demonstrating the dependence of TauΔ1-250 inhibition by RI-AG03. B: A log10 
scatter graph of the same data employing a curve fitting algorithm to calculate the IC50 (the 
concentration of RI-AG03 required for 50% inhibition of Tau aggregation) of 7.83 µM. 
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Figure 5.19 demonstrated that RI-AG03 is as potent at inhibiting aggregation of TauΔ1-250 in the presence 
of Tau seeds as it is heparin. The residual fluorescence with the Tau seeds is presumable due to the 













Figure 5.19: Thioflavin data using a FlexStation 3 plate reader. End-point aggregation 









Figure 5.20 demonstrated that after adding RI-AG03 after one hour, it can halt the aggregation of TauΔ1-





Figure 5.20: Thioflavin data using a FlexStation 3 plate reader. Aggregation kinetics of TauΔ1-




5.3.10 RI-AG03 INHIBITS β-SHEET FORMATION 
Figure 5.21 A, demonstrated that RI-AG03 partially prevents TauΔ1-250 from shifting from unordered to β-sheet structure, as seen by a reduced 
dip at 220nm, when compared to the control. The figure also suggests that in both samples, insoluble material is being formed due to a reduction 
of signal in the y-axis, suggesting protein is precipitating out of solution. Figure 5.12 B demonstrated that RI-AG03 has no secondary structure and 
that heparin does not force RI-AG03 to transition into a defined secondary structure. This was useful to investigate because it helped to validate 
the phenomena observed in Figure 5.21 A; that changes in spectra were not associated with changes in the secondary structure of the inhibitor. 
Figure 5.21: CD spectroscopy data A: After incubation with heparin and RI-AG03 at 37°C for 5 hours; TauΔ1-250 (20μM) has a reduction in β-sheet 








Figure 5.22 demonstrated that TauΔ1-250 when stained with congo red, appears red when viewed under 
uncrossed polarisers, however when viewed between crossed polarisers at 90˚C, the sample emits an 
apple green coloured birefringence. This suggests that the protein has β-sheet secondary structure. When 
TauΔ1-250 is incubated with RI-AG03 and stained with congo red, it appears red when viewed under 
uncrossed polarisers, however when viewed between crossed polarisers at 90˚C, no birefringence can be 









TauΔ1-250 + RI-AG03 
Figure 5.22: Birefringence data using Zeiss axioscope A1 microscope. TauΔ1-250 with 
and without the presence of RI-AG03, stained with congo red and visualised under 
uncrossed lens and crossed (90˚) polarising lens. 
 
Uncrossed lens                               90˚ Crossed lens 
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Figure 5.23 demonstrated that when aggregated using heparin, TauΔ1-250 formed fibrils, however when 
in the presence of equimolar RI-AG03, no fibrils were formed; Instead ~36nm diameter spherical 
structures are formed, as quantified by Table 5.2. 
 
Figure 5.23: Negative stain TEM images using a Joel JEM-1010 following aggregation of TauΔ1-
250 (20 μM) at pH 7.4 in the presence of Tris buffer (30 mM), DTT (1 mM), heparin, (5 µM), with 
and without RI-AG03 (20 µM) and incubated at 37°C for 24 hr. Note absence of fibrils in the 





Table 5.2 provided quantitative analysis of the TEM images, suggesting that the inhibitor altered the 




Area (nm²) Perimeter (nm) Diameter (nm) 
Mean 1024.30 112.53 35.82 
Minimum 456.03 75.70 24.10 
Maximum 1868.88 153.25 48.78 
Standard Deviation 262.16 14.46 4.60 





















Table 5.2: Table quantifying area, perimeter and diameter of 200 oligomeric-like structures seen 










Figure 5.24 demonstrates that after 24 hours of incubation at 37˚C, RI-AG03 reduced aggregation of of 
TauΔ1-250 by ~87% whereas RI-AG03 decorated liposomes (total lipid concentration 20 µM, peptide 
concentration 0.5µM) reduced aggregation ~94%. Plain liposomes did not inhibit aggregation at all. When 





Figure 5.24: Thioflavin data using FlexStation 3. Aggregation of TauΔ1-250 (20μM) alone (grey), TauΔ1-250 
with equimolar concentration of either RI-AG03, RI-AG03 Liposomes or plain liposomes (white) and RI-AG03, 
RI-AG03 Liposomes or plain liposomes alone (black); using conditions as before.  Concentration of liposomes 






This first part of this chapter successfully completed the aim of recombinantly producing Tau via a 
bacterial expression system at a large scale. TauΔ1-250 was used instead of full-length Tau as it aggregates 
much faster as it consists of all four repeat domains and the C-terminus but without the flanking N 
terminus containing the positively charged proline rich regions present (Gustke et al., 1994). Full length 
Tau can take days to aggregate whereas TauΔ1-250 plateaus at ~4-8 hours (Okuda et al., 2015). This was 
advantageous as it meant that there was a much quicker turnover of results, less machine time use, less 
risk of contamination or having to include antimicrobials such as sodium azide which could subsequently 
interfere. Potential problems of using a more aggressively aggregating fragment of Tau are that the 
inhibitors may be ineffective at keeping up with the rate of aggregation in the fragments, however could 
be useful in a more clinically relevant setting with full length Tau which aggregates more slowly. Another 
downside of using TauΔ1-250 is that it does not include the N-terminus and so may be less clinically 
relevant than using full-length Tau and inhibitors may behave differently if the fuzzy coat from the N 
terminus in Tau is present.  In both cases, if either full-length TauΔ1-250 was synthesised, neither would 
be phosphorylated, which is another drawback to clinical relevance as in AD the Tau is 
hyperphosphorylated. Alternatively, inhibitors could be tested against recombinant Tau proteins which 
are phosphorylated in-vitro using kinases such as ERK2 kinase (Despres et al., 2017). Producing enough 
pathophysiologically relevant hyperphosphorylated Tau is a major hurdle. Sui et al. (2015), used the 
Zippers-Assisted Catalysis sytem which co-expresses 1N4R Tau and GSK-3β in E. coli as leucine zipper 
fusion proteins, to produce hyperhosphorylated Tau. It is important to note that proteins produced 
chemically, rather than recombinantly may have different characteristics, such as in the way they fold, 
which will alter the aggregation potential (Finder et al., 2010). It is also important to note that heparin 
induced Tau filaments are polymorphic and are different to those seen naturally in AD and Picks disease 
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(Fichou et al., 2018 and Zhang et al., 2019). Although in-vitro experiments using recombinant Tau protein 
have their limitations, they are still a decent guideline to predict what may occur in vivo. To understand 
what would truly occur in a clinically relevant setting, in vivo experimentation is necessary. Based on the 
average of four separate purified expression batches, purity of Tau was ~94%. The low yield of 10mg/L 
culture for this prep may be accountable for the loss of protein during the early centrifugal stages of the 
purification process and again during the 0.1M NaCl wash stage. The gel bed could be increased to allow 
more binding of Tau to the column, which may result in a reduced amount of 20kDa protein in the flow 
through. KrishnaKumar and Gupta (2017), stated that recombinant Tau expression is a challenge because 
BL21(DE3) usually provides low yields due to E.coli synonomously using non-preferential codons, 
particularly those which encode arginine and proline residues as they obstruct translation. Due to the 
intrinsically disordered nature of Tau it is also prone to bacterial proteolysis which results in further loss 
of protein yield (Suskiewicz et al., 2011). Nevertheless, the purity of the product was acceptable based on 
densitometric analysis shown in Figure 5.13. To improve Tau protein yields deficient tRNA can be 
supplemented which enhances translation. Direct boiling without a previous cell lysis step also improves 
yield as it reduces the duration for proteases to potentially interact with Tau (KrishnaKumar and Gupta 
2017). 
The second part of this chapter focused on developing and investigating potential peptide-based 
inhibitors of Tau aggregation derived from the hot spot binding region corresponding to residues 
306VQIVYK311. The rationale being the prevention of monomeric or misfolded Tau molecules from 
interacting at this accessible binding site; thereby impeding further aggregation. The techniques utilised 
to determine this were ThT fluorescence (Sections 5.2.1-7), CD (Section 5.2.8), Congo red birefringence 
(Section 5.2.8) and TEM (Section 5.2.9). The two peptides that were used as a starting point for peptide 
development were VQIINK and VQIVYK. Although VQIINK did not come up in the Aggrescan and Camsol 
results, the literature suggests plays a very important in Tau aggregation and that it interacts with VQIVYK, 
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therefore, it was worth investigating Mukrasch et al., 2005; Von Bergen et al., 2000). Heparin was used to 
induce aggregation of Tau, however the optimum ratio of heparin:Tau had to be first determined, as too 
low a concentration of heparin may not be enough and too high may retard aggregation due to unbound 
free heparin increasing the ionic strength of the medium. Tau aggregation was also retarded for the same 
reasons from experiments using increasing salt concentrations with a fixed heparin concentration (Zhu et 
al., 2010).  According to Goedert et al. (1996), the formation of Tau filaments is dependent upon the 
concentration of Tau and on the ratio of Tau:sulphated glycosaminoglycan. Both Ferrari and Rüdiger 
(2019) and Ambadipudi et al. (2017), mention that the optimal ratio of Tau:heparin:Tau is 4:1. According 
to Figure 5.14 the optimum ratio of Tau:heparin was 4:1 which corresponds to the ratio used by other 
researchers as well (Ambadipudi et al, 2017; Hattori et al., 2008, Yao et al., 2003, Jeganathan et al., 2008, 
Goedert et al., 1996). Since heparin is electronegative as it has high sulphur content and the inhibitors are 
electropositive as they contain polyarginine chains, it is plausible to assume the two may interact. This 
was important to elucidate to determine whether true inhibition of aggregation was occurring or 
reductions in ThT signal were the result of the inhibitor sequestering heparin from solution (due to 
attracting charges) and thereby preventing heparin from interacting with Tau and initiating nucleation. 
Figure 5.15 suggests that the inhibitors do not reduce aggregation as a function of sequestering heparin 
from solution through charge interactions. It shows that the inhibiors also prevent Tau from aggregating 
when the inducer of aggregation is Tau seeds, or Aβ seeds, instead of heparin. However, a better way of 
establishing this would be to test the inhibitors against aggregation of Tau∆K280 which aggregates 
without heparin. It has been demonstrated that the prion-like spread of extracellular Tau aggregates into 
neurones via micropinocytosis is mediated by heparan sulfate on the surface of cell surfaces but in 
cultured cells and primary neurones this process is inhibited by heparin. As a result, it was suggested that 
the glycosamino glycan and Tau interaction has a more prominant relationship in AD pathology than 




Table 5.3: Table describing the evolutionary steps for the peptide inhibitor. 1) chose the target binding sequence, 2) investigated charge effects 
associated with aggregation, 3) utilising a rigid amino acid to disrupt chain interactions, 4) attaching a cell penetrating sequence so the inhibitor can 
enter cells to target Tau, 5) utilising accetyllysine to promote binding to VQIVYK, 6) integrated previous peptide designs to form AG03 and tested its 




The data from Figure 5.16 and Figure 5.17 summarised in Table 5.3 explains the evolution of the inhibitors 
where the first step chose the initial binding sequence. As AG01 [RG-VQIINK-GR] self associated and AG02 
[RG-VQIVYK-GR] did not, the latter was chosen for further development. Since Tau aggregation is largely 
facilitated by electrostatic interactions, the second step was to test charge effects. Peptides AG02R4 [RRG-
VQIVYK-GRR], AG02R5 [RG-VQIVYK-GRRRR], AGR502 [RRRRG-VQIVYK-GR] and AG02R6 [RG-VQIVYK-
GRRRRR] investigated the effects of different chain lengths of positively charged arginines on the N and C 
terminals, in different conformations. There appeared to be some added inhibitory effect with additional 
chained arginine residues, until reaching ~5 arginine residues, at which little difference is seen with 
additional residues. There also appeared to be no prominent difference to which terminus the arginne 
residues were located. The third step examined AG02PR5 [RG-VQIVYKP-GRRRR] which had the addition 
of proline added to the end of the VQIVYK peptide core to mimick its natural position in the native Tau 
sequence. Proline is reported as a β-sheet breaker and provides rigidity to peptides and prevents 
backbone interactions which are essential for amyloid aggregation. Since the polyarginine chain followed 
the peptide binding region, the proline residue will change the angle direction the chain projects at. Based 
on experiments there appeared to be little difference with the addition of proline, however it was retained 
as an evolutionary step as it may be more useful with a longer poly-arginine chain attached to it to obstruct 
Tau interactions. The fourth step investigated potential cell penetrating sequences and the peptides 
tested were AG02R9 [RG-VQIVYK-GRRRRRRRR] and AG02TAT [RG-VQIVYK-GRYGRKKRRQRRR]. Again, 
there appeared to be little difference with regards to additional inhibition when comparing them to 
AG02R5, however AG02TAT appeared to self aggregate slightly more, so polyarginine was retained. The 
fifth step investigated the predictions from chapter 1 with regards to replacing isoleucine or valine with 
acetyllysine. AG02∆I [RG-VQK(Ac)VYK-GR] and AG02∆V [RG-VQIK(Ac)YK-GR] demonstrated inhibition to 
aggregation however AG02∆I self associated, therefore it was discarded and AG02∆V was retained. The 
combination of acetyllysine residues seen in AG02∆I and AG02∆V was not used because the peptide would 
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lose specificity by changing the hexapeptide recognition sequence and hydrophobic interactions too 
much, thus preventing it from binding to its target. 
Elements from AG02PR5 (proline), AG02R9 (octa-arginine chain) and AG02∆V (replacement of valine with 
acetyllysine) were combined to form AG03 [RG-VQIK(Ac)YKP-GRRRRRRRR]. Octa-arginine was desireable 
as Tau aggregation occurs intracellularly, so the inhibitor would need to be able to cross cell membranes. 
AG03 demonstrated enhanced inhibitory effects at ~53% inhibition when compared to AG02R9 and 
AG02TAT which inhibited aggregation at ~40. Figure 5.17 confirmed that the inhibitory properties of AG03 
were not simply due to the polyarginine positive charge or due to the global charge of the peptide 
residues. Polyarginne and a scrambled version of AG03 were tested, both of which displayed no inhibitory 
properties. Before testing in cells, AG03 had to be made proteolytically stable, therefore two versions of 
it were created: An N-methylated version AG03M [RG-V(m)QI(m)K(Ac)Y(m)KP(m)-GRRRRRRRR] and a 
retro-inverted version RI-AG03 [rrrrrrrrG-pkyk(ac)iqv-Gr].  
Based on ThT fluorescence, AG03M did not appear to have any additional inhibitory effects when 
compared to AG03, however RI-AG03 inhibited aggregation by ~94%. Therefore RI-AG03 was chosen as 
the lead peptide to be taken forward for additional experiments. A dose-dependent experiment of RI-
AG03 was conducted to establish potency whereby an IC50 of 7.83 µM was calculated, as seen in Figure 
5.18. RI-AG03 demonstrated its ability to inhibit aggregation of Tau in the presence of Tau seeds and to 
also prevent further aggregation of Tau when added during the growth phase of aggregation as seen in 
Figures 5.19 and 5.20, respectively (Section 5.2.6). Individual L- and D- amino acids are optical isomers of 
each other, however the retro-inverted RI-AG03 sequence is not an enantiomer of its original AG03 
sequence. Although the sidechains for AG03 and RI-AG03 havie similar orientations, the difference 
between them is that the amino acid backbones are reversed, and the resulting hydrogen bonds are 
therefore different. In addition, the N and C terminal domains are on opposite ends due to inversion of 
the peptide sequence. The stability of amyloid fibres is generated by backbone interactions, so it is 
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impressive that RI-AG03 still has activity with a reversed backbone. These findings suggest that the subtle 
changes in peptide inhibitor backbone and N and C terminal domains can influence aggregation. The 
increased solubility of the amide functional group in RI-AG03 may offer greater inhibitory properties when 
it is localised close to the Valine in the inhibitor binding sequence. Ree et al. (2018), stated that affixing 
an acetyl group on the N-terminal amino group results in altered charge, hydrophobicity and size of the 
terminus; resulting in altered binding properties. Moving the more hydrophobic acetyl group further away 
from the binding sequence may also be beneficial as it will increase the local area hydrophilicity. The acetyl 
methyl group may also interfere with binding. These terminal modifications may create new protein 
interaction surfaces, enhance peptide metabolic and enzymatic stability as well as enhance peptide 
activity (Ree et al., 2018). Arispe et al., (2008) mentioned that capping the N-terminus and C-terminus 
through acetylation and amidation, respectively, promotes aromatic interactions. This may be due to the 
peptide and its Tyrosine group behaving more like it does in its native form than as a peptide with open 
ends. This has relevance to RI-AG03 as it contains Tyrosine in the binding residue. It may also be that the 
bond angles in the retro peptides are not perfect mimicks and as such the D-amino acid inhibitors have 
slightly altered binding properties. 
Professor David Allsop’s research group previously developed an Aβ peptide aggregation inhibitors OR-2 
[H2N-RGKLVFFGR-NH2] and its retro-inverted counterpart RI-OR2 [Ac-rGffvlkGr-NH2] which was more 
effective than OR-2 as an inhibitor (Matharu et al, 2010; Taylor et al., 2010). This resembles the difference 
between AG03 and RI-AG03 in their effectiveness as aggregation inhibitors. Taylor et al, (2010) suggested 
that RI-OR2 prevented aggregation of Aβ1-42 by outcompeting monomers for the KVLFF region on Aβ1-
42 peptide. When tested in vivo with the attachment of TAT sequence to penetrate the blood brain 
barrier, Aβ oligomer levels were reduced in cerebral cortex of 10-month-old APPswe/PS1DE9 mice 
following daily i.p. injections of RI-OR2-TAT over 21 days (Parthsarathy et al., 2013). Obasse et al. (2017), 
developed Amylin peptide aggregation inhibitors IO8 (H2N-RGANFLVHGR-NH2) and its retro-inverted 
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counterpart RI-IO8 (Ac-rGhvlfnaGr-NH2). The L-amino acid inhibitor partially inhibited amylin aggregation 
whereas, surprisingly, the retro-inverted version stimulated aggregation. The differences between IO8 
and RI-IO8 are again the reversed backbone and the N-terminal domains which are free amine and acetyl, 
respectively. Again, this is a conversion from positive to neutral charge in IO8 and RI-IO8, respectively. It 
is also important to note that in both examples the positive amine charge flanks residues on the opposite 
end of the sequence due to peptide inversion. To make IO8 proteolytically stable, Obasse et al (2017), N-
methylated alternate amino acid residues form NI-IO8 which did not appear to have enhanced 
aggregation properties when compared to IO8 in ThT assays. This resembled the data in this PhD research 
as AG03 and AG03M seemed to be both inhibit Tau aggregation relatively equally. Alternate N-
methylation of peptides blocks one face of the peptide from hydrogen bonding due to the replacement 
of backbone NH groups with N-methyl groups (Kokkoni et al., 2006). Therefore, simple N-methylation or 
retro-inversion of peptide aggregation inhibitors do not necessarily mean they will become more effective 
inhibitors. With regards to retroinverted peptides, changes in amino acid backbones and local charge can 
potentially improve inhibition of aggregation or even seed it. 
RI-AG03 has a high positive charge whereas heparin is heavily negatively charged. It is important that RI-
AG03 can inhibit aggregation of Tau in the presence of seeds as it acts as a control for heparin. It 
demonstrates that previous inhibition of heparin induced Tau aggregation was not as a result of RI-AG03 
sequestering heparin rendering it unable to interact with Tau. The fact that RI-AG03 can also inhibit 
pathological aggregation of Tau when added during the elongation phase means that it is able to block 
Tau assembly even after this process has been initiated, which is promising for development of an 
inhibitor to slow disease progression.  
Thioflavin-T fluorescence can detect the presence of β-sheet protein species, but it fails to detect the 
presence of oligomers. CD on the other hand can identify secondary structure of oligomeric species 
(Persichilli et al., 2011; Maezawa et al. 2008; Lasagna-Reeves et al., 2010); Li et al., 2009). Figure 5.21 
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demonstrates that incubation of Tau with heparin at 37°C for 5 hours results in a shift from unordered 
structure to β-sheet structure. When co-incubated with RI-AG03 under the same conditions there is a 
reduction in transition to β-sheet structure, which agrees with the Thioflavin-T data and further supported 
by Congo red birefringence (Figure 5.22).  Since heparin induces aggregation of Tau, it is plausible that RI-
AG03 results in the formation of Tau aggregates which are not Thioflavin-T reactive. CD data in Figure 
5.21 confirmed that RI-AG03 does not form β-sheets itself in the presence of heparin; supporting previous 
CD and Thioflavin-T data. The techniques discussed so far only determine secondary structure; to truly 
confirm the results morphological analysis is necessary.  
TauΔ1-250 constructs aggregated to display highly ordered structures; both straight fibrils and PHFs with 
the characteristic twist. This twist is hypothesised to be due to interactions between VQIINK and VQIVYK 
found in the second and third repeats, respectively (Xu et al., 2016). Most of the fibrils appear to be 
straight (Figure 5.23) which agrees with the findings of Barghorn and Mandelkow, (2002) who aggregated 
K18 using heparin. As mentioned previously, K18 is a recombinant construct of Tau that only comprises 
the 4R repeat domains, whereas Tau∆1-250 also contains the C terminus. TEM data in Figure 5.23 
demonstrates that when Tau was incubated in the presence of RI-AG03 no fibrils were formed. Instead 
~36nm diameter spherical structures can be seen, as quantified in Table 5.2, suggestive of large granular 
Tau oligomers (GTO) (Maeda et al., 2018). Maeda et al. (2007) suggested that once GTOs reach an average 
diameter of 20 nm they can form fibrils, however the structures seen in this research appear to be locked 
in their granular form (Cowen et al., 2015).  The structures formed in the TEM images are not necessarily 
the same as structures formed in the sigmoidal curve of amyloid production in the absence of inhibitor. It 
is not known whether the Tau-inhibitor complex structures in this research were toxic however, according 
to literature its possible that they may not be toxic and in fact may follow an insoluble and neuroprotective 
pathway (Cowan et al., 2015; Ali et al., 2112).  These unknowns need investigating further to be sure.  
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RI-AG03-Cys decorated liposomes via click chemistry in a 1:1 ratio (Figure 5.25). Maleimide is a sulfhydryl-
reactive chemical group and at pH 6.5-7.5, it selectively crosslinks with the free/reduced sulfhydryl group 
on the side-chain of cysteine to form a stable and non reversible covalent thioether linkage. Total lipid 
concentration was 20 μM but only 5% of the lipid was DSPE-PEG-MAL. Therefore only 5% of the lipid 
concentration (1 μM) could bind RI-AG03. Assuming 50% of the decorated peptides were outward facing 
and that 100% of the peptides bound; then the lipids contained ~2.5% peptide (0.5 μM). Figure 5.24 
demonstrated that liposome-peptide (0.5 μM) vs Tau (20 μM) elicited a similar inhibition response than 
free peptide (20 μM) vs Tau (20 μM). As a result, RI-AG03 liposome was approximately x40 better than 
the free peptide version. This agrees with previous research using free and peptide-bound Aβ aggregation 
inhibitors (Taylor et al., 2010). 
One of the barriers to this research is that TauΔ1-250 is a truncated construct so it can not be certain that 
the structure of the in vitro Tau aggregates is comparable to those manifested naturally in AD (Barghorn 
and Mandelkow, 2002). Ultimately this leaves a blank space in our knowledge as to whether Tau is 
behaving in a similar fashion in the lab in comparison to the disease and if advances in inhibiting 
aggregation in vitro will be equally effective in clinical trials. In addition, it is important to note that 
heparin-induced filaments are different from those found in AD and Pick’s disease (Fichou et al., 2018). 
The two types of filaments observed in AD include PHFs and SFs which are ultrastructural polymorphs 
consisting of two matching protofilaments with a C-shaped core comprising amino acids 304–380. The 
two types of filaments observed in Picks disease include narrow filaments with a J-shaped core comprising 




amino acids 254-378 and wide filaments which are made from two narrow filaments (Zhang et al., 2019). 
Using cryo-EM, Zhang et al (2019), identified heparin-induced 2N4R filaments adopt four different 
conformations: snake, twister, jagged and hose filaments. These conformations have differences in loop 
regions based on a subtle 20° adjustment to the backbone conformation of the 310YKP312 turn which causes 
alternative β-sheet packing conformations. The outward facing residues for AD and Picks filaments have 
alternating positive and negative charges, however in heparin-induced Tau filaments these residues are 
mainly positively charged. This results in R4 being disordered in heparin-induced Tau filaments (Zhang et 
al. 2019). The differences between disease (Alzheimer fold, Pick fold) and heparin-induced 2N4R Tau (4R-
snake, 4R-twister, 4R-jagged) are summarised in Figure 5.26. It may be possible that since the inhibitors 
are targeted against VQIVYKP, they may be interfering with the backbone conformation 310YKP312 resulting 
in off-pathway aggregates as previously demonstrated by the TEM image in Figure 5.23. This leads to 
further requirement to test if the structures formed in the presence of the inhibitor are toxic or not and 
to also test the effect of the inhibitor on Tau in an in vivo setting. Overall it suggests Tau has very versatile 
side-chain interactions resulting in variable cross-β packings, which with the right intermediate e.g. RI-
AG03, could completely alter the pathogenic aggregation pathway. Seidler et al. (2018), stated that 
VQIVYK inhibitors can only block filament formation of 3R Tau, whereas VQIINK inhibitors can block 
filament formation of 4R Tau. RI-AG03 is based on the VQIVYK sequence but can block filament formation 






Figure 5.26: Illustration of disease and heparin-induced Tau structures. A:  Colour coded filament β-strand 
and loop regions between R1–R4 for B: Schematic Tau folds for AD (PHF and SF), PiD (NPF and WPF), 4R-s 
(Snake), 4R-t (Twister) and 4R-j (Jagged). C: Structural differences between disease and heparin-induced 2N4R 
Tau filaments (Zhang et al., 2019). 
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6. TESTING RI-AG03 IN VIVO 
6.1 INTRODUCTION 
 
6.1.1 CELL UPTAKE 
 
As Tau aggregates are formed intraneuronally it is important that the inhibitory peptide RI-AG03 can enter 
cells where it can inhibit Tau aggregtion.  In addition, for the peptide to get into the brain it must pass 
through the blood-brain barrier (BBB, so it needs to be taken up and released by the cells that form the 
BBB. In this research the lead peptide utilises octa-arginine as a CPP enters cells via direct penetration and 
endocytosis. Polyarginine peptides are hydrophilic cationic CPPs due to their polar properties however 
mechanisms of CPP cellular uptake and delivery are still not understood completely (Langel, 2019). The 
structural component of arginine providing it with its cell uptake properties as a polymer is the 
guanidinium head group. This is supported by Yamashita et al. (2016), who demonstrated that 
polycitrulline was unable to penetrate cells when the nitrogen of guianidine was replaced with oxygen. 
The optimum arginine chain length for efficient cellular uptake are 7-15 arginine residues and the most 
commonly used are between 8-10 residues. Less than 7 residues may be insufficient for cell uptake and 
above 15 results in less efficient uptake (Mitchell et al., 2000). Futaki (2005), stated that octa-arginine has 
high translocation efficiency and for this reason has gained significant attention. If intracellular insoluble 
Tau oligomers are too difficult targets for the peptide inhinitors, then soluble extracellular Tau released 
from dead neurones or possibly even secreted from cells could be targeted instead. In doing so this could 
possibly indirectly reduce intra-neuronal Tau levels by means of shifting the equilibria of pathogenic Tau 
molecules. This is supported by De Calignon et al., (2012) who suggested based on animal models that 
Tau and aggregates can be secreted and propagated between neurones with a transynaptic mechanism 
like prions. As a result, potential therapeutic interventions may include preventing the initial formation of 
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seeds and the dispersion of extracellular soluble Tau aggregates (Giacobini and Gold, 2013).  Furthermore, 
extracellular Tau may also be toxic on top of having a role in spreading of Tau pathology in the brain. This 
is supported by Frost et al., (2009) who suggested that extracellular Tau aggregates, not monomers, can 
be taken up by cultured cells and as a result displace tubulin, co-localise with dextran and subsequently 
induce fibrillation of intracellular Tau 441. Giacobini and Gold, (2013) stated that anti-Tau antibodies may 
reduce Tau pathology and neurodegeneration by inhibiting transynaptic transmission of Tau pathology 
and so acts extracellularly but may indirectly reduce intracellular Tau. RI-AG03 should be able to enter 
cells as it contains a the octa-arginine transit sequence which is known to be used for brain delivery of 















6.1.2 DROSOPHILA ROUGH EYE MODEL OF TAUOPATHY 
 
Drosophila melanogaster were initially introduced as a research model by Thomas Hunt Morgan and have 
been used to answer biological questions for over a century and are versatile enough to cover various 
topics in neurobiology such as degeneration, development, behaviour and cirdadian rhythems (Gistelinck 
et al., 2012; Bellen et al., 2010; Morgan, 1910). They are particularly useful as they do not require ethical 
approval, are much cheaper to conduct in vivo experiments on than mice are and provide a faster turn-
around of results due to short their life-cycle, as seen in Figure 6.1. On top of short life cycles, they also 
have high fecundity, providing researchers with plenty of potential research samples. They are ~3 mm 
long and are routinely kept in small vials ~30 mL containing 5-10 mL food which can sustain the flies for 
around one month. Furthermore Reiter et al. (2001), suggested that ~77% of distinct disease genes in 
humans are orthologous to Drosophila sequences, providing an insight into human disease. 
Figure 6.1: The relatively rapid life cycle of Drosophila at 25 ˚C takes ~10 days. Development is split 
into several stages including embro, larva, pupa and adult (adapted from Ong et al. 2014). 
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Various transgenc Drosophila models have been used to investigate neurodegeneration based on human 
expression of Tau and Aβ, particularly the rough-eye model due to association of Tau and Aβ correlating 
with retinal toxicity (Chouhan et al., 2016; Cao et al., 2008; Shulman and Feany, 2003). In these models’ 
proteins are expressed solely in the eye and aggregation of these proteins results in retinal toxicity causing 
a loss of retinal cells, disordered ommatidia and bristle abnormalities (Chatterjee et al., 2008). The 
Drosophila Tauopathy models of aggregation replicate human disorder features such as accumulation of 
Tau, adult onset, progressive neurodegeneration and early death, however filamentous aggregates are 
not observed in these models (Wittmann, 2001). The rough-eye model is usually induced via the GMR-
GAL4 (glass multiple reporter GAL4) driver and expresses proteins throughout development (Chouhan et 
al., 2016). The binary GAL4/UAS system has been extensively used for transgene expression in Drosophila. 
To specifically express transgenes in the developing eye one of the most commonly utilised drivers of 
expression is the GMR-GAL4 driver which under the control of GMR (glass multiple reporter) expresses 
yeast transcription factor GAL4 (Li et al., 2012). Expression of the desired transgene is then driven under 
control of the GAL4 sequence (Li et al., 2012; Brand and Perrimon, 1993).  In this fly line full length human 
Tau is overexpressed and phosphorylated in the eye, which results in the formation of toxic non-
filamentous aggregates. Chatterjee et al. (2009), demonstrated that this misexpression of Tau induced 
neurodegeneration in Drosophila, manifested by early onset cell death in larval eye discs and then reduced 
eye size and rough-eye phenotype in adults with disordered ommatidia, abnormal bristles and loss of 
photoreceptor neurons in the retinal architechture. In addition, abnormal wing phenotype, or missing 
wings may also be observed due to up and down regulation of Notch or Drosophila wingless (Wg) 
pathways under the GMR-GAL4 driver (Li et al., 2012). Cagan and Ready (1989), stated that Notch is 
involved in tissue remodelling and is required for the hexagonal rearrangement of pigment cells in the 
Drosophila eye. Bao (2014), suggested that Notch is involved with cell adhesion in the Drosphila eye 
through control of epithelial remodelling. Bao demonstrated that cone cells communicated with primary 
 179 
 
pigment cells using Notch signalling. These primary pigment cells would activate transcription of genes 
hbs and sns which code for the Nephrin group adhesion molecules that bind to Rst and Kirre. In addition, 
primary pigment cells inactivated transcription of genes rst and kirre which code for the Neph 1 group. 
Notch has a clear involvement in the developing eye and is also either up or down regulated by the GMR-
GAL4 driver which could skew data in some flies. These flies are also reported to display loss of nerve cells, 
deficits in behaviour and a reduced lifespan (Passarella and Goedert, 2018). This agrees with phenomena 
seen in humans, whereby oligomers were detected in AD brains and so were believed to be the cause of 
toxicity (Ali et al, 2012; Wittman et al., 2001). Passarella and Goedert (2018), demonstrated that in a 
Drosophila models of Tauopathy which over expressed Δ306–311 human Tau-383 there was reduced Tau 
phosphorylation, no detectable degeneration and they had higher percentage survival. However, those 
flies which did express amino acid residues 306-311 displayed rough-eye phenotype signs of degeneration 
and had lower percentage of survival. They also demonstrated degeneration was evident in an age-
dependent manner, therefore investigating GMR-hTau eyes feeding on RI-AG03 over time will be 
important to observe. As the rough eye model is a genetic model, to observe changes in the fly eye 
phenotype or biochemistry through use of a peptide inhibitor may be challenging. This is because the flies 
are genetically engineered to overexpress Tau which is a process that can not be interfered with using 
peptide aggregation inhibitors. So, although the inhbitors may prevent aggregation of Tau, the flies will 
continue to overexpress Tau. Furthermore, the Tau is only expressed in the eye and the inhibitors will 
penetrate other cells after ingestion. This means that a small portion of the ingested inhibitor will reach 
the eye. Chouhan et al. (2016), also stated that degeneration progressed with aging, therefore the most 
profound effects of RI-AG03 would be seen in newly eclosed flies, as expression of Tau begins throughout 






Stability, cell-uptake and toxicity assays were conducted in preparation for experiments in Drosophila.  
6.2.1 ENZYME STABILITY 
 
Before conducting experiments in cells or in-vivo, the lead peptide had to be resistant to enzymatic 
degredation. Densitometric analysis of Figure 6.2 suggested that AG03 was completely processed by 
trypsin, whereas RI-AG03 was only partially processed, with a 19% reduction in signal.  
  26.6 – 
 6.5 – 
  3.4 – 
kDa 
Figure 6.2: 15% SDS PAGE gels of AG03 (100µM) and RI-AG03 (100µM) treated with and without 
equimolar Trypsin concentration for 24-hours at 37˚C. AG03 has no signal in the presence of Trypsin 
whereas RI-AG03 has a strong signal in the presence of Tyrpsin. Digests were conducted in triplicate 
and densitometric analysis suggested a 19% reduction in signal after equimolar incubation of RI-AG03 
with Trypsin for 24-hours at 37˚C. 
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6.2.2 CELL UPTAKE AND TOXICITY 
Before conducting experiments in cells or in-vivo, the lead peptide also had to be able to enter cells. Figure 
6.3A demonstrated that RI-AG03 was successfully taken up into cells. The inhibitor could be in vesicles 
but as it contains an octa-arginine chain they may have escaped into the cytoplasm. Notice that some cells 
are green everywhere so the inhibitor could potentially also be in the nucleus. Before conducting 
experiments in-vivo RI-AG03 had to be tested for toxicity. Figure 6.3B demonstrated that after 
concentrations of 30μM. the peptide started becoming toxic to cells. This was deemed acceptable before 




Figure 6.3: HEK-293 cells. A: Cellular uptake of FAM-RI-AG03 (15μM) by HEK-293 cells over 24-hours. Almost 
no peptide is visible in the medium, suggesting that majority of the peptide was taken up into the cells. B: 
Varying concentrations of RI-AG03 were co-incubated with HEK-293 cells and cytotoxicity was analysed 







6.2.3 EXTENDED STABILITY 
Figure 6.4 demonstrated that RI-AG03 is stable after 8 days incubation at 25°C with a 1-hour incubation at 55°C. Figure 6.4A illustrates no changes 
in UV absorbance. Figure 6.4B highlights the raw charge state data. Figure 6.4C demonstrated the maximum entropy deconvolution of the raw 
data. This is an algorithm-based approach to transform the average m/z raw spectra into a zero-charge spectrum. The basic principle involves 
identifying realistic solutions as those with minimal information whilst simultaneously retaining compatability with the data (Raab and Jung-
Richardt, 2015). This approach reduces the complexity of the data and improves resolution in comparison to raw data (Reinhold and Reinhold, 




























































































































































































































































2470.0 2472.5 2475.0 2477.5 2480.0 2482.5 2485.0 2487.5 2490.0 2492.5 m/z
C. 
Figure 6.4: RP-UPHPLC MS data for RI-AG03 at time zero (top) and after 8 days incubation at 25˚ and heated to 55˚C for one hour (bottom). A: 
UV Chromatogram, 254 nm at B: MS 3.7min retention C: MS with maximum entropy deconvolution isotopic cluster peaks using Dalton units. 
This demonstrates that RI-AG03 remains unchanged over 8 days and heating. 








































Figure 6.5 demonstrated that RI-AG03 exists as three species, each with either octa, hepta or hexa 
arginine chains. Variation in monoisotopic mass is due to the loss of one arginine (Mr = 174) and the 
addition of one H2O molecule (Mr = 18) which equals out at 156. In electrospray the [M+H]+ m/z is 
unknown, so it was calculated from energy state values 3+ to 6+. Therefore species 1 is the epexcted 
amino acid sequence [rG-pkyk(Ac)iqv-Grrrrrrrr], whereas species 2 has -1 arginine and +1 H2O and species 
3 has -2 arginine +2 H2O compared to species 1. The hexa-arginine chain for species is below the previously 
discussed recommended polyarginine chain length for cell uptake. 
 
 
Charge States  m/z 
[M+H]+* 2477.50 2321.00 2165.30 
[M+H]2+ 1239.26 1161.20 1083.10 
[M+H]3+ 826.51 774.50 722.40 
[M+H]4+ 620.14 581.10 542.10 
[M+H]5+ 496.31 465.10 433.80 
[M+H]6+ 413.00 387.70 361.90 
[M+H]7+ 354.79   
 Species 1 Species 2 Species 3 
Figure 6.5: RP-UPHPLC MS data for RI-AG03 A: Demonstrated RI-AG03 exists as three separate species, 
B: Outlines the charge states for the three species. Species 1 (C104H189N49O22) has monoisotopic mass 
of 2476.5, RI-AG03 species 2 (C98H177H45O21) has a monoisotopic mass of 2320.4 (-156.1), RI-AG03 










As RI-AG03 was added to the drosophila food which includes heating during preparation, it was important 
to determine if heat could force the inhibitor to change its secondary structure. Figure 6.6 confirmed that 









Figure 6.6: Thermal CD spectroscopy data demonstrating that temperature does not induce RI-AG03 
(20μM) to adopt a specific secondary structure.  
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6.2.4 PRELIMINARY ROUGH-EYE MODEL DATA 
 
Using BLASTP 2.8.1+ a standard align sequences protein BLAST between Human Tau 441 and Drosophila 
Tau 370 was conducted (Appendix C). The E-value suggests the number of expected hits with similar 
quality. lower the E-value the stronger the alignment match. The E-value for this BLASTP search was 1e-
33 and suggested an identical alignment of 38% between amino acids 193-384 and 97-303 for Human Tau 
and Drosophila Tau, respectively (Altschul et a., 1997; Altschul et al., 2005). Neither the 306VQIVYK311 or 















Figure 6.7 Visually demonstrated that 1-day old GMR-hTau adults which have been fed RI-AG03 as larvae 
have slighty larger eyes than untreated flies, more like those seen in the healthy control. 
Figure 6.7: Shows experimental pilot data of Drosophila over-expressing Tau in the eye (GMR-hTau) and 
healthy Drosophila (GMR-GAL4) treated with RI-AG03 (40μM). Tau expression causes toxicity resulting in 
morphological changes in the eye shape and width at the middle of the eye. Notice the increased size of 
the eye when the Tau fly is treated with RI-AG03. Error bar = 100μm. 
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Figure 6.8 demonstrated that the width of the middle portion of the eye and the vertical length of the eye increased with RI-AG03 40 μM, when 





























Figure 6.8: Shows experimental data of Drosophila over-expressing Tau in the eye (GMR-hTau) treated with various concentrations 
of RI-AG03 and healthy Drosophila control (GMR-GAL4). A: Width of the eye at the middle increased with 40 μM treatment. B: 
Vertical length of the eye increased with 40 μM treatment. Data presented as means (n=5/condition) and standard deviation. One 








































6.2.4.1 SCANNING ELECTRON MICROSCOPY 
 
Figures 6.9 demonstrated the striking change in the ommatidia which seems most severe on the leading edge of the eyes. RI-AG03 appeared to 































Figure 6.9: Drosophila eye SEM data of (from left to right) healthy GMR-GAL4, GMR-hTau treated with 20μM RI-AG03 and GMR-hTau without 
treatment. A: Notice the overall shape and size difference of the eyes B: Notice the ommatidia in the treated fly eye are more ordered 






Before RI-AG03 could be experimented in cells and in vivo, proteolytic resistance first had to be confirmed. 
According to ExPASy peptide cutter, Trypsin cuts AG03 [RGVQIK(Ac)YKPGRRRRRRRR] at lysine and arginine 
residues.  Figure 6.2 demonstrated that AG03 is degraded by Trypsin but RI-AG03 is resistant to Trypsin 
degradation for at least 24 hours at 37°C. Proteolytic resistance is expected as RI-AG03 constitutes D-
amino acids which are known to be proteolytically resistant (Taylor et al., 2010). On a molecular level the 
peptide can’t be degraded by trypsin because the backbone is reversed and so is the conformation in the 
active site, therefore the catalytic triad of the trypsin molecules are not pointed in the right direction and 
no longer fit the residues, therefore it can not conduct cleavage. Although limited due to budget and 
availability of enzymes in the lab, this provided some reassurance that RI-AG03 would not be 
proteolytically degraded in future experiments. RI-AG03 also had to demonstrate that it could enter cells 
for it to be effective as an inhibitor of intracellular Tau aggregation and that itself is not toxic to cells. 
Figure 6.3A illustrated the ability of FAM-RI-AG03 to penetrate cells, perhaps through cell mediated 
endocytosis or an electrostatic interaction mediated process as CPPs such as polyarginne have a high 
capacity to cross cell membranes unaided by receptors (Oller-Salvia et al., 2016, Lu, 2012). He et al. (2016), 
mentioned that polyarginine utilises both direct penetration and endocytosis systems however the exact 
mechanisms are still poorly understood. They demonstrated that octa-arginine forms hydrophilic holes in 
the membranes of giant unilamellar vesicles and penetrate through. It was suggested that this interaction 
was based largely upon electrostatics and hydrophilic interactions. Direct penetration involves 
interactions between the CPP and the phosphate groups of the lipid bilayer where the the positive charges 
on arginines and their guanidinium side-chains nucleate theformation of transient pores (Futaki, 2005). 
Endocytosis pathways can be inhibited by treating cells at 4°C. Khalil et al. (2004), identified that 
incubation of cells treated at 4°C did not inhibit internalisation of octa-arginine. This suggests that octa-
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arginine translocation is not limited to endocytosis. Macropinocytosis is a cellular uptake pathway 
involving polymerised actin filaments to extend from the plasma membrane like a sweeping hand to 
engulf cargo. Alternatively, Nakase et al. (2004), reported that uptake of octa-arginine was significantly 
supressed in the presence of macropinocytosis inhibitors ethylisopropylamiloride and cytochalasin D, 
suggesting an important role for micropinocytosis in the uptake of octa-arginine. However, Nakase et al 
(2004), also reported that micropinocytosis inhibitors demonstrated a greater inhibition effect for 
internalisation of R16 than octa-arginine, suggesting that micropinocytosis has a greater involvement in 
ceullar up take of R16 than octa-arginine. Upon cell uptake of CPP’s, they must also be able to escape 
endosomes so they may exert biological activity in the cytosol. It is presumed polyarginine may cause the 
endosomal membranes to become leaky however this remains unclear. Calnan et al. (1991), reported that 
the arginine guanidinium head group forms hydrogen bonds with phosphate backbones in RNA and other 
phospholipids/divalent anions found in lipid bilayers Sakai et al (2004), suggested that octa-arginine can 
escape endosomal membranes through counteranion-mediated phase transfer, where counter anions 
form complexes with arginines and increase their hydrophobicity. The negative voltage within mammalian 
cells is a driving force for the uptake of cationic CPPs, perhaps through counteranions the positive charges 
can be neutralised and drive them outwards (Futaki, 2006). Figure 6.3B demonstrated the low toxicity 
levels of RI-AG03, as generally expected of a protein drug (Carter, 2011; Goodman, 2009; Leader et al., 
2008). Potential side effects of using cationic cell penetrating peptides (CPPs) at high concentrations 
include membrane leakage and pertubation, reduction in cell viability, haemolysis and influence pore 
formation (Langel, 2019; Madani et al., 2011). This agrees with the increase in toxicity seen in Figure 6.3A 
at high concentrations of peptide. Kuo et al. (2009), treated human U-937 cell lines with octra-arginine 
and reported that octa-arginine did not release pro-inflammatory cytokines. To treat Drosophila with RI-
AG03 the flies had to orally ingest the inhibitor. Therefore, the fly food which involves high temperatures 
during preparation, was supplemented with RI-AG03. The flies would feed on this drug food for 1 week 
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before being transferred to fresh drug food. This helped to ensure that the flies were constantly feeding 
on fresh inhibitor. Figure 6.4 illustrated that RI-AG03 is stable after 8 days incubation at 25°C with a 1-
hour incubation at 55°C; to simulate the cooling process of the Drosophila food. This suggested that there 
is no detrimental effect to the inhibitor when it is supplemented to the hot Drosophila food.  Figure 6.4A 
showed no change in the UV absorbance of the sample at time zero and after 8 days incubation, suggesting 
no degredation. Figure 6.4B highlighted the raw charge state data that was then deconvoluted in Figure 
6.4C which considered different isotopes (e.g. 1.1% of all Carbon12 is Carbon13) and demonstrated that the 
neutral monoisotopic mass is 2476.50. Severn Biotech reported the molecular weight of RI-AG03 as the 
average mass of 2477.99, perhaps because they used a MALDI-TOF machine without the ability to show 
separate isotopes. Any change in ion numbers could be due to calibration. Changes in intensity could be 
due to dilution error resulting in a change in concentration which can also affect retention time. Figure 
6.5 showed that RI-AG03 exists as three species, each with either octa, hepta or hexa arginine chains, 
respectively. This variation in monoisotopic mass resulting in these three species is due to the loss of one 
arginine (Mr = 174) and the addition of one H2O molecule (Mr = 18) which equals out at 156. The 
monoisotopic mass of RI-AG03 (octa-arginine) is 2477.50, however 2477.50 – 156 = 2321.00 which is 
species 2 with hepta-arginine. Therefore species 3 is 2321.00 – 156 = 2165.30.  In electrospray the [M+H]+ 
m/z is unknown, so it was calculated from energy state values 3+ to 6+. Therefore species 1 is the epexcted 
amino acid sequence [rG-pkyk(Ac)iqv-Grrrrrrrr], whereas species 2 has -1 arginine and +1 H2O and species 
3 has -2 arginine +2 H2O compared to species 1. The three species may be present due to error in peptide 
synthesis and as Severn Biotech used MALDI-TOF it is possible the main peak swamped their spectra and 
so they collected the peak fraction which included the three species. To ensure that RI-AG03 did not 
change its fold at high temperatures when supplementing it to the fly food, thermal CD was performed. 
If the inhibitor folded into β-sheets due to high temperature, then it could potentially seed aggregation 
of Tau.  Ambadiputi et al. (2017), demonstrated that Tau in the absence of heparin aggregates at high 
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temperatures >65 °C. Figure 6.6 confirmed that RI-AG03 did not gain any secondary structure, despite 
being heated up to extremely high temperatures. With general confidence regarding the stability of RI-
AG03, the inhibitor was taken forward for experimentation in a Drosophila Tau model. A BLAST was 
conducted (Appendix C) to view similarities between human Tau and Drosophila Tau to ensure that RI-
AG03 did not target any VQIVYK or VQIINK sequences present in the natural Tau in the Drosophila. Despite 
sharing similarities (~38%) there are no VQIxxK sequences in the Drosophila Tau amino acid sequence. 
Therefore, there is some confidence that RI-AG03 only interacts with the Human Tau441 in the eye rather 
than the with the native Drosophila Tau. Figure 6.7 visually demonstrated that Tau flies treated with the 
inhibitor have slighty larger eyes, more like those seen in the healthy control. Figure 6.8 provided 
quantitative analysis of fly eyes demonstrating that the width of the middle of the eye and the vertical 
length of the eye significantly increased with RI-AG03 40 μM. By analyzing the diameters of GMR-hTau fly 
eyes which were treated and untreated with RI-AG03 and comparing them to the GMR-GAL4 flies which 
do not express Tau in the eye, it is evident that RI-AG03 40 μM rescused eye phenotype in flies 
overexpressing Tau. Heidary and Fortini (2001), expressed 0N4R Tau and Δ306–311 0N4R Tau (without 
VQIVYK sequence) in the photoreceptors and nerve cells of Drosophila and identified that 
neurodegeneration occurred in the 0N4R flies but not in the Δ306–311 0N4R Tau flies. This suggests that 
VQIVYK is essential for Tau to assemble into toxic β-sheets. As RI-AG03 targets VQIVYK this finding also 
complies with the data in Figures 6.7- 6.8 which suggest that RI-AG03 inhibits toxic Tau aggregation and 
that the inhibitor/Tau complexes formed were less toxic than aggregated Tau. Figures 6.9 shows the 
striking change in the ommatidia which seems most severe on the leading edge of the eyes. RI-AG03 
appeared to reduce the roughness of the eye and increase the number of bristles, resulting in a much 
more ordered looking eye when compared to the healthy control. This illustrated the ability of RI-AG03 to 
work in vivo in the rough-eye model system. It is important to note that because RI-AG03 consists of octa-
arginine, it will penetrate other cells upon ingestion, therefore only very little peptide will reach the eye. 
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Furthermore, the peptide was demonstrated to exist as 3 separate species, one of which has nn 
unsufficient poly-arginine chain length for cell penetration meaning that even less inhibitor reached the 
eyes. It can be argued this model does not reflect neurodegeneration adequately and that the protein 
misfolding and toxicity is irrelevant for model of AD. Rincon-Limas et al. (2012), stated that some disease 
associated proteins (including Tau and Aβ) cause a rough eye phenotype whereas others such as prion 
protein and α-synuclein do not. They also highlighted that different phenotypes are observed in the eyes 
such as different size, fused ommatidia, disorganised lattice, glassu surface and loss of pigment, as seen 
in Figure 6.10. This suggests that specific pathways are interacted with, which is supported by the fact 
that the Aβ and Tau genes demonstrate similar phenotypes. Casas-Tinto et al. (2011), suggested that Aβ 
causes a rough eye phenotype whether it is photoreceptors or all cell types, providing evidence that the 
phenotype is caused by toxicity to photoreceptors and not by neighbouring cells. 
 
 
Figure 6.10: Micrographs of Drosophila eye disruption by different amyloidogenic protein expression. A: healthy 
control, B: Expressing Atx1-82Q, C: Expressing Atx3-78Q, D: Expressing Htt093Q, E: Expressing α-synuclein, F: 
Expressing Prion protein, G: Expressing Aβ, H: Expressing Tau (Rincon-Limas et al, 2012). Notice how both the Aβ 




To this day there is still no clinically viable option to treat AD as the only drugs currently available are 
symptomatic. This leaves a huge hole in not only science but also the market. The research provided in 
this thesis presents a novel approach to prevent Tau aggregation using the retro-inverted peptide RI-
AG03, which can also be bound to a liposome to improve efficacy.  
To begin designing this peptide aggregation inhibitor the amino acid sequence of Tau was first screened 
for regions of low intrsinsic solubility and aggregation hot spots. The results from this highlighted region 
VQIVYK as the region with the lowest intrinsic solubility and the only aggregation hot spot. This provided 
an informed starting place to design a peptide aggregation inhibitor targeting VQIVYK. This prediction 
coincides with literature stating that VQIVYK is the main hexapeptide sequence for the aggregation of Tau 
and that in its absence Tau is unable to aggregate. 
This peptide was based upon the native VQIVYK sequence in Tau so that it may retain high target 
selectivity. The aggregation propensity was investigated for the VQIVYK sequence with exhaustive 
mutagenesis the the second valine of VQIVYK. Mutagensis was conducted to reduce the aggregation 
propensity of the peptide so it would not seed aggregation as polarity and hydrophilicity are important in 
avoiding self-association (Sormanni et al., 2015). The second valine was chosen for mutagenesis because 
the VQIVYK and VQIINK sequences in Tau both share the reference motif VQIxxK. Tyrosine was not chosen 
for mutagenesis because as an aromatic amino acid it is useful as an anchoring residue through aromatic 
stacking interactions. Furthermore, following computational optimal binding experiments it was 
predicted that isoleucine and tyrosine are important binding molecules, which supported the rational of 
not altering the tyrosine residue. It is a logical assumption that there is a fine line between between 
pathogenic aggregation and functionality of proteins, therefore the amino acid chosen to replace valine 
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had to have a relatively high aggregation propensity, but not above the aggregation hot spot threshold. 
The VQIVYK binding sequence was altered using a lysine replacement for the second valine so that it no 
longer had the propensity to self-associate but retained a degree of intrinsic insolubility so it may bind 
effectively to its target. To further improve binding the newly introduced lysine was acetylated, rendering 
It a hydrogen bond donor. This enhanced its interactions with the hydrogen bond acceptor rich region of 
VQIVYK in native Tau. The natural residue in Tau after the VQIVYK sequence is proline. As proline is a 
known β-sheet breaker, it was included onto the end of the modified VQIKYK binding sequence of the 
inhibitor.  
Molecular docking experiments predicted that VQIKYKP had the strongest energy bind to Tau than VQIVYK 
and VQIKYK did, however on average the binding conformations were very similar to each other. Both 
VQIVYK and VQIKYKP were predicted to interact with the VQIVYK and VQIINK sequences in Tau.  
VQIVYK has been cited in literature to interact with VQIINK. Both peptides were predicted to mainly bind 
in parallel to both the VQIVYK and VQIINK sequences. This interaction of the peptides with both VQIVYK 
and VQIINK residues was suggested to be due to the VQIxxK recognition sequences and the asparagine 
and tyrosine residues in VQIINK and VQIVYK, respectively, interacting via polar-π interactions (Chakravarty 
et al, 2018). In some cases, however both peptides also demonstrated to also bind in anti-parallel in some 
cases as well. This agrees with Cheon et al. (2012), who observed that free VQIVYK peptides formed β-
sheets consisting of both parallel and anti-parallel strands which stacked to then form disordered or 
irregular protofilaments. These predictions suggest that the inhibitors designed in this thesis are VQIxxK 
inhibitors as they are suggested to interact with both VQIINK (including neighbouring amino acids L282, 
N297, Y310, S316), and VIQVKY (including neighbouring amino acids G302, H374, N286, S285, Q288).  
A variety of other peptides were also drafted for analysis in the wet lab. Tau aggregation is largely 
facilitated by charge interactions. These peptides utilised arginine residues to investigate the effects of 
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their global charge and local charge (depending on the terminus arginine residues were added to) on Tau 
aggregation. The rationale behind these peptide designs was to prevent monomeric or misfolded Tau 
molecules from interacting at the VQIVYK accessible binding site; thereby impeding further aggregation 
Wet lab experiments were conducted using recombinantly expressed Tau∆1-250 (~94% purity). This 
truncated construct only takes ~8 hours to aggregate, whereas full length Tau can take up to ~72hours to 
aggregate (Crespo et al., 2018; Taniguchi et al., 2005). Tau was expressed in E.coli BL21(DE3) and induced 
for 3 hours with IPTG at 37˚C. This Tau aggregated in the presence of heparin in an optimal Tau:heparin 
ratio of 4:1. 
A major concern when testing the inhibitors against heparin-induced Tau aggregation was the possibility 
of the positively charged inhibitors from sequestering negatively charged heparin from solution, thereby 
preventing heparin from interacting with Tau. AG02R5 [RG-VQIVYK-GRRRR] suggested that it was able to 
inhibit seed-induced Tau aggregation in a ThT assay, suggesting that previous inhibition of heparin-
induced Tau was not due to the peptide sequestering heparin. 
AG03 [RG-VQIK(Ac)YKP-GRRRRRRRR] comprised the valine replacement with lysine, the acetylation of this 
lysine residue, the added proline residue, glycine spacers and a CPP polyarginine sequence. Although ThT 
fluorescence does not quantitatively measure fibrilisation it does indicate the presence of amyloid. AG03 
reduced ThT fluorescence (~30%) more than the other drafted peptide inhibitors which only comprised 
at least one of these elements AG03 had. This suggested that combining these elements together 
generated the most effective Tau aggregation inhibitor. The inhibitory effects of AG03 against heparin-
induced Tau were confirmed by testing a scramble peptide of AG03 and the octa-arginine sequence. 
Neither the scramble peptide or octa-arginine inhibited Tau aggregation. Before testing AG03 in cells or 
in vivo it had to be resistant to proteolysis, therefore an N-methylated version (AG03M) and a retro-
inverted version (RI-AG03) of AG03 were prepared. N-methylation did not appear to particularly improve 
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inhibitory effects against heparin-induced Tau aggregation, however retro-inversion almost completely 
blocked both heparin-induced and seed-induced Tau aggregation due to the reversal of the peptide 
backbone resulting in different hydrogen bonds. Despite the reversal of the backbone the peptide still 
retains activity. Ree et al. (2018), stated that affixing an acetyl group on the N-terminal amino group 
results in altered charge, hydrophobicity and size of the terminus; resulting in altered binding properties. 
RI-AG03 was also able to inhibit Tau aggregation when added during during the growth phase of Tau 
aggregation. The IC50 of RI-AG03 was calculated at 7.83μM. These data suggest that retro-inversion 
improved efficacy by perhaps altering the aggregation pathway of Tau. Hydrogen bond interactions 
calculated through molecular docking simulations illustrated that the RI-AG03 binding sequence 
interacted with neighbouring amino acids in addition to its target sequences, which provided additional 
evidence that the peptide may be able to alter the aggregation pathway of Tau. This was reinforced by 
TEM which showed that RI-AG03 locked Tau into spherical structures with an average diameter of ~36 
nm, indicative of insoluble GTOs. These structures were not ThT or Congo red sensitive. CD demonstrated 
that incubation of Tau with RI-AG03 reduced β-sheet content of Tau, suggesting that the inhibitor is 
interfering with the way Tau normally folds in the presence of heparin.  
The other peptide-inhibitors which were used to investigate different arginine chain lengths on Tau 
inhibition found no real difference beyond an addition of five arginnes. RI-AG03 comprised an octa-
arginine sequence to provide it with cell penetrating properties which demonstrated to be enough to 
penetrate cells using fluorescence microscopy. After passing stability assays, RI-AG03 demonstrated to be 
relatively not toxic to HEK-293 cells and in a Drosophila model of tauopathy appeared to partially rescue 
the rough-eye phenotype according to light and SEM microscopy by displaying vertically longer and 




8. RECOMMENDATIONS FOR FUTURE RESEARCH 
It is important to confirm that the RI-AG03-Tau species formed are not toxic and so varying concentrations 
will be incubated with cultured neuroblastoma SH-SY5Y cells, due to the difficulties of obtaining primary 
neurones. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and LDH assays of cell 
survival/proliferation will be employed to assess any undesirable toxicity on this cell type. The LDH assay is 
a colorimetric assay to determine cytotoxicity. When cells are damaged, they release LDH which catalyses 
the oxidation of lactate to form pyruvate with parallel reduction of NAD to NADH resulting in an absorbance 
shift which can be detected at 340 nm (Fotakis and Timbrell, 2005). The MTT assay is another colorimetric 
assay to determine cell viability MTT enters the mitochondria of cells where it is reduced by microchondrial 
succinate dehydrogenase into insoluble formazan. Cells are solubilised with organic solvent which releases 
the solubilised formazan and absorbance is read at 570 nm (Lie et al., 1997). DNA damage can also be 
assessed by detecting 8-oxo-guanine, a marker of DNA oxidation and damage. It has already been suggested 
in Figure 6.3 that RI-AG03 is not overtly toxic to HEK-293 cells at concentrations of up to 30 μM, however 
the inhibitor-Tau complexes formed in-vitro have not been tested for toxicity against cells. The Ames test 
can also be employed to determine potential carcinogenicity by detection of point mutations in DNA. 
Dynamic light scattering can also be useful to determine the solubility of the inhibitor-Tau complexes 
formed in solution as it can identify non-fibrillar intermediates as well as fibrils. If the species formed are 
insoluble, they will crash out of solution. 
Since Tau is a microtubule binding protein (MAP) it is important to investigate if RI-AG03 also binds, as its 
binding sequence is based on the VQIVYK sequence found in the microtubule binding domain of Tau. This 
can be achieved using a microtubule binding spin down assay kit. Microtubules can be freshly assembled 
in the lab using general tubulin buffer, α-tubulin, β-tubulin, MAP fraction (including Tau) and taxol solution 
to stabilise the microtubules. If RI-AG03 is seen to associate with microtubules it can be compared with 
 202 
 
the NAP peptide which is a known microtubule stabiliser to see if RI-AG03 also has microtubule stabilising 
properties. By phosphorylating the microtubules in solution theoretically they should disassemble, 
however if RI-AG03 can stabilise the microtubules, there should be less occurance of disassembly. 
The two main hexapeptide sequences in full length Tau responsible for aggregation are VQIINK and 
VQIVYK. RI-AG03 is designed to bind to VQIVYK and based on molecular docking simulations is predicted 
to interact with VQIVYK and VQIINK. Although RI-AG03 successfully achieved the goal of this thesis to 
develop a peptide-based aggregation inhibitor against Tau, the mechanism by which inhibits aggregation 
of Tau is still not entirely clear. It is assumed that the peptide interacts with VQIVYK and VQIINK and 
perhaps alters the normal aggregation pathway of heparin-induced Tau aggregation. However, it has not 
yet been confirmed in-vitro if this is occuring. By incubating VQIVYK or VQIINK hexapeptides in the 
presence of RI-AG03 and analysing rate and extent of aggregation via Thioflavn-T fluorescence assay, it 
can be determined if RI-AG03 can block fibrilisation of these hexapeptide sequences. Based on the 
computational predictions and the specific design of the inhibitor being a VQIxxK peptide, it should 
interact with both VQIVYK and VQIINK and inhibit aggregation of these hexapeptides. 
RI-AG03 will be incubated in the prescence of proteolytic enzymes andanalysed using RP-HPLC with a C18 
x 2.0 mm column and a gradient produced from 0.01 % trifluoroascetic acid (TFA) in dH2O (Buffer A) and 
0.1 % TFA in 100 % acetonitrile (Buffer B). Peptides will be eluted with a linear gradient of 0-60% 
acetonitrile 0.01% TFA over 40 minutes at 1 mL/min flowrate and measure absorbance at 214 nm and 275 
nm. The absorbance value of 214 nm will be used because the peptide bonds in VQIVYK absorbs strongly 
at this wavelength. The absorbance value of 275 nm will be used because tyrosine has a distinctive 
absorption profile at 275 nm due to chromophores in its aromatic side chain (Prasad et al., 2017).Enzymes 
to be investigated will be those calculated by ExPASy to be capable of cutting L-amino acid AG03 such as 
Arg-C proteinase, Chymotrypsin, Clostripain, LysC, LysN, Pepsin (pH>2), Proteinase K, Thermolysin and 
human plasma. This will thoroughly characterise the enzymatic stability of RI-AG03. 
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Repeating the studies conducted in the 2N4R Tau fly eye model, and in a healthy control group with 
greater number of flies, to clarify whether RI-AG03 can rescue eye phenotype when observed under 
scanning electron microscope and confocal microscope. The normal flies and 2N4R Tau flies (n=100 per 
treatment) will be fed on food supplemented with two different concentrations (20 µM, 0.08 µM) of 
RI-AG03 and will be euthanised the day they eclosed and prepared for microscopy. Longevity and climbing 
assays in a pan neuronal driver 2N4R Tau ELAV Drosophila melanogaster model of Tauopathy, and in a 
healthy control group (Bloomington Stock Centre). The purpose is to obtain toxicity data that may be 
relevant to humans. The normal flies and 2N4R Tau flies (n=100 eggs per treatment) will be fed on food 
supplemented with two different concentrations (20 µM, 0.08 µM) of RI-AG03 and, will be monitored 
over a period of 2 months. The percentage of hatched eggs pupated and eclosed flies with be will be 
recorded. As human Tau flies are reported to have abnormalities in wing phenotype as well is potentially 
missing wings or limps, climbing assays will also be suitable to observe the effects of RI-AG03. Differential 
fractionation of 2N4R Tau in ELAV Drosophila melanogaster model can also be conducted to biochemically 
analyse the percentage difference of monomeric, oligomeric and insoluble fractions. This can indicate how 
RI-AG03 is interacts in in vivo and to what extent it can prevent aggregation.  
Some experimentation has been attempted to investigate the binding affinity of RI-AG03 and liposome-
RI-AG03 at the University of Rome using surface plasmon resonance however was unsuccessful due to 
unspecific binding of the peptide. Other potential avenues to investigate this may include NMR 
spectroscopy and affinity membrane chromatography. Conducting further experiments using the 
liposome bound RI-AG03 peptide such as CD, TEM and its effects in Drosophila including potential 
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Appendix A: Current pipeline treatments in clinical development for AD associated with Aβ. 18 are active, 16 are 









Janssen Active Immunotherapy Mild-Moderate AD Phase 2 NCT00960531 Terminated 
2 Affitope AD02 AFFiRiS AG Active Immunotherapy 
Mild-Moderate AD, 
Early AD 
Phase 2 NCT01357629 Terminated 
3 CAD106 Cystos/Novartis Active Immunotherapy Mild AD Phase 2 NCT02565511 Active 
4 ACI-24 AC Immune Active Immunotherapy 
Mild-Moderate AD; 
Down Syndrome 
Phase 1 NCT02738450 Active 
5 UB-311 United Biomedical Active Immunotherapy Mild AD Phase 2 NCT03531710 Active 
6 LU AF20513 Lundbeck/Otsuka Active Immunotherapy Mild AD Phase 1 NCT02388152 Active 
7 Affitope AD02 AFFiRiS AG Active Immunotherapy Mild-Moderate AD Phase 2 NCT02008513 Terminated 
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Merck & Co. BACE inhibitor 
Prodromal or Mild- 
Moderate AD 








Janssen BACE inhibitor Early AD Phase 2 NCT02406027 Terminated 
















BACE Inhibitor AD Phase 1 NCT02254161 Terminated 
18 LY2886721 Eli Lilly BACE Inhibitor MCI or Mild AD Phase 1 NCT01561430 Terminated 











Merck Sharp & 
Dohme Corp. 




Neurochem, Inc. Dietary Supplement Mild-Moderate AD Phase 3 NCT00314912 Unknown 
23 
Epigallocatechin 
 Gallate (EGCG) 






















Eli Lilly Passive Immunotherapy Early AD Phase 2 NCT03367403 Active 
29 MEDI1814 AstraZeneca Passive Immunotherapy Mild-Moderate AD Phase 1 NCT02036645 Completed 
30 BAN2401 Eisai Inc. Passive Immunotherapy Mild AD Phase 2 NCT02094729 Completed 
31 Bexarotene 
Biogen, Eisai Co., 
Ltd. 




Amgen, Inc., Pfizer Passive Immunotherapy Mild-Moderate AD Phase 2 NCT01716637 Completed 
33 GSK933776 GlaxoSmithKline Passive Immunotherapy MCI or Mild AD Phase 1 NCT01424436 Completed 
34 Immune Globulin 
Baxalta now part of 
Shire 




Janssen Passive Immunotherapy Early AD Phase 2 NCT02569398 Active 
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36 Octagam®10% Octapharma Passive Immunotherapy Mild-Moderate AD Phase 2 NCT00812565 Completed 








Janssen Passive Immunotherapy Mild-Moderate AD Phase 2 NCT00606476 Terminated 
40 CAD106 Novartis Passive Immunotherapy MCI Phase 2 NCT02565511 Active 
41 LY2599666 Eli Lilly Passive Immunotherapy Mild-Moderate AD Phase 1 NCT02614131 Terminated 








AZTherapies, Inc. Small Molecule 
Early AD / 
Inflammation 




Actavis/Allergan plc Small Molecule Mild-Moderate AD Phase 2 NCT01078168 Completed 
46 Azeliragon Neurochem, Inc. Small Molecule Mild AD Phase 3 NCT02080364 Terminated 




Small Molecule MCI Phase 2 NCT01303744 Completed 
48 Elayta (CT1812) 
Cognition 
Therapeutics 




Small Molecule MCI or Early AD Phase 2 NCT01661673 Completed 
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50 Pinitol (NIC5-15) 
Humanetics 
Corporation 




Small Molecule Early AD Phase 2 NCT00471211 Completed 
52 PF-06648671 Pfizer Small Molecule AD Phase 1 NCT02407353 Terminated 
53 PF-06751979 Pfizer Small Molecule AD Phase 1 NCT02509117 Terminated 
54 PQ912 Probiodrug AG Small Molecule Early AD Phase 2 NCT02389413 Completed 


































Appendix B: Current therapeutic strategies for AD (Anand et al., 2014). 
 
 
• Modulating neurotransmission 
o Acetylcholinesterase inhibitors 
o NMDA receptor antagonists 
o GABAergic modulation 
o Serotonin receptor modulation 
o Histaminergic modulation 
o Adenosine receptor modulation 
• Tau based therapies 
o Tau phosphorylation inhibition 
o Microtubule stabilization 
o Blocking Tau oligomerization 
o Enhancing Tau degradation 
o Tau based immunotherapy 
• Amyloid based strategies 
o Secretase enzymes modulation 
o Amyloid transport 
o Preventing amyloid aggregation 
o Promoting amyloid clearance 
o Amyloid based immunotherapy 
• Oxidative stress reduction 
o Exogenous antioxidant supplementation 
o Augmenting endogenous defence 
• Modulating intracellular signalling cascades 
• Mitochondrial targeted therapy 
• Modulation of cellular calcium homeostasis 
• Anti-inflammatory therapy 
• Others 
o Gonadotropin supplementation 
o Lipid modifiers – Statins 
o Growth factor supplementation 
o Metal chelation 
o Epigenetic modifiers 
o Caspase inhibitors 
o Nitric oxide synthase modulation 
o Nucleic acid drugs 
o Multi-target directed ligands 












































Appendix I: HPLC-MS data for AG02PR5. 
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Appendix M: HPLC-MS data for AG02ΔI. 
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Appendix N: HPLC-MS data for AG02ΔV. 
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Appendix V: HPLC-MS data for TAT. 
 
 
 
